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INTRODUCTION
At the acquisition date of a business combination, Financial Accounting Standards
Board (FASB) Statement of Financial Accounting Standards No. 141, Business
Combinations, requires that an entity allocate the cost of the acquired company (that is,
the purchase price) to tangible and intangible assets acquired and liabilities assumed
based on fair value.1 Paragraph 35 of FASB Statement No. 141 states that an acquiring
company should assign a portion of the purchase price to the assets acquired and
liabilities assumed based on their estimated fair values at the date of acquisition. That
allocation includes any assets resulting from research and development (R&D) activities
of the acquired company or to be used in R&D activities of the combined enterprise.
Independent appraisals may be used as an aid in determining the fair values of assets
and liabilities.
FASB Interpretation No. 4, Applicability of FASB Statement No. 2 to Business
Combinations Accounted for by the Purchase Method, clarifies the accounting treatment
for assets to be used in R&D activities acquired in a purchase business combination.
FASB Interpretation No. 4 specifies that “the accounting for the cost of an item to be
used in research and development activities is the same under paragraphs 11 and 12 of
Statement No. 2, whether the item is purchased singly, or as part of a group of assets,
or as part of an entire enterprise in a business combination accounted for by the
purchase method.”2
FASB Interpretation No. 4 requires that at the acquisition date, the acquiring company
should charge to income costs allocated to assets acquired to be used in R&D activities,
unless the assets have an alternative future use. Costs allocated to assets to be used in
R&D activities that have an alternative future use and assets resulting from R&D
activities are capitalized. After initial recognition, those assets acquired are accounted
for in accordance with the provisions of FASB Statement No. 142, Goodwill and Other
Intangible Assets.
The allocation of purchase price of an acquired business can significantly affect the
financial reporting of current and future operating results of the combined enterprise. In
the past, the amount of goodwill the combined enterprise amortized to income in future
periods was directly affected by the immediate charge to income of amounts allocated
to assets acquired to be used in R&D activities that have no alternative future use.3
1

Paragraph 9 of Financial Accounting Standards Board (FASB) Statement No. 141, Business
Combinations, states that “a business combination occurs when an entity acquires net assets that
constitute a business or acquires equity interests of one or more entities and obtains control over that
entity or entities.” (Footnote references omitted) Emerging Issues Task Force (EITF) Issue No. 00-5,
Determining Whether a Nonmonetary Transaction Is an Exchange of Similar Productive Assets, and EITF
Issue No. 98-3, Determining Whether a Nonmonetary Transaction Involved Receipt of Productive Assets
or of a Business, provide guidance on assessing whether a transaction is a business combination.
2 While best practices within this Practice Aid are written in the context of a business combination
transaction, they also apply to an asset to be used in research and development (R&D) activities that is
acquired singly or as part of a group of assets. The valuation of an asset acquired singly in a monetary
transaction is relatively straightforward and is not addressed in this Practice Aid.
3 The FASB recently issued FASB Statement No. 142, Goodwill and Other Intangible Assets, which
requires that goodwill not be amortized, but rather tested in subsequent periods for impairment.
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Amounts assigned to assets acquired to be used in R&D activities (including specific inprocess research and development [IPR&D] projects), which are immediately charged
to income, reduce the amount of excess purchase price that would otherwise be
recorded as goodwill.
The financial reporting of assets acquired to be used in R&D activities, especially
specific IPR&D projects, recently has come under increased scrutiny by management,
analysts, investors, regulators, valuation specialists, and auditors. Until the early 1990s,
amounts allocated to specific IPR&D projects acquired purchase business combinations
were not significant. Later, however, amounts assigned to acquired IPR&D became an
increasing portion of the total purchase price—in some instances more than 75 percent
of the total purchase price.
Financial reporting constituents in the software, electronic devices, and pharmaceutical
industries have expressed concern about the lack of comparability among entities for
the: (1) definition of what constitutes assets acquired to be used in R&D activities,
including specific IPR&D projects; (2) methodologies and assumptions used to value
specific assets acquired to be used in R&D activities, including specific IPR&D projects;
and (3) level of disclosures made for amounts allocated to assets acquired to be used in
R&D activities, including specific IPR&D projects. In addition, some, including staff of
the United States Securities and Exchange Commission (SEC), are concerned about
valuations of assets acquired to be used in R&D activities, including specific IPR&D
projects, that appear to be unreasonable determinations of fair value, and some are
concerned about the adequacy of procedures employed in audits of financial statements
that include a charge for the acquisition of assets acquired to be used in R&D activities,
including specific IPR&D projects. As a result, on September 9, 1998, the Chief
Accountant of the SEC released a letter to the chair of the AICPA SEC Regulations
Committee (available on the SEC’s Web site at www.sec.gov) citing a number of issues
relating to the valuation of assets acquired in a purchase business combination that the
SEC staff noted in its review of public registrant filings.
The AICPA responded to these concerns by forming a task force comprising
representatives from various constituencies to study the issues and to prepare a best
practices publication that would benefit all parties interested in the financial reporting of
assets acquired to be used in R&D activities, including specific IPR&D projects, in the
software, electronic devices, and pharmaceutical industries (though generally accepted
accounting principles underlying the best practices apply to all industries).
This Practice Aid identifies what the task force members perceive as best practices
related to defining and accounting for, disclosing, valuing, and auditing assets acquired
to be used in R&D activities, including specific IPR&D projects.
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CHAPTER 1
CONCEPT OF FAIR VALUE
1.1

OVERVIEW

1.1.01
Acquiring assets in a business combination requires ascertaining the cost of
the acquired company (that is, purchase price) and assigning that cost to the assets
acquired and liabilities assumed on the basis of their fair values.
1.1.02
In accordance with paragraph 37 of Financial Accounting Standards Board
(FASB) Statement of Financial Accounting Standards No. 141, Business Combinations,
the portion of the purchase price assigned to an asset is affected by the acquiring
company’s plans for that asset. If the acquiring company expects to abandon an
acquired asset, that asset would be assigned a portion of the purchase price equal to
that asset’s salvage value. If the acquiring company expects to sell the acquired asset,
that asset would be allocated a portion of the purchase price equal to its fair value less
cost to sell. (See FASB Statement No. 121, Accounting for the Impairment of LongLived Assets and for Long-Lived Assets to Be Disposed Of, and Emerging Issues Task
Force [EITF] Issues No. 87-11, Allocation of Purchase Price to Assets to Be Sold, and
No. 95-21, Accounting for Assets to Be Disposed Of Acquired in a Purchase Business
Combination.) If the acquiring company plans to hold the acquired asset for use in its
operations or for investment, that asset initially would be assigned a portion of the
purchase price based on its fair value. Valuation specialists would not take into
consideration any company-specific benefits or cost savings in estimating fair value of
assets acquired because “investment value” and “buyer-specific value” do not conform
to the concept of fair value, as that term is defined by generally accepted accounting
principles (GAAP).
1.1.03
As noted in the glossary to FASB Statement No. 141, Business Combinations,
the fair value of an asset for financial reporting purposes is defined as the amount at which
the asset could be bought or sold in a current transaction between willing parties, that is,
other than in a forced or liquidation sale. GAAP uses a hierarchy for evidential matter to be
used in determining fair value. Quoted market prices in active markets are the best
evidence of fair value and would be used as the basis for the measurement, if available. If a
quoted market price is not available, the estimate of fair value should approximate the price
at which the asset would be expected to be bought or sold in a current transaction between
a willing buyer and seller and would be based on the best information available in the
circumstances. The estimate of fair value should consider prices for similar assets and the
result of valuation methods to the extent available in the circumstances. Examples of
valuation methods cited in accounting literature include (a) the present value of estimated
future cash flows using discount rates commensurate with the risks involved, (b) the
present value of probability-based expected future cash flows using a risk-free discount
rate, and (c) option-pricing models. The valuation methods selected for measuring assets
should be consistent with the objective of measuring fair value. Those methods should
incorporate assumptions that market participants would use in their estimates of values,
future revenues, future expenses, and interest rates (if applicable).
3

1.1.04
It is presumed that absent evidence to the contrary, the assumptions used by
the acquiring company and acquired company in negotiating the value of the
consideration exchanged in the transaction is indicative of assumptions that market
participants would use in making estimates of fair value.1 If the acquiring company pays
the owners of the acquired company any significant consideration for synergistic or
strategic benefits in excess of those expected to be realized by market participants, the
valuation specialist would identify those excess benefits and remove them from the
valuation of assets acquired. The ultimate assumptions used in making estimates of fair
value would reflect the best estimate of how market participants would benefit from use
of the asset being valued.
1.1.05
The IPR&D Task Force believes that market participants include all potential
buyers (other than financial buyers and investors that would not intend to take an active
role in managing the acquired company) whether or not the potential buyers are
engaged in discussions with the seller of the business. In considering which potential
buyers may be market participants, the valuation specialist would consider only those
potential buyers that appear to have the ability to acquire the assets being valued.
Ability would be evaluated in the context of financial wherewithal, or ability to obtain it,
as well as a plausible postcombination operating strategy for the assets being valued.
Market participants would include competitors in the same line of business as the
company being acquired.

1.1.06
CONCEPT OF FAIR VALUE TO BE USED IN VALUATIONS
PREPARED FOR FINANCIAL REPORTING PURPOSES
1.1.07
The Task Force believes that the concept of fair value in the accounting
literature does not have an equal in the appraisal literature. Historically, valuation
specialists may have used premises/standards of value in assigning cost to assets
acquired in a business combination that include “liquidation,” “in-exchange,” “in-use,”
or “investment” value. These premises/standards of value should be neither used nor
referred to in valuation reports that will be used in assigning cost to assets acquired
in a business combination pursuant to FASB Statement No. 141; these
premises/standards of value would not be appropriate because GAAP requires the
use of fair value.

•

Liquidation value. This premise/standard suggests that the seller is compelled to
sell. The buyer may be a willing buyer but the seller must sell, unwillingly. Generally
there are two levels of liquidation value: forced and orderly. Forced is a one-day
“gavel” or auction sale; orderly may take place over a period of time. Liquidation
value for most intangible assets would be zero or close to it because there are
infrequent sales of intangible assets in such a setting. However, liquidation value
may be an appropriate basis for determining fair value only in those cases where an
asset has been identified for immediate disposal.

1 Paragraph B174 of FASB Statement No. 141, Business Combinations, provides that an entity may use its
estimates of cash flows if market participant assumptions are not available without undue cost and effort.
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•

•

•

In-exchange value. This premise/standard typically includes the traditional fair
market value (FMV) definition, which emanates from the income tax literature, albeit
on a piecemeal basis. It is further described by some appraisers as the value of an
asset “on the loading dock,” which is a tangible asset concept. FMV is often
considered stand-alone value or value to a financial buyer. Real estate appraisers
generally use the term market value as being synonymous with FMV, as their
literature generally avoids value being associated with the word fair in relation to
some sort of perceived fairness doctrine (which might be construed as a legal
concept). Some appraisers argue that liquidation value is simply a subset of inexchange value, because liquidation is also an exchange transaction. In-exchange
value generally is impossible to assess for many intangibles as they are not sold
piecemeal (for example, workforce, company infrastructure, base (or core)
technology2), but instead, are bundled with other assets of a particular going
concern. The willing buyer-willing seller transaction is taking place at an enterprise
level, and the asset is expected to continue to be used as it is currently by the
hypothetical willing buyer (commonly referred to as FMV-in-use). In-exchange value
is premised on the willing buyer-willing seller concept that is contained in the
concept of fair value, and it would be an appropriate basis for determining fair value
if an active market existed for the asset being valued. However, assets to be used in
research and development (R&D) activities, including specific in-process research
and development (IPR&D) projects, seldom are sold other than in the sale of an
entire business, and sufficient data to conclude on the value of assets acquired to be
used in R&D activities based on similar transactions rarely, if ever, would exist.
In-use value. This premise/standard also might include FMV, as described
previously, but the important distinction is that the asset is looked at, not on a
piecemeal basis, but in concert with the other assets of the enterprise of which it is a
part. For tangible assets, the premise/standard of value includes installation costs
and sales tax. For intangible assets, the premise/standard of value may include the
contribution of the asset to the enterprise of which it is a part. In-use value generally
considers the present value of the benefits contributed by the asset to the enterprise
when it works in concert with the other assets of the enterprise. Because the
hierarchy of evidentiary matter to be used to determine fair value includes
discounted cash flow analysis, in-use value may seem to be an appropriate basis for
determining fair value. However, the discounted cash flow analysis for determining
in-use value should not be used to determine fair value, as defined by GAAP.
Investment value. This premise/standard is often described as synergistic or
strategic value. Investment value also can be part of both in-exchange or in-use
value, with the distinction that the willing buyer is not a hypothetical marketplace
buyer but rather is a particular buyer with specific expectations about future events,
cost of capital, tax circumstances, and other issues. Investment value, with regard to
intangibles, implies not only an in-use premise/standard of value, but also the value
as expected to be deployed by a particular buyer, in a strategic or synergistic sense,
as opposed to the current user (that is, the seller). Investment value is not an
appropriate basis for determining fair value, as it would encompass benefits
expected by a particular buyer of the asset that are different from those available to
market participants in general.

2 Terms defined in the glossary of terms (see appendix A) are set in boldface type the first time they
appear in this Practice Aid.
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1.1.08
FAIR VALUE OF AN ACQUIRED ASSET IS BASED ON A
SEPARATE STAND-ALONE BASIS
1.1.09
Except for a few specific industries (for example, pharmaceutical),
intangible assets seldom are exchanged on a separate stand-alone basis (that is, a
piecemeal basis). Instead, intangible assets typically are exchanged in combination
with other assets that make up a business. A willing buyer would factor into the
amount that it would be willing to pay the seller to acquire the seller’s business a
portion of the incremental cash flows resulting from the acquisition that are
expected to inure to the benefit of that buyer. The incremental cash flows would
include those resulting from enterprise or going-concern components and synergies
between the businesses of the buyer and seller. Thus, the cost of the acquired
company may include an element of enterprise or going-concern value and
synergistic value. If the buyer pays the seller any significant consideration for
going-concern and synergistic benefits in excess of those expected to be realized
by market participants, the valuation specialist would identify those excess benefits
and remove them from the valuation of assets acquired. For purposes of assigning
cost to the assets acquired in accordance with FASB Statement No. 141, the
amount of the purchase price allocated to an acquired intangible asset would not
be based on that intangible asset’s contribution to the enterprise or going-concern
value or synergistic value. The fair value of an acquired intangible asset would be
based on an asset-by-asset analysis, and would be the hypothetical market price
for that asset on a piecemeal basis as if that asset were traded on an established
market. The hypothetical market price would incorporate assumptions that market
participants would use in their estimates of values.
1.1.10
Paragraph 39 of FASB Statement No. 141 provides guidance on when an
intangible asset should be recognized as an asset apart from goodwill. That paragraph
states, in part, “An intangible asset shall be recognized as an asset apart from goodwill
if it arises from contractual or other legal rights (regardless of whether those rights are
transferable or separable from the acquired entity or from other rights and obligations).
If an intangible asset does not arise from contractual or other legal rights, it shall be
recognized as an asset apart from goodwill only if it is separable, that is, it is capable of
being separated or divided from the acquired entity and sold, transferred, licensed,
rented, or exchanged (regardless of whether there is an intent to do so).”
1.1.11
The task force believes that assets acquired to be used in R&D activities,
which meet the criteria for separate recognition apart from goodwill, also should
possess the characteristics and attributes of an asset (that is, control, economic
benefit, measurability, and for specific acquired IPR&D projects, substance and
incompleteness). Often a combination of assets (which may include tangible and
intangible assets) is necessary to generate identifiable cash flows. Those cash
flows may be the basis for the valuation of specific intangible assets within that
combination and, therefore, a basis for the allocation of the purchase price to
certain assets acquired. An issue arises over whether certain assets acquired in
the business combination may be aggregated or combined and treated collectively
as a single asset for financial reporting purposes in allocating the cost of the
acquired company to the assets acquired. Paragraph A14 of FASB Statement No.
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141 provides examples of intangible assets that meet the criteria for separate
recognition apart from goodwill.
1.1.12
Each “single asset” for financial reporting purposes would be allocated a
portion of the purchase price based on its fair value.
1.1.13
Example—Value of an Acquired Asset Is Determined on a
“Single Asset” Basis
1.1.14
Company A acquired Company X in a business combination. Company A
engages a valuation specialist to value the assets acquired in the business combination.
The valuation specialist, in consultation with the respective management teams of
Companies A and X, identifies a list of assets to be valued, in accordance with
paragraph 5.3.26. The valuation specialist started the process by using a broad list of
potential assets, such as that shown in paragraph 5.3.60. Based on procedures
performed by the valuation specialist, assets identified include trade name; customer
base; and technology, including its subcomponents base (or core), developed, and inprocess.3 Each of these assets is valued individually. The valuation specialist performs
a separate analysis for each asset, estimating the price at which that asset would be
exchanged between a willing buyer and seller, on an individual basis. Individual asset
values would not include synergies or benefits attributed to other assets.

1.1.15
STRATEGIC OR SYNERGISTIC VALUE EXCLUDED FROM VALUE
ASSIGNED TO ACQUIRED ASSETS
1.1.16
A willing buyer may factor into the amount that it would pay to acquire the
seller’s business a portion of the incremental cash flows that are expected to inure to
the benefit of that buyer. The incremental cash flows may include those resulting from
strategic or synergistic components. If the buyer pays the seller any significant
consideration for strategic or synergistic benefits in excess of those expected to be
realized by market participants, the valuation specialist would identify those excess
benefits and remove them from the valuation of assets acquired.4 Thus, the cost of the
acquired company may include an element of synergistic value (that is, investment
value). However, for purposes of assigning cost to the assets acquired in accordance
with FASB Statement No. 141, the amount of the purchase price allocated to an
acquired asset would not include any entity-specific synergistic value. Fair value does
not include strategic or synergistic value resulting from expectations about future events
that are specific to a particular buyer because the value associated with those
components is unique to the buyer and seller and would not reflect market-based
assumptions. Therefore, entity-specific value associated with strategic or synergistic
components would be included in goodwill. Fair value would incorporate expectations
about future events that affect market participants. If the acquiring company concludes
that the discounted cash flow method best approximates the fair value of an acquired
3

The FASB recently issued FASB Statement No. 141, which provides guidance on determining which
intangible assets should be recognized apart from goodwill in the allocation of purchase price in a
business combination.
4 See footnote 1 in chapter 1 of this Practice Aid.
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asset, the discounted cash flows would incorporate assumptions that market
participants would use in their estimates of fair values, future revenues, future
expenses, and discount rates (if applicable).
1.1.17

Example—Exclude Effects of Synergies From Value of Assets Acquired

1.1.18
Company A acquired Company X in a business combination. At the
acquisition date of the combination, Company X has specific IPR&D projects that meet
the characteristics and attributes set forth in this Practice Aid. Company A concludes
that a discounted cash flow method best approximates the fair value of the specific
IPR&D projects. In estimating the cash flows expected to be generated from the
successful development of the specific IPR&D projects, Company A should estimate its
distribution costs associated with selling the completed products resulting from the
successful development of the IPR&D. Company A’s historical distribution costs have
averaged 20 percent of product revenue. After the combination, Company A expects its
distribution costs to be consistent with its historical experience. Company X’s historical
distribution costs have averaged 30 percent of product revenue. Market participants’
historical distribution costs have averaged 25 percent of product revenue.
1.1.19
Company A would use 25 percent of product revenue as the cost of
distribution in its estimate of future cash flows for purposes of valuing the acquired
specific IPR&D projects because it reflects the assumption that market participants
would use in their estimates of future cash flows. The excess of the anticipated benefits
to be derived from Company A’s expected postcombination distribution costs of 20
percent of product revenues over the market participants’ distribution costs of 25
percent would be excluded from the value assigned to assets acquired to be used in
R&D activities.

1.1.20

SUMMARY OF FAIR VALUE

1.1.21
The fair value of an acquired asset, including an intangible asset, for financial
reporting purposes is the amount at which that asset would be bought or sold on a
piecemeal basis in a current transaction between the seller and a hypothetical
marketplace buyer (that is, a market participant) in other than a forced or liquidation
sale. GAAP uses a hierarchy for evidential matter in determining the fair value of an
asset. In the absence of quoted market prices, the technique used to estimate fair value
would be the method that produces a fair value that would best approximate quoted
market prices. Because quoted market prices do not exist for most intangible assets,
the technique used to value identifiable intangible assets would be the technique that
produces a value that best approximates a hypothetical market price. The application of
the multi-period excess earnings method (a form of discounted cash flow analysis),
as discussed in chapter 5, would reflect assumptions used by market participants.
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CHAPTER 2
VALUATION APPROACHES TO ESTIMATING FAIR VALUE OF
ASSETS ACQUIRED—GENERAL DISCUSSION
2.1

OVERVIEW

2.1.01
All valuation methodologies applied to a valuation of an asset may be broadly
classified into the cost, market, or income approaches. In a valuation study, all three
would be considered, and the approach or approaches deemed most indicative of fair
value, as that term is defined by generally accepted accounting principles (GAAP),
would then be selected as the proper approach(es) to use in the valuation of that asset.
See paragraph 1.1.06.
2.1.02
All three approaches have application in the valuation of assets acquired in a
business combination, depending on the nature of the asset being valued. However,
most assets acquired to be used in research and development (R&D) activities,
including specific in-process R&D (IPR&D) projects, are valued by the income approach
or, in limited circumstances, the cost approach. Except for certain limited circumstances
in a few specific industries (for example, pharmaceutical), the market approach rarely is
used due to the absence of observable market values for comparable assets acquired
to be used in R&D activities.

2.1.03

COST APPROACH

2.1.04
The cost approach establishes value based on the cost of reproducing or
replacing the asset. The principle behind the cost approach is that the fair value of
an asset should not exceed the cost to obtain a substitute asset of comparable
features and functionality. In other words, replacement cost is the greatest amount
that a buyer would pay for a specific asset. By its very nature, the relationship
between cost incurred and value created is tenuous at best for assets acquired to be
used in R&D activities, including specific IPR&D projects. For example, certain R&D
projects may go on for years at great expense without ever producing a
commercially viable product. In that case, the cost of reproducing the historical
development steps may overstate the value of the technology. Conversely, great
discoveries may be made for little cost. In this case, the cost of reproducing the
historical development steps would be low compared with the value of the resulting
technology. The principle of substitution, which is discussed in the tenth edition of
The Appraisal of Real Estate, published by the Appraisal Institute, states that a
buyer would pay no more than the costs to recreate the asset for itself. This principle
is applicable when a perfect substitute can be developed in-house, as opposed to
purchasing the asset from a third party. Unfortunately, many assets are one-of-akind, novel, or proprietary, and do not lend themselves to this make-versus-buy
decision pattern. As a consequence, the IPR&D Task Force believes that it would be
rare where the cost approach would be appropriate for use in valuing assets
acquired to be used in R&D activities, including specific IPR&D projects. However,
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the cost approach may be the only applicable approach in those cases where
“substitutability” does exist, and for specific IPR&D projects where the stage of
development while demonstrating substance is, nonetheless, so early that reliable
forecasts of future benefit do not exist, or where no market exists for sale or transfer
of comparable discoveries. Under these facts and circumstances, the cost approach
may be deemed to result in a reasonably reliable estimate of fair value.
2.1.05
For purposes of assigning costs to the assets acquired in accordance with
Financial Accounting Standards Board (FASB) Statement No. 141, Business
Combinations, the valuation of an acquired asset using the cost approach, when
appropriate, would be based on replacement cost. Paragraph 37 of FASB Statement
No. 141 states that property and equipment to be used would be valued at current
replacement cost for similar capacity unless the expected future use of the asset
indicates a lower value to the acquiring company. Footnote 12 to paragraph 37 states
that replacement cost would be approximated from replacement cost new less
estimated accumulated depreciation in the absence of a used asset market price. The
task force believes that best practices would extend the guidance in paragraph 37 and
footnote 12 to the valuation of acquired intangible assets in those rare instances when
the cost approach is used to value assets acquired to be used in R&D activities
(including specific IPR&D projects).

2.1.06

MARKET APPROACH

2.1.07
The market approach is used to estimate value through the analysis of recent
sales of comparable assets. However, sales prices of intangible assets seldom are
available because intangible assets typically are transferred only as part of the sale of a
business, not in piecemeal transactions. Furthermore, because intangible assets are
unique to a particular enterprise, comparison between enterprises is difficult. For these
reasons, the market approach seldom is used and rarely is appropriate in the valuation of
intangible assets, unless exchanges of individual assets comparable to the subject asset
can be observed. However, in certain limited circumstances in a few specific industries
(for example, pharmaceutical), active markets exist for the purchase by operating
companies of early-stage discoveries from academic institutions. These prices may
provide the best indication of value for early-stage discoveries. For early-stage
technologies in which comparable technology exchanges recently have occurred, prices
reflected in those exchanges may serve as a reasonably reliable estimate of fair value.

2.1.08

INCOME APPROACH

2.1.09
The term income as used in this approach is a general term that suggests
future benefits that can be quantified in the form of expected future cash flows. It does
not imply that the income approach should be used only with forecasts of net income in
the financial reporting sense. Rather, the income approach involves two general steps.
The first is establishing a forecast of the estimated future net cash flows expected to
accrue directly or indirectly to an investor resulting from ownership of the asset or a
group of assets. The second step involves discounting these estimated future net cash
flows to their present value.
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2.1.10
The valuation of intangible assets is most commonly quantified under the
general principles of the income approach in which there is an identifiable stream of cash
flows. This stream of cash flows can manifest itself in many ways; among them are—

•

•

•

•

Multiperiod excess earnings. In cases where the intangible assets result in unique
products (for example, pharmaceuticals), or the intangible assets are necessary to
compete in an industry (for example, semiconductor design), a multiperiod excess
earnings method may be the best indicator of value. This method requires a forecast
of cash inflows, cash outflows, and pro-forma charges for economic returns of and
on tangible assets employed (for example, working capital and property, plant, and
equipment). It also may be necessary to charge a return on other enabling intangible
assets, such as trademarks, distribution channels, or relationships with customers,
as well as base (or core) technologies. Cash outflows include direct and indirect
expenses for costs to complete, manufacturing, sales, marketing, routine technical
maintenance, general, and administrative and taxes. The net cash inflows (or
multiperiod excess earnings) are ascribable to the intangible asset and, when
discounted to present value, provide an estimate of its fair value.
Royalties not paid through ownership of the asset. Because the owner enjoys the
right to manufacture and sell products that incorporate the intangible assets without
having to pay a royalty fee to the inventor, the “relief from royalty” is a cash flow
savings that can be discounted to present value. See paragraph 2.1.12 for best
practices regarding the use of the relief from royalty method.
Manufacturing cost savings. An intangible asset may afford its owner a cost savings
over the next best alternative available (that is, a reduced or eliminated cash
outflow). These cost savings also represent a measure of the benefits enjoyed by
the owner of the intangible asset. The present value of the cost savings would be
included in the estimate of fair value of the intangible asset provided that the cost
savings would be available to market participants if they owned the intangible asset.
Incremental revenue. The intangible asset may allow the owner to charge premium
prices for the product, as it incorporates features, functions, or capabilities that the
alternative cannot offer (that is, a higher cash inflow). The premium price is a direct
measure of the benefits derived from ownership of the intangible asset and would be
included in its estimate of fair value provided that the premium price would be
available to market participants if they owned this intangible asset.

2.1.11
The income approach may be broken down into two basic sub-component
methods: (a) single-period capitalization and (b) multiperiod discounted cash flow. The
single-period-capitalization method is used primarily in the valuation of small
businesses, professional practices, certain types of real property, and constant growth
intangible assets that are expected to exist in perpetuity. This method rarely is of use in
the valuation of assets acquired to be used in R&D activities because the assumptions
as to perpetual existence and continuous growth would be inappropriate. The
multiperiod discounted cash flow method is most commonly used and takes on many
methodological forms (for example, the relief-from-royalty method and the multiperiod
excess earnings method).
2.1.12
Relief-from-royalty method. A relief-from-royalty method may be appropriate
for certain categories of intangible assets. For instance, trademarks and tradenames,
patents, developed product technology, and base (or core) technology are all categories of
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intangible assets that frequently are licensed in exchange for a royalty payment.
Ownership of the asset relieves the owner of the need to pay a royalty to a third
party for use of the asset. A key challenge in applying this method is to develop a
royalty rate that is comparable to ownership of the specific asset (for example, a rate
that equates to worldwide, exclusive rights to use that asset in perpetuity in any
manner desired).
2.1.13
The basic tenet of the relief-from-royalty method is that without ownership of
the subject intangible asset, the user of that intangible asset would have to make a
stream of payments to the owner of the asset in return for the rights to use that asset.
By acquiring the intangible asset, the user avoids these payments.
2.1.14

•
•
•
•

Generally, the relief-from-royalty method would be appropriate in cases where—

The intangible asset makes a contribution to the relevant cash flows that is
comparable to that made by a comparable licensed asset (for example, licensed
assets typically do not represent the only or major source of return; they are usually
sub-components or ancillary items).
The intangible asset can reasonably be separated from other assets and it is
practical and possible to separately license it.
The rights of ownership can reasonably be compared to the rights under a license
(for example, similar geographic market coverage, duration, exclusivity, limitation,
technology, and type of customer).
Verifiable objective information regarding royalty rates can be obtained, including rates
for agreements that confirm comparable economic rights for similar intellectual
property. Typically the best source of information would be other licensing agreements
made by the acquired company or acquiring company for comparable technologies.
Use of industry average rates or other broad benchmarks would not be acceptable.

2.1.15
The task force believes that the relief-from-royalty method rarely would be
appropriate in the valuation of specific IPR&D projects due to a lack of observable
comparable royalty rates. However, it may be appropriate as a means of measuring the
value of contributory assets needed to generate the expected cash flows from specific
IPR&D projects (for example, royalties paid for the use of trademarks, developed
product technology, base (or core) technology, subject to the points discussed in
paragraph 2.1.14). See paragraph 5.3.54 for guidance on contributory asset charges.
2.1.16
Multi-period excess earnings method. The multi-period excess earnings
method is a specific application of the discounted cash flow method under the income
approach. The principle behind the multi-period excess earnings method is that the
value of an intangible asset is equal to the present value of the incremental after-tax
cash flows attributable only to the subject intangible asset. The incremental after-tax
cash flows attributable to the subject intangible asset are then discounted to their
present value. This method is discussed in detail in chapter 5 of this Practice Aid.
2.1.17
Real option method. Recent finance and valuation literature describe
emerging methods and techniques for economic analysis and valuation employing the
use of option pricing models. Option pricing models (for example, binomial, econometric
[such as Shelton and Kassouf], and riskless-hedge arbitrage [such as Merton, Black
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Scholes, Noreen Wolfson, and Gastineau Madansky]) historically have been used to
value financial contracts, such as warrants and options. The use of these models
recently has been extended to value strategic choices (in effect, options) and assets
subject to strategic choices. This class of economic analysis and valuation modeling
has been referred to in the literature as “real options,” signifying its use with corporate
(real) assets as opposed to financial assets.
2.1.18
Real option methods, when used to value assets, may be classified as a
subset of the income approach because those methods are forward-looking. Real
option methods can be considerably different, in terms of calculations, from other
methods under the income approach. As opposed to viewing the future as a singular
best estimate outcome, or even multiple outcomes subject to probability factors used to
calculate expected value, real option methods look at the optionality inherent at various
future milestones, considering the success achieved at those various milestones and
the multiple probabilistic outcomes then to be contemplated.
2.1.19
Real option methods have begun to achieve acceptance as a superior
method for evaluating income streams subject to both uncertainty and choice. For
example, in the discounted cash flow method, when using very high discount rates
(such as with some early stage research project cash flows), the negative cash outflows
occur at the beginning of the estimation period (in which the present value interest
factor is still relatively significant), and the positive cash inflows occur at the end of the
estimation period (in which the present value interest factor has become exponentially
lower), thus often resulting in negative present values. Management often will still invest
in those projects because they have the choice either to stop investing or to continue
investing based on either failing to reach or reaching or exceeding certain targets at
certain time-based milestones. They are still willing, however, to invest small amounts in
a portfolio of projects (which they can discontinue midstream, on an individual project
basis) in anticipation of the occasional big payoff. A tradition-based observer might
conclude that management has acted irrationally to invest in a project with negative net
present value, while emerging theory might suggest that the discounted cash flow
method is inaccurate or incomplete when used in a circumstance of high risk
(uncertainty) and multiple-choice points in the future.
2.1.20
The use of real option methods has yet to become readily accepted as a
valuation tool, and the level of standardization among practitioners has not yet reached
a point for inclusion in this Practice Aid. The real option method warrants mention,
however, as it may be increasingly used in the future as a supplement to the basic
multiperiod excess earnings method described in this Practice Aid.
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CHAPTER 3
DEFINITION OF ASSETS ACQUIRED THAT ARE TO BE USED IN
RESEARCH AND DEVELOPMENT ACTIVITIES
3.1

INTRODUCTION

3.1.01
This chapter sets forth what the IPR&D Task Force believes are best
practices in defining assets acquired in a business combination that are to be
used in research and development (R&D) activities, including specific in-process
R&D (IPR&D) projects, for purposes of applying Financial Accounting Standards
Board (FASB) Interpretation No. 4, Applicability of FASB Statement No. 2 to
Business Combinations Accounted for by the Purchase Method, and related
accounting guidance. The task force notes that business combinations involving
the software, electronic devices, and pharmaceutical industries recently have
exhibited the greatest proportional amount (in terms of total value) of assets
acquired to be used in R&D activities. Accordingly, the task force chose examples
that focus on those industries.
3.1.02
This chapter’s “Introduction” and “Key Concepts” sections are supplemented
by section 3.3, “Explanatory Comments,” which expands on the definition and sets forth
the task force’s support for the determination of best practices. In addition, section 3.3
includes questions and the task force’s answers, which are intended to aid in the
application of the best practices.
3.1.03
FASB Statement of Financial Accounting Standards No. 2, Accounting for
Research and Development Costs, sets forth broad guidelines on the activities that
constitute R&D activities and defines R&D for purposes of applying generally
accepted accounting principles (GAAP) in the United States. In a business
combination, assets acquired to be used in R&D activities are separately
identifiable assets and each one is allocated a portion of the cost of the acquired
company based on its fair value. Assets to be used in R&D activities subsequently
are accounted for under FASB Interpretation No. 4, and are either reported as an
asset if an alternative future use exists for the asset or immediately charged to
income. Such separately identifiable assets include both tangible and intangible
assets, including intangible assets representing specific IPR&D projects to be
pursued by the combined enterprise. Each specific IPR&D project must have been
the result of activities undertaken by the acquired company, the costs of which
qualified as R&D costs under FASB Statement No. 2 and related guidance.
3.1.04
The following diagram illustrates an overall description of assets acquired in a
business combination. This Practice Aid focuses on the assets that are italicized and in
bold type.
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Assets Acquired
Not Used in R&D Activities

To Be Used in R&D Activities

Tangible

Intangibles

Goodwill

Intangibles
(including assets resulting
from R&D activities)

3.2

Tangible

Intangibles
(including specific IPR&D
projects)

KEY CONCEPTS

3.2.01
Best practices suggest that assets acquired to be used in R&D activities
should exhibit certain essential characteristics and one attribute, as described in the
following paragraphs.
3.2.02

•
•

Control—An acquiring company’s interest in each asset is controllable by the
enterprise (that is, the consolidated entity and its equity investees) so that it can
obtain benefit from the asset and control others’ access to the asset.
Economic benefit—An acquiring company anticipates that each asset singly, or in
combination with other assets of the combined enterprise, will be used in its postcombination R&D activities.

3.2.03

•

Characteristics of Assets to Be Used in R&D Activities

Attribute of Assets to Be Used in R&D Activities

Measurability—The fair value of each asset is estimable with reasonable reliability.

3.2.04
With respect to specific IPR&D projects to be recognized initially as assets to
be used in R&D activities (which are then immediately expensed), there also is
persuasive evidence that each of the projects has substance and is incomplete.

•
•

Substance—For a specific IPR&D project of an acquired company to give rise
initially to an asset, the acquired company performed R&D activities that constitute
more than insignificant efforts and that (a) meet the definition of R&D under FASB
Statement No. 2 and (b) result in the creation of value.
Incompleteness—Incompleteness means there are remaining risks (for example,
technological or engineering) or certain remaining regulatory approvals at the date of
acquisition. Overcoming those risks or obtaining the approvals requires that the
combined enterprise will incur additional R&D costs.

3.2.05
In summary, for costs to be allocated to assets acquired to be used in R&D
activities, the task force believes that each asset should possess the characteristics of
control and anticipated economic benefit and the attribute of its fair value being
estimable with reasonable reliability. Further, if the asset to be used in R&D activities is
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a specific IPR&D project, that project should have substance and be incomplete. Finally,
for the allocated cost to be charged to income immediately, the asset acquired should
have no alternative future use, as discussed in the following paragraphs.
3.2.06
Alternative future use. If an asset acquired to be used in a current R&D
activity has no alternative future use, FASB Interpretation No. 4 requires that the portion
of the purchase price allocated to that asset be immediately charged to income by the
combined enterprise. If there is an alternative future use that is identified by the
acquiring company at the acquisition date or through the allocation period, the purchase
price allocated to that asset is capitalized by the combined enterprise (an acquired
intangible is capitalized if it meets the criteria in paragraph 39 of FASB Statement No.
141, Business Combinations).
3.2.07
For an asset acquired for use in an R&D activity to have an alternative future
use, the task force believes that (a) it is reasonably expected1 that the combined
enterprise will use the asset acquired in the alternative manner and anticipates
economic benefit from that alternative use, and (b) the combined enterprise’s use of the
asset acquired is not contingent on further development of the asset subsequent to the
acquisition date (that is, the asset can be used in the alternative manner in the condition
in which it existed at the acquisition date).
3.2.08
If the use of the acquired asset is only in one or more other R&D projects of
the combined enterprise that have commenced2 at the acquisition date, the task force
believes that use represents a present (as opposed to a future) R&D activity and the
purchase price allocated to that asset should be immediately charged to income. If the
asset’s use (see paragraph 3.2.07) is in an R&D project to be commenced at a future
date, the task force believes that such use is an alternative future use and that the
purchase price allocated to that asset should be capitalized.
3.2.09
The task force believes that the determination of whether there is an
alternative future use for an asset is based on specific facts and circumstances.
However, for an acquired tangible asset to be used in R&D activities (for example,
computer testing equipment used in an R&D department), the task force believes that
there is a rebuttable presumption that such asset has an alternative future use (see
paragraph 3.2.07) because that asset generally has separate economic value
independent of the successful completion and commercialization of the IPR&D project.
This presumption would be overcome, for example, if it were reasonably expected that
the combined enterprise will use that asset only in a specific IPR&D project that had
commenced before the acquisition date.

1

For purposes of this Practice Aid, reasonably expected is used in the context of its meaning as provided
in footnote 18 of paragraph 25 of Financial Accounting Standards Board (FASB) Concepts Statement No.
6, Elements of Financial Statements (that is, believed on the basis of available evidence or logic but is
neither certain nor proved). The task force believes that reasonably expected connotes a slightly greater
than 50 percent chance of occurring.
2 A research and development (R&D) project is considered to have commenced when more than
insignificant costs that qualify as R&D costs in accordance with FASB Statement of Financial Accounting
Standards No. 2, Accounting for Research and Development Costs, have been incurred.
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3.2.10
Whether an acquired intangible asset to be used in R&D activities has an
alternative future use (see paragraphs 3.3.06 and 3.2.07) depends on specific facts and
circumstances. Facts and circumstances that suggest the presence of an alternative
future use include: (a) it is reasonably expected that the combined enterprise will use
the intangible asset being acquired in its current condition in another currently
identifiable R&D project to be commenced at a future date (for example, the acquired
intangible asset represents base [or core] technology that is reasonably expected to be
used in future R&D projects), or (b) a specific IPR&D project comprises a number of
subprojects or parts, certain of which are complete and for which it is reasonably
expected that the subprojects or parts will be used other than in a current R&D project
(see paragraphs 3.3.58 and 3.3.59). Those circumstances suggest that the acquired
intangible assets have alternative future uses.
3.2.11
Facts and circumstances that suggest the absence of an alternative future
use include intangible assets that represent incomplete specific IPR&D projects that are
narrow in focus and for which the technology involved has the likely potential of being
obsolete if the acquired specific IPR&D project fails or is terminated. Those
circumstances suggest that if the specific IPR&D project were to be unsuccessful,
management of the combined enterprise would abandon (or potentially block a
competitor from, or both) the specific IPR&D project and direct its future R&D spending
to areas using a different technology. Therefore, the specific IPR&D project as it existed
at the date of the business combination would not have an alternative future use.
3.2.12
However, if the combined enterprise expects to sell an acquired tangible
or intangible asset associated with the acquired company’s R&D activities, the task
force believes that the asset would be treated as an asset held for sale. The FASB
and the Emerging Issues Task Force (EITF) have established criteria that should
be satisfied to demonstrate commitment to a disposition (see FASB Statement No.
121, Accounting for the Impairment of Long-Lived Assets and for Long-Lived
Assets to Be Disposed Of, and EITF Issues No. 87-11, Allocation of Purchase Price
to Assets to Be Sold, and No. 95-21, Accounting for Assets to Be Disposed Of
Acquired in a Purchase Business Combination). The task force believes that an
asset held for sale would not be accounted for under the guidance of FASB
Statement No. 2 and FASB Interpretation No. 4; instead, the asset would be
reported by the combined enterprise as an asset held for sale and recorded at an
amount equal to its fair value, less cost to sell.

3.3
3.3.01

EXPLANATORY COMMENTS
Scope of R&D Activities

3.3.02
Paragraphs 8 through 10 of FASB Statement No. 2 set forth broad guidelines
on the activities whose costs are and are not to be classified as R&D. More particularly,
paragraphs 9 and 10 identify activities that are and are not within FASB Statement No.
2’s definition of R&D activities. These paragraphs are reproduced here (paragraph
3.3.16 discusses R&D activities conducted for others):
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9.

The following are examples of activities that typically would be included
in [R&D]…:
a. Laboratory research aimed at discovery of new knowledge.
b. Searching for applications of new research findings or other knowledge.
c. Conceptual formulation and design of possible product or process
alternatives.
d. Testing in search for or evaluation of product or process alternatives.
e. Modification of the formulation or design of a product or process.
f. Design, construction, and testing of preproduction prototypes and models.
g. Design of tools, jigs, molds, and dies involving new technology.
h. Design, construction, and operation of a pilot plant that is not of a scale
economically feasible to the enterprise for commercial production.
i. Engineering activity required to advance the design of a product to
the point that it meets specific functional and economic requirements
and is ready for manufacture.

10. The following are examples of activities that typically would be excluded
from [R&D]…:
a. Engineering follow-through in an early phase of commercial production.
b. Quality control during commercial production including routine testing
of products.
c. Trouble-shooting in connection with break-downs during commercial
production.
d. Routine, on-going efforts to refine, enrich, or otherwise improve upon
the qualities of an existing product.
e. Adaptation of an existing capability to a particular requirement or
customer’s need as part of a continuing commercial activity.
f. Seasonal or other periodic design changes to existing products.
g. Routine design of tools, jigs, molds, and dies.
h. Activity, including design and construction engineering, related to the
construction, relocation, re-arrangement, or start-up of facilities or
equipment other than (1) pilot plants…and (2) facilities or equipment
whose sole use is for a particular research and development project.
i. Legal work in connection with patent applications or litigation, and the
sale or licensing of patents.
In addition to paragraph 10 of FASB Statement No. 2, other authoritative literature that
limits the scope of activities that qualify as R&D activities includes—

•

•
•

Paragraph 4 of FASB Interpretation No. 6, Applicability of FASB Statement No. 2 to
Computer Software, which states, “The Board’s intent in Statement No. 2 was that
the acquisition, development, or improvement of a process by an enterprise for use
in its selling or administrative activities be excluded from the definition of research
and development activities.”
Paragraph 2 of FASB Statement No. 2, which excludes from its scope R&D activities that
are conducted for others under a contractual arrangement (for which FASB Statement
No. 68, Research and Development Arrangements, provides accounting guidance).
Statement of Position (SOP) 98-1, Accounting for the Costs of Computer Software
Developed or Obtained for Internal Use, which provides that costs incurred to
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develop internal-use software are not R&D costs unless they meet the limited
exceptions provided in paragraph 18 of that SOP. Paragraph 12 of that SOP states
that internal-use software has the following characteristics: (a) the software is
acquired, internally developed, or modified solely to meet the entity’s internal needs
and (b) during the software’s development or modification, no substantive plan exists
or is being developed to market the software externally. The task force believes that
the circumstances when a project to develop internal-use software would be
accounted for as a specific IPR&D project are rare. (Also see EITF Issues No. 00-2,
Accounting for Web Site Development Costs, and No. 00-3, Application of AICPA
Statement of Position 97-2 to Arrangements That Include the Right to Use Software
Stored on Another Entity's Hardware.)
3.3.03

Questions and Answers3

3.3.04
Question 1: Company A acquired Company X in a business combination.
Company X produces a personal financial management software package and currently is
marketing Version 4.2 of that product. Company X provides periodic upgrades to its
customers who have subscribed to post-contract customer support—these releases are
sometimes referred to in the industry by the term right of dot releases. At the acquisition date,
development of Version 4.3 was underway and was approximately 60 percent complete. Do
the efforts to develop Version 4.3 meet the scope requirements of R&D activities?
3.3.05
Answer: No. Paragraph 10 of FASB Statement No. 2 provides examples of
activities that typically are excluded from its definition of R&D. In describing activities
that are not typically R&D, paragraph 10(d) says that “routine, on-going efforts to refine,
enrich, or otherwise improve upon the qualities of an existing product” do not meet the
definition of R&D. The task force believes that right of dot upgrades generally are used
to identify and correct minor programming errors, or “bugs,” and do not significantly
improve or extend the life of the existing product. The activities described with respect
to the development of Upgrade 4.3 fall within the type of activities described in
paragraph 10(d) of FASB Statement No. 2 and, therefore, are not R&D activities. The
purchase price allocated to Version 4.2 should reflect the value of the improvements
made through the efforts to develop Version 4.3 and would be capitalized as an
intangible asset provided the asset meets the criteria in paragraph 39 of FASB
Statement No. 141 for separate recognition apart from goodwill. In contrast, the task
force believes that left of dot upgrades generally are used to identify significant
enhancements to the features and functionality of an existing product.
3.3.06
Question 2: Company A acquired Company X, a telecommunications company,
in a business combination. At the acquisition date, Company X was developing new
software to run its switches that are necessary for various telephone services (for example,
voice mail and call forwarding) that it provides to its customers. Company X does not plan
to sell, license, or market the software under development; rather, Company X plans to use
the software internally to help provide the telephone services to its customers. Company A
decided that the combined enterprise would continue the development of the new software.

3 The task force developed the following Q&As to provide guidance on the scope of FASB Statement No. 2
and related accounting literature.
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Do the efforts to develop the new software meet the scope requirements of an IPR&D
project (that is, an asset to be used in R&D activities)?
3.3.07
Answer: No. To qualify as IPR&D, the activities and costs should be R&D, as
described in FASB Statement No. 2 and related guidance. SOP 98-1 provides that the
costs related to the development of the new software that will be used internally are not
R&D costs. In that case, the purchase price allocated to the internal-use software
project should be capitalized (provided the asset meets the criteria in paragraph 39 of
FASB Statement No. 141 for separate recognition apart from goodwill) and accounted
for in accordance with the provisions of SOP 98-1. However, if Company X also were
engaged in licensing software as an element of its switching equipment and had a
substantive plan in existence or under development to externally market the acquired
software under development and Company A intended to carry through on that plan, the
activities and costs of the new software under development would qualify as R&D in
accordance with FASB Statement No. 2 and the software development project would
meet the scope requirements of an IPR&D project (that is, an asset to be used in R&D
activities). Costs on that project incurred subsequent to the consummation of the
business combination would be accounted for in accordance with the provisions of
FASB Statement No. 86.
3.3.08
Question 3: Company A acquired Company X in a business combination.
Company X produces a well-known cardiovascular product to treat hypertension.
Company X has been working on a process change to increase its production yields
and create more efficiency in its manufacturing process. The process change is
significant and considered to be nonroutine. Food and Drug Administration (FDA)
approval of the process change is required due to the nature of the expected change
and the approval had not been obtained at the acquisition date. Do the efforts to
develop the process change meet the scope requirements of R&D activities?
3.3.09
Answer: Yes. Paragraph 9 of FASB Statement No. 2 provides examples of
activities that typically are included in R&D activities. The task force believes that
because FDA approval of the process change is required, the process modifications fall
within example 9(e), which specifically addresses modification of the formulation or
design of a product or process.
3.3.10

Control, Economic Benefit, and Measurability

3.3.11
The task force notes that both Accounting Principles Board (APB) Opinion
No. 16, Business Combinations (which is superseded by FASB Statement No. 141),
and FASB Interpretation No. 4 were promulgated before the FASB developed its
Concepts Statements. Consequently, the standards for accounting for assets acquired
to be used in R&D activities did not explicitly consider the notions of control, economic
benefit, and measurability contained in the Concepts Statements. The task force also
notes that the FASB has indicated a possible future interest in reconsidering the
requirements of FASB Statement No. 2 and FASB Interpretation No. 4.
3.3.12
The task force noted that (a) the requirement that an asset acquired to be
used in R&D activities that has no alternative future use is accounted for as if it were an
asset, albeit only for purposes of allocating the purchase price, and (b) the FASB’s
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Concepts Statements (No. 2, Qualitative Characteristics of Accounting Information; No.
5, Recognition and Measurement in Financial Statements of Business Enterprises; and
No. 6, Elements of Financial Statements) address characteristics of assets. The task
force was particularly challenged by FASB Concept Statement No. 6’s definition of an
asset representing “probable future economic benefits” in light of the FASB’s basis for
conclusions in paragraph 39 of FASB Statement No. 2, which states: “There is normally
a high degree of uncertainty about the future benefits of individual research and
development projects, although the element of uncertainty may diminish as a project
progresses.” The comments in the following paragraphs provide the task force’s bases
for setting forth as a best practice that assets acquired to be used in R&D activities
possess the characteristics of control and anticipated economic benefit and the attribute
of being estimable with reasonable reliability.
3.3.13
Control. The characteristics of control and economic benefit that are
incorporated by the task force in the definition of assets acquired to be used in R&D
activities are derived from the definition of an asset in paragraphs 25 and 26 of FASB
Concepts Statement No. 6. That definition states the following:
Assets are probable future economic benefits obtained or controlled by a
particular entity as a result of past transactions or events…. An asset has
three essential characteristics: (a) it embodies a probable future economic
benefit that involves a capacity, singly or in combination with other assets, to
contribute directly or indirectly to future net cash inflows, (b) a particular entity
can obtain the benefit and control others’ access to it, and (c) the transaction
or other event giving rise to the entity’s right to or control of the benefit has
already occurred.
3.3.14
With respect to control, examples of circumstances that provide evidence that
the acquiring company obtains the benefit of and controls others’ access to an asset to
be used in R&D activities include the following:

•
•

The combined enterprise has the ability to separate or divide, and sell, transfer,
license, rent, or exchange its rights to the asset acquired to be used in R&D
activities.
The combined enterprise has proprietary intellectual property rights, which it
believes could be successfully defended if its rights thereto were to be legally
challenged.

Proprietary intellectual property that has not been patented or otherwise been legally
protected may have been, or could be in the future, independently developed or
duplicated by a limited number of third parties. Such a circumstance could give rise to
more than one party having access to substantially the same intellectual property (for
example, a nonexclusive license). The task force believes that such a circumstance
does not violate the control characteristic merely because the third parties cannot be
legally estopped from using their similar intellectual property or undertaking such
development activities. However, the ability of third parties to duplicate an enterprise’s
intellectual property, or their possession of similar intellectual property, would diminish
its fair value.
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3.3.15
The combined enterprise may control some but not all rights to the benefits of
a particular asset. For example, assume the acquired company had the exclusive right
to the exploitation and control of the results of a specific IPR&D project in the United
States and an unrelated enterprise had the exclusive rights to non-U.S. exploitation of
the results. The task force believes that the U.S. exploitation rights possessed by the
combined enterprise would meet the control characteristic.
3.3.16
Accounting for the costs of R&D activities conducted for others under a
contractual arrangement is excluded from the scope of FASB Statement No. 2 and
instead falls within the scope of FASB Statement No. 68. Therefore, assets acquired to
be used in R&D activities do not include the ongoing benefit arising from the
continuation of those R&D activities being conducted by the acquired company for
others under a contractual arrangement, even if the combined enterprise might receive
economic benefit from its participation in that arrangement. For example, a contractual
R&D arrangement previously entered into by the acquired company might have
provided that the acquired company will realize additional economic benefits based on
the subsequent exploitation by the funding party of any assets that might result from the
R&D efforts of the acquired company. The task force believes that such potential
benefits constitute contingent consideration owed to the acquired company for having
performed the contract R&D activities and do not constitute control of the benefits of the
R&D. The potential benefit from such right may represent an intangible asset for
purposes of applying the allocation provisions of FASB Statement No. 141. On the other
hand, if an R&D arrangement grants the acquired company rights to exploit all or a part
of the resulting technology, the task force believes that such rights would satisfy the
control characteristic.
3.3.17
Economic Benefit. A characteristic of an asset acquired to be used in R&D
activities set forth herein is that it embodies an anticipated future economic benefit that
involves an entity using such asset in its postcombination R&D activities. The task force
acknowledges that an anticipated future economic benefit is less likely of occurring than
a probable future economic benefit, which is part of the definition of an asset in FASB
Concepts Statement No. 6 (as cited in paragraph 3.3.12 of this Practice Aid). However,
the task force believes that many of the assets acquired to be used in R&D activities
would not satisfy a requirement that there be a probable future economic benefit for
many of the same reasons that the FASB concluded in FASB Statement No. 2 that R&D
costs should not be capitalized as assets.
3.3.18
In circumstances in which an alternative future use for an asset acquired to
be used in R&D activities exists (see paragraph 3.2.06), the task force believes that
such use would demonstrate a probable future economic benefit that would inure to the
combined enterprise when the asset is consumed. Accordingly, that asset would be
capitalized provided the asset meets the criteria in paragraph 39 of FASB Statement
No. 141 for separate recognition apart from goodwill. If there is no alternative future use
or if the alternative use is another current IPR&D project, the asset acquired to be used
in R&D activities is similar to any R&D cost. The FASB cited in the basis for its
conclusions in paragraph 45 of FASB Statement No. 2: “Although future benefits from a
particular research and development project may be foreseen, they generally cannot be
measured with a reasonable degree of certainty.” As a result, the FASB concluded that
the cost of R&D should not be capitalized.
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3.3.19

Economic Benefit: Question and Answer 4

3.3.20
Question: Company A acquired Company X in a business combination. At the
acquisition date, Company X was pursuing completion of ten in-process research and
development projects. In evaluating Company X’s R&D activities during the due-diligence
process before the acquisition date, management of Company A concluded that two of
the in-process projects would not be pursued subsequent to the consummation of the
business combination. Company A also concluded that there was no alternative future
use for the two projects, nor did it have any expectation to sell the projects in their present
incomplete states. Therefore, management of Company A concluded it would abandon
further development of the two projects. Do the two projects have an anticipated
economic benefit to Company A?
3.3.21
Answer: No. The task force believes that specific IPR&D projects that (a) will
not be used in the activities of the combined enterprise and (b) are believed to have no
value on a stand-alone basis result in no economic benefit to the acquiring company.
Therefore, Company A should not allocate any portion of its purchase price of Company
X to the two projects.
3.3.22
Measurability. The attribute of fair value being estimable with reasonable
reliability, incorporated by the task force in the description of an asset acquired to be
used in R&D activities, is derived from paragraph 23 of FASB Concepts Statement No.
6, which states the following:
To be included in a particular set of financial statements, an item must not only
qualify under the definition of an element but also meet criteria for recognition
and have a relevant attribute (or surrogate for it) that is capable of reasonably
reliable measurement or estimate. Thus some items that meet the definitions
may have to be excluded from formal incorporation in financial statements
because of recognition or measurement considerations. [Emphasis added]
3.3.23
Paragraph 76 of FASB Concepts Statement No. 5 provides that “information
about some items that meet a definition may never become sufficiently reliable at a
justifiable cost to recognize the item….” [Emphasis added] In citing a “definition,” FASB
Concepts Statement No. 5 is referring to definitions of the elements of financial
statements found in FASB Concepts Statement No. 3, which has since been
superseded by FASB Concepts Statement No. 6, cited earlier. Paragraph 75 of FASB
Concepts Statement No. 5 states, “To be reliable, information about an item must be
representationally faithful, verifiable, and neutral.” Paragraph 89 of FASB Concepts
Statement No. 2 states that verifiability:
… means no more than that several measurers are likely to obtain the same
measure. It is primarily a means of attempting to cope with measurement
problems stemming from the uncertainty that surrounds accounting measures
and is more successful in coping with some measurement problems than
others. Verification of accounting information does not guarantee that the
information has a high degree of representational faithfulness.…
4

The task force developed the following Q&A to provide guidance on economic benefit.
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Paragraphs 72 through 74 of FASB Concepts Statement No. 7 address the relevance
and reliability of present value measurements.
3.3.24
The task force concluded that the measurement criteria for assets to be used in
R&D activities and to be accounted for pursuant to FASB Interpretation No. 4 should be set
at the level of “estimable with reasonable reliability.” The fact that the portion of the
purchase price allocated to assets to be used in R&D activities is immediately charged to
income does not obviate the requirement that such assets be estimable with reasonable
reliability. There may be circumstances in which the fair value of an intangible asset to be
used in R&D activities cannot be estimated with reasonable reliability for accounting
purposes. In those circumstances, that asset would not be recognized separately in the
financial statements; rather, it would become an element of reported goodwill.
3.3.25
The task force believes that the existence of an independent valuation report,
in and of itself, is not sufficient evidence that the fair value of an asset acquired to be
used in R&D activities is estimable with reasonable reliability for accounting purposes.
Valuations that are consistent with the best practices methodologies discussed in
chapters 2 and 5 of this Practice Aid may not result in reasonably reliable estimates of
fair value because the variability of the estimates underlying the valuation may be so
great that different valuation specialists would estimate fair values that are not within a
reasonable range.
3.3.26
Circumstances in which the fair value of an asset acquired to be used in R&D
activities can be estimated with reasonable reliability might include a specific IPR&D
project for which the economic benefit of the product, service, or process anticipated
from the R&D effort is sufficiently determinable so a reasonably reliable estimate of the
future expected net cash flows can be made based on assumptions that are verifiable.
For example, the expected attributes of a product under development may be
sufficiently known, and the combined enterprise’s knowledge of the expected market
based, in part, on its operating experience in those markets would allow the acquiring
company to estimate with reasonable reliability the—

•
•
•
•
•
•

Size and duration of the market for the product.
Time and costs to commercialize and market.
Potential customers.
Share of market.
Selling price.
Production and related costs for the product.

3.3.27 The task force believes that those circumstances would allow one to conclude
that the fair value of the asset acquired to be used in R&D activities can be estimated
with reasonable reliability. If the attributes listed above had been identified and
contemporaneously documented, and the assumptions supported before the acquisition
date, the task force believes that the likelihood that a reasonably reliable estimate of fair
value could be determined is increased. The converse also would be true.
3.3.28
In measuring the fair value of a specific IPR&D project that is anticipated to
significantly improve an existing product, service, or process, the task force believes
that the fair value is limited to the economic benefit derived from the significant
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improvement. Therefore, as discussed in chapter 5 of this Practice Aid, the fair value of
any such project would exclude the value of the base (or core) technology to which the
improvements are to be made. The fair value of the base (or core) technology
represents a separate intangible asset acquired that is to be allocated (based on its fair
value) a portion of the cost of the acquired company provided the base (or core)
technology meets the criteria in paragraph 39 of FASB Statement No. 141 for separate
recognition apart from goodwill.
3.3.29
In addition, the fair value of the specific IPR&D project excludes the value of
the acquiring company’s existing assets that are unique to the acquiring company and
that are anticipated to contribute to the economic benefits to be realized by the
combined enterprise upon completion of the specific IPR&D project (referred to as
buyer-specific synergies).5 See chapter 5 of this Practice Aid for a discussion of
methodologies to be used in determining the fair value of a specific IPR&D project, base
(or core) technology, and the effects of buyer-specific synergies.
3.3.30

Measurability: Questions and Answers6

3.3.31
Question 1: Company A acquired Company X in a business combination. Two
months before the combination, Company X had initiated an IPR&D project that had
progressed to the point that its substance could be demonstrated at the acquisition
date. Nevertheless, because the time envisioned to complete the project was so long,
management, in consultation with valuation specialists, concluded that, under the
traditional present value approach, a discount rate of 70 percent was appropriate to
reflect the completion and market risks in measuring the present value of expected
future net cash flows. Does the use of such a large discount rate provide evidence that
the fair value of the specific IPR&D project is not estimable with reasonable reliability?
3.3.32
Answer: Not necessarily. If sufficient evidence exists to support the
assumptions used to value the IPR&D project and the conclusion is that the valuation
was reasonably reliable (and, as a result, verifiable), the task force believes that the use
of a 70 percent discount rate is not evidence, by itself, that the resulting estimate of fair
value is not reasonably reliable. See chapter 5 of this Practice Aid for best practices in
selecting discount rates under the traditional present value approach.
3.3.33
Question 2: Company A acquired Company X in a business combination.
Company X is engaged in the biotechnology business. At the time of the acquisition,
Company X had a compound in phase II clinical trials (efficacy trials in a small
population of humans) for the indications of treatment of osteoporosis and breast
cancer. Compounds in this stage of development for Company X have historically had
approximately a 20 percent chance of ultimately receiving regulatory marketing approval
by the FDA. Company A’s experience with the FDA approval process for similar
compounds and that of other market participants allows it to reasonably estimate the
time required for final FDA approval. Even though a specific manufacturing plan does
not yet exist, Company A can make estimates, which it believes are reasonable, of the
5

Paragraph B174 of FASB Statement No. 141, Business Combinations, provides that an entity may use its
estimates of cash flows if market participant assumptions are not available without undue cost and effort.
6 The task force developed the following Q&As to provide guidance on measurability.
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costs to manufacture and sell the drug and how the drug will be priced based upon its
and market participants’ experiences with other drugs. In the pharmaceutical industry,
once the market has been identified, a company generally can determine the market
size, the competition that exists or will exist in that market, and an estimate of the
market share it may be able to obtain. Can Company A estimate with reasonable
reliability the fair value of Company X’s specific IPR&D project?
3.3.34
Answer: Yes. Because the potential markets for the product under
development have been identified and future costs can be reasonably estimated, the task
force believes that Company A should be able to estimate the fair value with reasonable
reliability. The low probability of success is not evidence, by itself, that the resulting
estimate is not reasonably reliable. The valuation of each of the projects should consider
their individual stage of development, as discussed in paragraph 5.3.85.
3.3.35
Question 3: Company A acquired Company X in a business combination.
Company X is engaged in the development and marketing of software products. At the
date of acquisition, Company X was developing a new version of an existing product
that it believed would significantly extend the functionality and improve the operating
characteristics of the current product. Nevertheless, the new version is still expected to
process data for the same purpose as the present version and carry over much of the
design characteristics of its present version. Does the value of the technological
processes incorporated in the existing product and the institutional knowledge with
respect to the design of that product represent base (or core) technology whose value
would be excluded from the value of the specific IPR&D project to develop the new
version of the software product?
3.3.36
Answer: Yes. See chapter 5 of this Practice Aid for a discussion of best
practices in the measurement of the fair value of the base (or core) technology.
3.3.37
Question 4: Company A acquired Company X, a large company with operations in
a variety of business segments, in a business combination. For the previous six months,
Company X had been pursuing an R&D project to develop a “breakthrough” technology that
would allow for the production of small-scale nuclear reactors suitable for residential use. A
development plan that identified the anticipated significant technological hurdles had been
prepared and some of those hurdles had already been overcome, as documented in minutes
to the periodic status meetings among project managers and others in Company X.
Accordingly, Company X concluded that the project had substance. However, due to the
novel technologies that Company X hoped to develop and employ, it had not been able to
reasonably estimate the costs to complete the project, the potential demand for the
anticipated new product, and the manufacturing costs. Can the fair value of Company X’s
specific IPR&D project be estimated with reasonable reliability under the multiperiod excess
earnings methodology (as discussed in paragraph 5.3)?
3.3.38
No. Though Company X’s specific IPR&D project has substance and is
incomplete, the task force believes that the circumstances described would not permit
the fair value of the project to be determined under the multi-period excess earnings
methodology because any expected future net cash flows could not be estimated with
reasonable reliability, in part because the assumptions used would not be verifiable.
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3.3.39

Specific IPR&D Projects

3.3.40
R&D projects are managed in a variety of ways and, as a result, it is not
always clear when a specific project has substance or whether it has been completed.
One way to view an R&D project is to consider it as having a life cycle, which in a basic
form, might consist of four phases depicted below. Within the earlier phases, the
attribute of substance gradually evolves to the point at which it can be demonstrated;
within the later phases, the project reaches a point at which it is no longer considered
incomplete. At some point, concurrent with or subsequent to a project having first
demonstrated substance, the acquiring company likely will be able to estimate the fair
value with reasonable reliability. Those four phases (more than one of which may be
occurring simultaneously) are as follows:
a.

b.

c.

d.

Conceptualization—This phase entails coming up with an idea, thought, new
knowledge, or plan for a new product, service, or process, or for a significant
improvement to an existing product, service, or process, or it may represent a
decision by a company to focus its research activities within certain core
competencies. Management might make an initial assessment of the potential
market, cost, and technical issues for ideas, thoughts, or plans to determine
whether the ideas can be developed to produce an economic benefit.
Applied research—This phase represents a planned search or critical investigation
aimed at the discovery of additional knowledge in hopes that it will be useful in
defining a new product, service, or process that will yield economic benefits, or
significantly improve an existing product, service, or process that will yield
economic benefits. In addition, work during this phase assesses the feasibility of
successfully completing the project and the commercial viability of the resulting
expected product, service, or process.
Development—This phase represents the translation of research findings or other
knowledge into a detailed plan or design for a new product, service, or process, or
for a significant improvement to an existing product, service, or process, and
carrying out development efforts pursuant to the plan.
Preproduction—This phase represents the business activities necessary to
commercialize the asset resulting from R&D activities for the entity’s economic benefit.

Managers of the R&D project may require, at various points (or gates) during the life
cycle, an evaluation of the probability of success and the potential economic results. At
each gate, a decision may be made about whether to continue funding the project. (See
exhibit 3-1 for a further description of phases that are particular to the pharmaceutical
industry in the United States.)
3.3.41

A depiction of a project life cycle is as follows:

Conceptualization
Development
Idea
concept

Applied Research
Product
Product
definition
feasibility

Development

Preproduction

3.3.42
A future product, service, or process is defined and its potential economic benefits
are identified at some point within this life cycle after the project’s conceptualization. After
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the time that a future product, service, or process has been defined and its potential
economic benefits have been identified, a specific IPR&D project begins to demonstrate
substance. This generally occurs when more than insignificant R&D efforts have been
expended after the characteristics of the future product, service, or process have been
defined and management has approved continued project funding. In addition,
management has been able to make reasonably reliable estimates of the project’s
completion date, consider the impact of potential competition, and make reasonably
reliable estimates of costs to complete, sales volumes, average selling prices, and related
costs over the anticipated economic life of the expected product, service, or process. The
task force believes that at that time or at a later point, the project is far enough along to
enable an entity to make a reasonably reliable estimate of its fair value. See paragraph
3.3.44 for guidance on the attribute of substance.
3.3.43
At some point before commercialization (that is, before earning revenue), and
possibly before the end of the development or pre-production stages, the task force
believes that the R&D project is no longer considered incomplete for accounting
purposes (that is, ultimate completion of the project has occurred) and an asset
resulting from R&D emerges from what was previously an asset used in R&D. See
paragraph 3.3.54 for explanatory comments on the attribute of incompleteness.
3.3.44

Specific IPR&D Projects—Substance

3.3.45
The task force believes that any specific IPR&D project that has progressed
beyond project conceptualization to a degree that enables its fair value to be estimated
with reasonable reliability has substance. In contrast, if the acquired company has only
articulated a concept, this does not constitute substantive activities, nor does it create a
circumstance in which the acquiring company estimates the fair value of that concept
with sufficient reliability to meet the measurability attribute that defines an asset to be
used in R&D activities.
3.3.46
In many circumstances, there will be written evidence of the specific IPR&D
project’s economic and technical objectives (including identification of its technological,
engineering, and regulatory risks) in the acquired company’s records. In addition, there
will be periodic contemporaneously prepared evidence of the progress being made as
the specific IPR&D project evolves to completion. That data will aid in verifying that the
acquired IPR&D project had substance at the acquisition date. To the extent that the
economic objectives originally set forth by the acquired company are significantly
different from those reflected in the valuation of the IPR&D project by the acquiring
company, best practices are to reconcile and explain those differences.
3.3.47

Questions and Answers7

3.3.48
Question 1: Company A, a pharmaceutical company, acquired Company X, a
biotechnology company engaged in cancer research and development, in a business
combination. Company X is developing a small molecule compound that is thought to
have a therapeutic application in the cancer market. The company has incurred R&D
7

The task force developed the following Q&As to provide guidance on substance.
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costs in (a) screening approximately 5,000 compounds, (b) identifying eight lead
compounds, and (c) determining that they have the desired effect on the biological
“target” (a part of the body, such as a protein, receptor, or gene; or something foreign to
the body, such as a bacteria or virus that appears to play an important role in causing
certain diseases), whose function is understood and has been validated. The eight
compounds are considered potential drug development candidates and Company X has
gathered sufficient scientific data to decide to advance these compounds to phase I
clinical testing (that is, testing in humans). Based on Company X’s understanding of the
biological target’s function and scientific data available in the public domain, Company X
is able to make some general predictions on potential therapeutic benefits in treating
several types of cancer and side effects of the compounds, if successful. The activities
already undertaken by Company X have resulted in its reporting R&D expenses. A
multi-tumor cancer drug represents a significant market opportunity. While no detailed
market research has been conducted, market projections have been prepared based on
patient population and cancer incidence rates. The complexity of the manufacturing
process has not been thoroughly evaluated; however, manufacturing costs can be
reasonably estimated based on the complexity of the synthesis process of the current
lead compounds and raw material requirements.
Patent searches have been
completed with no findings of any patents that would block Company X’s plans for
further development and commercialization of the compounds. In addition, Company X
has filed for patent protection of these compounds. Have sufficient R&D activities been
undertaken for this small molecule program, such that, at the acquisition date, the
acquired IPR&D projects have substance and can be valued with reasonable reliability?
3.3.49
Answer: Yes. However, the decision about whether fair value can be
measured with reasonable reliability requires a significant amount of judgment. The
eight compounds that may lead to possible drug development candidates have
progressed far enough through the R&D life cycle to have substance and Company X
can estimate the fair value of these projects with reasonable reliability. Company X has
selected a specific biological target whose function is understood and has been well
validated. Company X has determined that the eight lead compounds have the desired
effect on the biological target and do not interact with other tissues in the body.
Consequently, it is reasonable to anticipate that these compounds may lead to a drug
for treating cancer. Company X has gathered enough scientific data to decide to
advance these compounds to phase I clinical testing. Market potential can be
reasonably estimated because incidence of cancer, by tumor type, is well documented
and tracked by several reputable independent organizations. Market share for a
particular compound can be estimated by reviewing data currently available in the public
domain that tracks patented programs, by biologic target, from preclinical through
market launch. Thus, Company X can determine the number of competitors conducting
research on a particular biologic target and estimate the potential order of entry given
the competitors’ stages of development. Company X can also estimate price and
revenue potential based on currently available drugs, incidence rates by specific tumor
type, and therapeutic benefit. Manufacturing costs can be reasonably estimated based
on the complexity of the synthesis process of the current lead compounds and raw
material requirements. Since the potential revenues and costs can be reasonably
estimated based upon data available in the public domain, the fair value of the eight
compounds, albeit at an early-stage development, can be measured with reasonable
reliability. While the facts in this example support the conclusion that the fair value of the

34

compounds can be measured with reasonable reliability, other situations with changes
from the fact pattern presented here may result in a different conclusion.
3.3.50
Question 2: Company A acquired Company X in a business combination.
Company X designs and markets switches for sale to telecom companies, which use
the switches to route telephone communications through their systems. Company X
developed a routing technology for a switch that it believes will be pivotal in creating the
next generation of switches to route Internet and video data over telephone systems
(that is, it had completed the conceptualization and research phases of the project).
Before the acquisition, Company X had surveyed several telecom companies to assist
in designing the specifications of the proposed switch. In addition, Company X had a
documented plan for development of the switches, which it expected would be complete
in eighteen months. As of the date of the acquisition, the R&D project had been
underway for two months. Have sufficient R&D activities been undertaken such that, at
the date of acquisition, the specific IPR&D project has substance?
3.3.51
Answer: Yes. As of the date of the acquisition, Company X had completed the
conceptualization and research phases of the project and was partially through
development of the new switch. As a result, the project satisfied the attribute of
substance of an asset acquired to be used in R&D activities. The facts presented are
insufficient to determine whether the measurability attribute can be satisfied. However, if
the measurability attribute could be satisfied, the fair value of the project would be
affected by the early stage of development.
3.3.52
Question 3: Company A acquired Company X in a business combination.
Company X was an established contract manufacturer of electronic components. An
important aspect of its manufacturing process involved the extrusion of copper wire into
extremely fine strands. The R&D department of Company X had targeted improvements
in this aspect of the manufacturing process as one of its top priorities. The basic objective
of such a project would involve significant improvements to the current process that would
further reduce the diameter of the copper strands without significantly increasing
manufacturing costs (for example, through lower yields of acceptable material or
increased consumption of energy and indirect materials). As of the date of the acquisition,
Company X’s R&D personnel had begun studying possible technological improvements
to the extrusion process by researching relevant technical and academic material that
was in the public domain. Company X’s R&D personnel also had conducted an all-day
“brainstorming” session in which a number of theoretical approaches were debated. As a
result of that meeting, a consensus on the most promising approach had been identified
and a project plan was being drafted that would define expected timing, resource
requirements, and key technical issues of the R&D project. Company X personnel were
excited about the novel approach and believed that the project had a fairly high likelihood
of ultimate success. Have sufficient R&D activities been undertaken such that, at the
acquisition date, the specific IPR&D project has substance?
3.3.53
Answer: No. At the date of the acquisition, Company X’s R&D project had
only been conceptualized. Company X had not expended a more than insignificant
effort in R&D activities to advance existing knowledge and technology toward the
project objective. As a result, even though the project concept was promising, the

35

project lacked substance at the acquisition date and would not qualify as an asset to be
recognized in the purchase price allocation.
3.3.54

Specific IPR&D Projects—Incompleteness

3.3.55
The attribute of incompleteness with respect to a specific IPR&D project
acquired as part of a business combination suggests that there are remaining
technological or engineering risks, or regulatory approvals. The task force notes that
once an R&D project is complete, it represents an asset resulting from R&D activities,
and the allocated portion of the purchase price representing its fair value would be
capitalized by the combined enterprise provided the asset meets the criteria in
paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill.
3.3.56
Factors or indicators that should be considered in evaluating whether
activities making up a specific R&D project are incomplete at the acquisition date
include both of the following:
a.

b.

Circumstances in which the combined enterprise expects to incur more than de
minimis future costs related to the acquired project that would qualify as R&D costs
under FASB Statement No. 2
Additional steps or milestones in a specific R&D project that remain for the
combined enterprise, such as successfully overcoming the remaining risks or
obtaining regulatory approvals related to the results of the R&D activities

3.3.57
Examples of circumstances that the task force believes demonstrate that the
ultimate completion of a specific R&D project would not have occurred at the date of
acquisition include the following:

•

•

•

Tangible products that are not subject to governmental regulations—The acquired
company’s project has not reached a level of completion such that “first customer
acceptance” (or a similar demonstration of completion for those products not subject
to first customer acceptance) of the product has occurred. The task force notes that
obtaining customer acceptance for a new product often requires a demonstration of
the product’s performance vis à vis planned operating measurements. Therefore,
obtaining first customer acceptance evidences completion of the project. Upon
achieving first customer acceptance (or a similar demonstration of completion for
those products not subject to first customer acceptance), the combined enterprise
would not incur additional costs that qualify as R&D pursuant to FASB Statement
No. 2 to further develop the product.
Software to be sold, licensed, or otherwise marketed—Technological feasibility for
the project has not been established under the criteria in paragraph 4 of FASB
Statement No. 86. The task force notes that the risks of successful completion of a
software project that has reached technological feasibility (and therefore is
considered complete) are sometimes greater than for a hardware project just before
first customer acceptance. However, in formulating the guidance for completion of a
specific IPR&D project for the development of software, the task force looked to the
requirements of FASB Statement No. 86.
Pharmaceutical products and processes related to right to market or use that are
subject to governmental regulations—The acquired company’s product or process
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has not been approved for marketing or production by the appropriate regulatory
body. Approval for marketing for this purpose includes only the approval of the
product to be marketed. For example, in the United States, the task force believes
that only FDA approval of a product is sufficient for a project to be complete (FDA
approval of a product for marketing also includes approval of the manufacturing
process). Approval of the label or, where applicable, the pricing is not necessary for
the project to be complete.
3.3.58
There may be circumstances in which a specific IPR&D project comprises a
number of subprojects that individually could be used by the combined enterprise in a
manner that would create an anticipated economic benefit. If any of those subprojects are
complete and it is anticipated that the combined enterprise will derive economic benefit
from the discrete exploitation of those subprojects (that is, an alternative future use exists
for the subprojects), then the fair values of the complete subprojects would represent
assets resulting from R&D activities. As a consequence, the purchase price allocated to
those projects would be capitalized and accounted for in accordance with the provisions
of FASB Statement No. 142 provided the assets meet the criteria in paragraph 39 of
FASB Statement No. 141 for separate recognition apart from goodwill. Such a
circumstance is similar to that described in paragraph 39 of FASB Statement No. 86.
3.3.59
For example, the acquired company may be in the process of developing a
variety of software products that can be marketed both individually and in combination
as an integrated suite of products (the suite). The development effort for certain of the
individual products is complete and the development of the others is incomplete.
Consequently, the development of the suite is incomplete. If it is anticipated that the
combined enterprise will market the discrete products individually and include the
discrete products as part of the suite, the task force believes that the purchase price
allocated to any of the individual products whose development is complete should be
capitalized as an asset resulting from R&D provided the asset meets the criteria in
paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill.
In addition, the task force believes that the value of the completed component
product(s) represents base (or core) technology, which is excluded from the
measurement of the fair value of the suite.
3.3.60

Questions and Answers8

3.3.61
Question 1: Company X was acquired in a business combination and had an
IPR&D project to develop the next generation of its microchip. The project was
estimated to be 70 percent complete in terms of costs incurred. The technological and
engineering hurdles remaining, though time-consuming and expensive, are not believed
to be high-risk development issues and are not considered particularly difficult to
accomplish. In fact, in similar previous development efforts, Company X consistently
demonstrated that it could accomplish the remaining tasks once it got to a similar stage
of completion. However, the remaining tasks are of the type described as R&D activities
in paragraph 9 of FASB Statement No. 2, rather than of the type of activities described
in paragraph 10 that are not considered R&D activities. Is the project incomplete?
8

The task force developed the following Q&As to provide guidance on incompleteness.
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3.3.62
Answer: Yes, because first customer acceptance of the microchip has not
occurred. Even though the likelihood of success in achieving first customer acceptance
may seem high based on Company X’s history, first customer acceptance has not
occurred and additional qualifying R&D costs will be incurred. Consequently, completion
of the project has not occurred at the date of acquisition.
3.3.63
Question 2: Company A acquired Company X in a business combination. At
the acquisition date, Company X had an R&D project in process to develop the next
generation of its job scheduling software. Company X had delivered a working model of
the software to several of its customers as part of the beta test stage. As of the
acquisition date, engineers were working to incorporate improvements discovered as a
result of the beta testing. Company A expects to complete the development and market
any resulting product in a manner generally consistent with the plans of Company X that
existed at the acquisition date. Is the project incomplete?
3.3.64
Answer: No. The task force believes that when a project reaches
technological feasibility as defined in FASB Statement No. 86, the project becomes an
asset resulting from R&D. Because Company X had provided a working model of its
software to several of its customers as part of the beta test stage, it met the
technological feasibility criteria described in paragraph 4 of FASB Statement No. 86. As
a result, a portion of the purchase price of the acquired company is allocated to the fair
value of the project and capitalized provided the asset meets the criteria in paragraph
39 of FASB Statement No. 141 for separate recognition apart from goodwill.
3.3.65
Question 3: Company A acquired Company X in a business combination. At
the acquisition date, Company X had an application to market a new drug pending FDA
approval. Both Company A and X believe that Company X had completed all necessary
tasks related to the filing (including having obtained satisfactory test results) and they
believe that they will ultimately obtain FDA approval. Is the project incomplete?
3.3.66
Answer: Yes. Industry experience shows that there are uncertainties about
obtaining approval for a new drug upon filing with the FDA. FASB Statement No. 2 does not
specifically address whether costs of obtaining FDA approval are R&D; however, the task
force believes that such future expenditures satisfy the condition that, to be considered
incomplete, additional R&D costs must be incurred by the combined enterprise.
3.3.67
Question 4: Company X was acquired in a business combination and was
involved in the design, manufacture, and marketing of consumer video communications
devices. Company X had a successful product in the market and had been working on
the next generation of the product, which involved significant improvements to features
and functions. (These improvements have no alternative future use outside the new
product.) Given the target market of young retail consumers, Company X planned to
debut the new product at an upcoming trade show, followed shortly after by a
nationwide marketing campaign. For competitive reasons, Company X did not allow
prototypes of the product outside of its facilities, although it did use focus groups
representing its target market demographics for feedback on design and features,
product and performance quality, and marketing approaches. As of the acquisition date,
Company X had approved the design and specifications of the latest prototype of new
product as being ready for commercial manufacture. As a result, Company X’s
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production facilities were preparing to begin mass production of product intended for
commercial sale. However, Company X had yet to finalize specifications of the product
shell (for example, color, ergonomic design, and brand graphics), which were still being
tested with the focus groups. Commercial manufacturing had not yet begun and no
products had been sold. Is the project incomplete?
3.3.68
Answer: No. The R&D project related to the significant improvement of the
existing product has been completed and there are no remaining R&D costs to be
incurred. The remaining tasks before commercial manufacture and product launch do
not involve technological or engineering risks, and the associated costs would not
qualify as R&D. Although “first customer acceptance” has not occurred, Company X has
demonstrated an equivalent internal milestone based on its product development
practices and life cycle.
3.3.69

Alternative Future Use

3.3.70
Paragraph 11 of FASB Statement No. 2 specifies that the costs of intangible
assets, materials and equipment, or facilities that are acquired or constructed for R&D
activities and that have alternative future uses (in R&D activities or otherwise) should be
capitalized (this is in accordance with FASB Statement No. 142).
3.3.71
The task force recognizes that the determination of whether an asset
acquired to be used in R&D activities has an alternative use (as discussed in paragraph
3.2.07) is based on management intent because at least one potential future use could
reasonably exist for most assets acquired. For example, the task force notes that the
possibility exists for an enterprise to sell many of the assets acquired to be used in R&D
activities; however, the task force believes that only an expectation of subsequent sale would
relieve management from considering whether an asset has an alternative future use.
3.3.72
The task force believes that an alternative future use that would require
capitalization in post-combination financial statements is one that is capable of using the
assets acquired as those assets exist at the acquisition date of the business
combination. Consider a circumstance in which successful completion of an IPR&D
project might give rise to additional R&D projects designed to significantly improve the
just-completed product. Because those subsequent projects are contingent on the
successful completion of the current project and would use the current R&D project in
its future completed condition, the task force believes that they do not constitute an
alternative future use at the acquisition date.
3.3.73
The task force believes that management of a combined enterprise should
search for alternative future uses in circumstances where (a) a significant portion of the
purchase price is allocated to assets acquired to be used in R&D activities and (b) the
allocation of purchase price to assets acquired to be used in R&D activities represents a
material expenditure of the acquiring company. This belief is founded on the premise
that contingency plans often are developed to maximize the return of assets acquired
that have a material cost. However, the mere existence of a plan to use the assets
acquired in an alternative manner does not represent an alternative future use unless
the conditions in paragraph 3.2.07 are met. The task force believes that best practices
for management of the combined enterprise are to document those considerations that
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lead to its determination of whether there are or are not alternative future uses for
assets acquired to be used in R&D activities.
3.3.74

Questions and Answers9

3.3.75
Question 1: Company A acquired Company X, a software company, in a
business combination. Before being acquired, Company X had two specific IPR&D
projects underway. Project 1 is a word-processing package to be used in hand-held
computing devices, and Project 2 is an advanced version of that project that incorporates
significant additional features and functionality. Project 2 is dependent on the successful
completion of Project 1. Is Project 2 an alternative future use for Project 1?
3.3.76
Answer: No. Since Project 2 builds off Project 1, and is therefore contingent
upon successful completion of Project 1, the task force believes that it is not an
alternative future use for Project 1 because Project 2 will only use the completed Project
1, and thus Project 2 would not have used Project 1 as it existed at the acquisition date.
Any allocation of purchase price to the fair value of Project 2 would exclude the value
that will be derived through use of the Project 1 technology. However, the task force
believes that the progress made in Project 1 through the date of the consummation of
the business combination would represent base (or core) technology with respect to
Project 2, the value of which would be excluded from the measurement of the fair value
of Project 2.
3.3.77
Question 2: Company A acquired pharmaceutical Company X in a business
combination. Company X owns a license that gives it the exclusive right to develop and
market a certain compound for the treatment of various diseases. At the time of the
acquisition, the compound was in early stage clinical trials as a drug for treating certain
cancers. The project met all of the criteria for an asset used in R&D activities. It is
believed the same compound also might be effective in treating a type of cardiovascular
disease. The cancer treatment projects were in early stage testing but had progressed
to the point that the fair value could be estimated with reasonable reliability. However,
human studies for toxicity (safety) of the compound were not yet completed. If the
results of those studies are negative, the project will be abandoned and the compound
would not be considered for use in a development project to address cardiovascular
disease. Should the potential use of the license rights to the compound for a project
addressing cardiovascular disease represent an alternative future use?
3.3.78
Answer: No. The task force believes that studies for toxicity represent a
contingency that must be resolved before an alternative future use is reasonably
expected. Unless the compound successfully completes the toxicity studies for the
indication for cancers, it will not be considered for use in treating any other disease. The
risk of failing the toxicity tests for the treatment of cancers would be considered in
estimating the fair value of the specific IPR&D project. However, there would be an
alternate future use if favorable toxicity results had already been obtained and it were
reasonably expected that the combined company would pursue the project to address
cardiovascular disease. If favorable toxicity results were obtained subsequent to the
acquisition date and the combined company then decided to pursue the cardiovascular
9

The task force developed the following Q&As to provide guidance on alternative future use.

40

indication, it would not constitute an alternative future use because the project would
have progressed to a state that was different from what existed at the acquisition date.
3.3.79
Question 3: Company A acquired custom software Company X in a business
combination. Before being acquired, Company X custom-designed software packages
based on specifications provided by its customers. Company X retained the rights to a
specific custom software package it recently had designed for one of its customers with
the intent of externally marketing that software. The custom software package had been
programmed to run on a proprietary operating system with interfaces to the customer’s
legacy systems. Company X intended to modify the software so that it would be
integrated into a widely used enterprise resource planning (ERP) package marketed by
Company B. Company A planned to pursue a project after the acquisition to modify the
Company X software so that it could be integrated into its own ERP software that
competes with that of Company B. However, Company A did not plan to pursue
modification of the Company X software to work with Company B’s package. Is the
Company B modification of the software package an alternative future use for the
acquired software?
3.3.80
Answer: No. The task force believes that an alternative future use is one that
is reasonably expected to occur. Because Company A did not have the intent to pursue
the Company B modification of the software package, that potential use, which was the
intended use by legacy Company X, is not an alternative future use. Company A would
still need to evaluate, however, whether (a) any of the technology represented by the
custom version of the software project represented base (or core) technology and (b) it
had another alternative future use for the custom software package.
3.3.81
Question 4: Company A acquired Company X in a business combination.
Company X has one product, a transdermal patch for the delivery of drugs. The patch
has been approved by the FDA for the delivery of Drug A, and Company X has been
selling that product for two years. In addition, Company X has commenced clinical trials
for delivery of Drug B via transdermal patch in anticipation of applying to the FDA for
approval for such use. It is expected that significant R&D costs will be incurred to
customize the transdermal patch technology to accommodate the unique characteristics
of Drug B before obtaining FDA approval for delivery of Drug B. Those actions are
underway and are approximately 50 percent complete, but the FDA has not approved
delivery of Drug B. Does the marketing of the patch for delivery of Drug A, while the
project to obtain FDA approval for delivery of Drug B is underway, constitute an
alternative future use for the transdermal patch?
3.3.82
Answer: No. The characteristics of Drugs A and B are different and the design
of a transdermal patch for each drug must reflect those different characteristics.
Therefore, the patch for Drug B will not use the design of the patch for Drug A as it
existed at the consummation of the business combination. However, the task force
believes that the technological processes and institutional knowledge represented by the
transdermal patch used for the delivery of Drug A that currently is marketed would
represent base (or core) technology, the value of which should be excluded from the
measurement of the fair value of the IPR&D project for use of the patch to deliver Drug B.
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3.3.83
Question 5: Company A acquired Company X in a business combination.
Company X has developed a compound for a new drug. Company A expects that its
only use for the compound will be in four of its currently active IPR&D projects for other
indications in addition to continuing Company X’s project for the initial indication. Do
Company A’s four currently active IPR&D projects constitute alternative future uses for
Company X’s project to develop the compound?
3.3.84
Answer: No. Company X’s compound is expected to be used only in
Company A’s currently active IPR&D projects and not in future IPR&D projects.
Therefore, the task force believes that Company A should allocate the amount of
purchase price assigned to Company X’s compound to all of the IPR&D projects, and
those amounts should be immediately charged to income. However, if any of Company
A’s four projects had instead been planned future projects (instead of currently active
projects) and the future projects were reasonably expected to occur, the planned future
project(s) would have been an alternative future use, and the fair value of Company X’s
compound would be capitalized provided the asset meets the criteria in paragraph 39 of
FASB Statement No. 141 for separate recognition apart from goodwill.
3.3.85
Question 6: Company A, a pharmaceutical company, acquired Company X in
a business combination. Company X’s assets include a library of molecules for highthroughput screening of drug candidates. Company X is using portions of the library in
its existing specific IPR&D projects and it is reasonably expected that other portions will
be used in currently identified future projects. Should the fair value of this library be
capitalized because it has an alternative future use?
3.3.86
Answer: Yes, provided the asset meets the criteria in paragraph 39 of FASB
Statement No. 141 for separate recognition apart from goodwill. The library of
molecules for high-throughput screening of drug candidates is a tool used in the R&D
process that is being used in current specific IPR&D projects and is reasonably
expected to be used in different future R&D projects. While portions of the library are
being used in current specific IPR&D projects, it is reasonably expected that the library
also will be used in several different currently identified future R&D projects. The task
force believes that the library represents an asset resulting from R&D activities.
3.3.87
Question 7: Company A acquired Company X in a business combination.
Company X’s assets include worldwide exploitation rights to Web-based access
technology. The rights supported an existing specific IPR&D project to develop a
product for exploitation in the United States. Company A does not have the resources to
exploit the potential product in foreign countries and, therefore, it reasonably expects
that it will sell the exclusive rights to exploitation in countries outside the United States.
Should the fair value of the non-U.S. exclusive exploitation rights be capitalized?
3.3.88
Answer: Yes, provided the asset meets the criteria in paragraph 39 of FASB
Statement No. 141 for separate recognition apart from goodwill. The expected sale of
the non-U.S. exclusive rights for exploitation in foreign countries is an intangible asset
that is separable and would be treated as an asset held for sale. The task force believes
that the fair value of the non-U.S. exclusive exploitation rights to the Web-based access
technology should be capitalized and accounted for in accordance with the provisions of
FASB Statements No. 141 and No. 142. The specific IPR&D project with respect to the
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development of a project for the U.S. market would be accounted for in accordance with
the best practices herein.
3.3.89 Question 8: Company A acquired Company X in a business combination.
Company X previously had purchased a unique piece of medical testing equipment for
use only in a specific IPR&D project. The combined enterprise will continue to pursue
the IPR&D project, and Company A reasonably expects that the combined enterprise
will use the equipment only in the specific IPR&D project. The combined enterprise can
measure the fair value of the equipment and related salvage value with reasonable
reliability. How should Company A account for the portion of the purchase price
allocated to the medical testing equipment?
3.3.90 Answer: The task force believes that Company A should immediately expense
the amount allocated, less salvage value, to the medical testing equipment because the
equipment does not have an alternative future use. Paragraph 11(a) of FASB Statement
No. 2 says, in part:
The costs of materials, equipment, or facilities that are acquired or constructed
for a particular research and development project and that have no alternative
future uses and therefore no separate economic values are research and
development costs at the time the costs are incurred.
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EXHIBIT 3-1
Phases of Development in the Pharmaceutical Industry∗

DISCOVERY RESEARCH PHASE—TWO TO FOUR YEARS

This is the earliest phase of the new drug research and development process. In the
discovery research phase scientists attempt to identify, from the literally millions of
molecules existing in the world, one that has a desired effect against a given disease or
illness. This whole process begins with the identification of a biological “target” that
appears to play an important role in causing the disease or illness in question. This
target could be something that is a part of the body itself, such as a protein, receptor, or
gene; or it could be something normally foreign to the body, such as a bacteria or virus.
The process of identifying lead molecules (or leads) is a trial-and-error process in which
tens of thousands of different molecules are tested or screened to see if they have a
desirable impact on the target. For example, if the target is a particular bacteria that
causes infection, those molecules that kill or inhibit the bacteria would be considered
leads and scientists go on to the next phase of development. The probability of any one
lead actually making it through the rest of the drug development process and becoming
a product is extremely low.
EARLY DEVELOPMENT PHASE—FOUR TO SIX YEARS

The drug development phase is all about taking a lead molecule, refining it, learning
how to manufacture it, and testing it for safety and efficacy. The initial testing takes
place in animals and looks for toxicity and other potential safety issues that might
preclude ever introducing the compound into humans. Standard predictive models
are used to project these findings from animals into potential toxicity and dosing
levels for humans. The first human tests (phase I) are conducted in a very small
group of healthy volunteers to assess the safety and the potential dosing range.
After a safe dose has been established, the drug is administered to a still relatively
small population of sick patients (phase II) to look for initial signs of effectiveness in
treating the targeted disease. In parallel to this animal and human testing, scientists
are also developing a manufacturing process that will allow the molecule to be
manufactured in a safe, efficient, and economical way. Long-term animal studies
continue to test for potential toxicology issues. The early development phase is a
very high-risk part of the overall process in which the vast majority of leads fail to
move on to the next phase of the process. Those molecules that do show some
initial signs of efficacy move on to the final phase of the research and development
process, known as the product phase.
PRODUCT PHASE—THREE TO FIVE YEARS

Those molecules that move on to the product phase (phase III) have already
demonstrated safety and preliminary efficacy and therefore have a much higher
likelihood of success. The drug is now tested in much larger patient populations to
∗ As mentioned in paragraph 3.3.40.
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prove efficacy in a more rigorous and statistically significant way. These trials are
generally global in nature and are designed to generate all of the data necessary for
inclusion in the regulatory submission documents. Often these studies will involve a
comparison of the new drug with existing competitive therapies, with placebo, or
both. All of the data is compiled and submitted to regulatory agencies around the
world. Often there will be several exchanges of questions and answers with the
regulators, and then, it is hoped, the drug is approved for marketing.
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CHAPTER 4
ACCOUNTING AND DISCLOSURE OF ASSETS ACQUIRED THAT ARE
TO BE USED IN R&D ACTIVITIES
4.1

ACCOUNTING QUESTIONS AND ANSWERS

4.1.01
The IPR&D Task Force identified the following questions as those where the
accounting in financial statements for transactions involving the application of Financial
Accounting Standards Board (FASB) Interpretation No. 4, Applicability of FASB
Statement No. 2 to Business Combinations Accounted for by the Purchase Method,
appears to reflect diversity in practice.
4.1.02
Question 1: In recording the purchase of a business, is discretion provided in
the timing for recording the allocation of purchase price to assets acquired to be used in
research and development (R&D) activities? For example, if information is not available
to make a reasonable allocation in the period that the business combination closes, can
an acquiring company employ some form of suspense accounting?
4.1.03
Answer: No. Paragraph 48 of FASB Statement of Financial Accounting
Standards No. 141, Business Combinations, provides guidance on when an acquiring
company should record the allocation to assets acquired to be used in R&D activities in
connection with recording the purchase of a business: “the date of acquisition ordinarily
is the date assets are received and other assets are given, liabilities are assumed or
incurred, or equity interests are issued.” In addition, paragraph B183 of FASB
Statement No. 141 (which retains the guidance of paragraph 36 of FASB Statement No.
38, Accounting for Preacquisition Contingencies of Purchased Enterprises), provides
that some allocations at the purchase balance sheet date are necessarily tentative.
The Board recognizes that completion of the allocation process that is required
by Opinion 16 may sometimes require an extended period of time. For
example, appraisals might be required to determine replacement cost of plant
and equipment acquired, a discovery period may be needed to identify and
value intangible assets acquired, and an actuarial determination may be
required to determine the pension liability to be accrued.
If a business combination is consummated toward the end of an acquiring
enterprise’s fiscal year or the acquired enterprise is very large or unusually
complex, the acquiring enterprise may not be able to obtain some of the data
required to complete the allocation of the cost of the purchased enterprise for
inclusion in its next annual financial report. In that case, a tentative allocation
might be made using the values that have been determined and preliminary
estimates of the values that have not yet been determined. The portions of the
allocation that relate to the data that were not available subsequently are
adjusted to reflect the finally determined amounts, usually by adjusting the
preliminary amount with the corresponding adjustment of goodwill.
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4.1.04
The existence of assets to be used in R&D activities in a business
combination involving software, electronic devices, and pharmaceutical companies is
commonplace and the guidance in paragraph 48 of FASB Statement No. 141 should be
followed. Therefore, the task force believes that an acquiring company should make an
allocation to assets acquired to be used in R&D activities based on its then best
estimate at the same time it makes other allocations of the purchase price (that is, at the
date of acquisition).
4.1.05
Best practices suggest that the acquiring company often is able to determine
its final allocation to assets acquired to be used in R&D activities in the same
accounting period that the business combination is consummated based on the due
diligence it performs before or immediately after agreeing to the terms of the acquisition.
Exceptions may be acquisitions of very large companies with significant R&D activities
and hostile takeover situations. In those circumstances, the task force believes that best
practice would be for the acquiring company to (a) record its best estimate within the
range of possible fair values of the assets acquired to be used in R&D activities for
purposes of its preliminary allocation, (b) disclose the range of significant estimates, and
(c) consider the disclosure requirements of paragraphs 12 through 19 of Statement of
Position (SOP) 94-6, Disclosure of Certain Significant Risks and Uncertainties, related
to significant estimates.
4.1.06
If the initial allocation to assets acquired to be used in R&D activities is
preliminary, paragraph 51(h) of FASB Statement No. 141 requires disclosure of reasons
why a purchase price allocation is not final and, in subsequent periods, the nature and
amount of material adjustments to the initial allocation. The “allocation period” ends
when the acquiring company is no longer waiting for information it has arranged to
obtain and is known to be available or obtainable. The allocation period generally
should not exceed one year.
4.1.07
The task force believes that changes in the preliminary allocation to assets
acquired to be used in R&D activities subsequent to the issuance of financial
statements or interim information in the allocation of purchase price should then be
evaluated by determining whether (a) the originally reported allocation was the result of
a preliminary evaluation of an ongoing data-gathering and evaluation process, which in
management’s opinion represented good faith best estimates based on the data then
available, and (b) the evaluation process is finalized in a reasonable period of time
subsequent to the acquisition, given the nature of the assets acquired to be used in
R&D activities. If an acquiring company meets both conditions, it should record any
adjustments by adjusting the preliminary amount of assets acquired to be used in R&D
activities (with a corresponding adjustment to goodwill), and it should treat the
adjustments as a change in accounting estimate in the period of change. If an acquiring
company does not meet both of these conditions, it would report the adjustment as a
correction of an error.
4.1.08
The Securities and Exchange Commission (SEC) staff had stated in Staff
Accounting Bulletin Topic No. 2.A.7 (which was issued before FASB Statement No.
141) that the acquiring company should disclose the circumstance related to allocation
of purchase price that is pending additional adjustments in the financial statements,
including in financial statements that are part of Forms 8-K and 10-Q filings. Absent
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disclosure of an open allocation period, it is the SEC staff’s view that the purchase price
allocation is presumed to be final.
4.1.09
Question 2: How should an acquiring company apply in-process R&D
(IPR&D) accounting requirements to initial investments in common stock that are to be
accounted for using the equity method, including circumstances in which the acquiring
company’s lack of control precludes access to reliable information on which to base a
determination of the existence of IPR&D projects, estimate their fair value with
reasonable reliability, or both?
4.1.10
Answer: Paragraph 19(b) of Accounting Principles Board (APB) Opinion No.
18, The Equity Method of Accounting for Investments in Common Stock, requires that
the difference between the cost of an investment and the amount of underlying equity in
net assets of an investee should be accounted for as if the investee were a consolidated
subsidiary. Accordingly, the task force believes the value related to the investor’s
proportionate interest in assets acquired to be used in R&D activities that have no
alternative future use should be charged to income in the period that the acquiring
company makes its equity investment in common stock, assuming the acquiring
company can satisfy the attribute of being able to estimate the fair value with
reasonable reliability.
4.1.11
Paragraph 19(n) of APB Opinion 18 (as amended by FASB Statement No.
142) states:
The carrying amount of an investment in common stock of an investee that
qualifies for the equity method of accounting as described in subparagraph (m)
may differ from the underlying equity in net assets of the investee. The
difference should affect the determination of the amount of the investor’s share
of earnings or losses of an investee as if the investee were a consolidated
subsidiary. However, if the investor is unable to relate the difference to specific
accounts of the investee, the difference shall be recognized as goodwill and
not be amortized in accordance with Statement No. 142. [Footnote reference
in paragraph 19(n) omitted]
4.1.12
Paragraph 4 of FASB Interpretation No. 35, Criteria for Applying the Equity
Method of Accounting for Investments in Common Stock, provides examples of
indications that an investor may be unable to exercise significant influence over the
operating and financial policies of an investee. For example, paragraph 4(d) provides
the following indication that the equity method may not be appropriate:
The investor needs or wants more financial information to apply the equity
method than is available to the investee’s other shareholders (for example, the
investor wants quarterly financial information from an investee that publicly
reports only annually), tries to obtain that information, and fails.
Nevertheless, the task force believes that an investee’s sensitivity to maintain
confidentiality with respect to the nature of its IPR&D projects may result in a
circumstance in which an investor that has significant influence cannot obtain needed
information to estimate the fair value of the investee’s IPR&D with reasonable reliability.

51

Consequently, while the task force believes that an acquiring company’s inability to
determine fair value of assets acquired to be used in R&D activities would preclude
recording a charge to income for those assets, that circumstance would not, of itself,
preclude the use of the equity method of accounting.
4.1.13
The task force believes that the answer to question 1 of this chapter also
applies to the allocation of the purchase price to an equity investment.
4.1.14
Question 3: How should an acquiring company classify an IPR&D charge in
its statement of cash flows?
4.1.15
Answer: Best practices suggest that an acquiring company should report its
cash acquisition of assets to be used in R&D activities as an investing outflow in its
statement of cash flows in the line item identifying payments for the purchase of a
company, net of cash acquired. The acquisition of assets to be used in R&D activities
would be reported in this fashion irrespective of whether acquired through a business
combination or a purchase of specific assets. In this regard, an acquiring company
should treat assets acquired to be used in R&D activities similar to how it reports other
acquired assets in the statement of cash flows.
4.1.16
In addition, when arriving at cash flows from operating activities under the
indirect method of reporting cash flows, best practices suggest that an acquiring
company should add back to net income the costs of assets acquired to be used in R&D
activities that are charged to income. That adjustment is necessary to eliminate from
operating cash flows those cash outflows of assets acquired to be used in R&D
activities that are reflected in investing activities.
4.1.17
Question 4: Subsequent to a business combination, but before the final
allocation of the purchase price, the combined enterprise abandons an IPR&D project
that existed at the acquisition date and met the definition of an asset to be used in R&D
activities. Should any portion of the purchase price be allocated to the IPR&D asset in
the final allocation?
4.1.18
Answer: The task force believes that whether a portion of the purchase price
should be allocated to the IPR&D asset in the final allocation depends on the
circumstances giving rise to the decision to abandon the project. If the abandonment
decision was based on circumstances that existed at the acquisition date (that is,
circumstances analogous to a Type I subsequent event, as discussed in Statement on
Auditing Standards [SAS] No. 1, Codification of Auditing Standards and Procedures
[AICPA, Professional Standards, vol. 1, AU sec. 560], “Subsequent Events”), the task
force believes that the abandoned IPR&D project should not be included in the final
allocation of the purchase price. An example of such circumstances might be if
management of the acquiring company had not had the opportunity to fully investigate
the project as part of its due diligence procedures before the acquisition and,
subsequent to the acquisition and before significant additional R&D costs had been
incurred, determines that the expected economic benefits and associated risks of
completion do not warrant continued funding of the project.
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4.1.19
However, if the abandonment decision was based on circumstances that
arose subsequent to the acquisition date (that is, circumstances analogous to a Type II
subsequent event), the task force believes that the fair value of the IPR&D project
should be included in the final allocation of purchase price. An example of such
circumstances might be if tests of the results of post-acquisition development efforts are
not promising and lead to the conclusion that the technological hurdles to successful
completion cannot be realistically overcome. Another example might be if, subsequent
to the acquisition, a competitor introduces a product with performance and pricing
characteristics that are superior to those envisioned for the planned product.
4.1.20
Question 5: Should subsequent events after the final allocation of the
purchase price cause the allocation to be revised (for example, a specific IPR&D project
to which value was assigned is subsequently abandoned or significantly reduced in
scope, or actual results are significantly different than the projections used to value the
IPR&D project)?
4.1.21
Answer: No. Generally accepted accounting principles (GAAP) do not permit
an acquiring company to consider previously unknown events that occur subsequent to
the final determination of fair value of assets acquired to be used in R&D activities. For
example, a decision made subsequent to the final allocation to abandon a project or
subsequent factors that are the result of circumstances that developed after the final
allocation have no impact on the determination of fair value as of the acquisition date of
a business combination. Additionally, consistent with internally developed R&D that is
subsequently abandoned or reduced in scope, or where actual results are significantly
different from projections, such events do not affect the determination of the amounts
already reported as having been expended for the acquired IPR&D project. As a result,
the allocation of the purchase price of the business combination should not be revised.
4.1.22
Question 6: Company A acquired Company X in a business combination. At
the initiation of the combination, Company X was working on one project that was in the
R&D stage. At the acquisition date, Company X had completed the R&D project. Should
Company A allocate any portion of the purchase price to assets acquired to be used in
R&D activities?
4.1.23
Answer: No. Paragraph 35 of FASB Statement No. 141 states, in part: “an
acquiring entity shall allocate the cost of an acquired entity to the assets acquired and
liabilities assumed based on their estimated fair values at date of acquisition.” Because
the R&D project was complete at the date of acquisition, it represents an asset resulting
from R&D activities that should be capitalized as an intangible asset, provided that it
meets the criteria in paragraph 39 of FASB Statement No. 141 for separate recognition
apart from goodwill.

4.2

DISCLOSURE

4.2.01
In considering best practices for disclosure of assets acquired in a business
combination to be used in R&D activities, the task force observed that the disclosures
required by GAAP and, for SEC registrants, Regulations S-K and S-X are somewhat
limited. For example, FASB Statement No. 2, Accounting for Research and
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Development Costs, requires disclosure only “of the total research and development
costs charged to expense in each period for which an income statement is presented.”
4.2.02
The task force also observes that FASB Statement No. 141 does not require
disclosure of valuation methods, and assumptions or qualitative information about
assets acquired. Paragraphs 51 through 57 of that Statement address required
disclosures for a business combination.
4.2.03
The task force notes that the SEC staff has requested public registrants to
disclose additional information about charges for IPR&D acquired in business combinations
in their financial statements and in management’s discussion and analysis (MD&A). In
January 1999, the SEC staff sent a letter to selected public company chief financial officers
setting forth certain expectations for disclosures about IPR&D, among other things. The
task force notes that the SEC staff’s letter was not specific about which disclosures should
be included in the financial statements and which disclosures should be included in MD&A.
Excerpts of that letter related to acquired IPR&D charges follow:
We understand that you will report significant charges in 1998 for asset writedowns, restructuring activities, or acquired in-process research and
development. In connection with our focus on transparent financial reporting
and potential earnings management issues, we may select your 1998 annual
report for review. For your consideration as you prepare that filing, this letter
identifies commonly requested MD&A and financial statements disclosures
that may be applicable in whole or part to the kinds of charges you incurred.
……….
Acquired In-Process Research & Development
Disclose:

• Specific nature and fair value of each significant in-process research and
•
•
•
•
•

development project acquired
Completeness, complexity and uniqueness of the projects at the
acquisition date
Nature, timing and estimated costs of the efforts necessary to complete the
projects, and the anticipated completion dates
Risks and uncertainties associated with completing development on
schedule, and consequences if it is not completed timely
Appraisal method used to value projects
Significant appraisal assumptions, such as—
— period in which material net cash inflows from significant projects are
expected to commence;
— material anticipated changes from historical pricing, margins and
expense levels; and
— the risk adjusted discount rate applied to the project's cash flows.

• In periods after a significant write-off, discuss the status of efforts to

complete the projects, and the impact of any delays on your expected
investment return, results of operations and financial condition
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4.2.04
In determining whether entities should provide additional disclosures about
IPR&D, the task force identified the following general considerations:

•
•
•

•

Financial statement disclosures need be provided only about items that are
qualitatively or quantitatively material—individually or in the aggregate.
Disclosures about IPR&D should be considered in the context of the financial
statements taken as a whole. The extent of disclosures about IPR&D should not give
undue emphasis to IPR&D when research and development is a relatively minor
aspect of the overall financial activities of the company.
To the extent that contemplated disclosures about IPR&D include forward-looking
information, a public company should consider the legal implications of including
those disclosures in the financial statements rather than outside the financial
statements, such as in MD&A. The task force noted that the safe harbor for forwardlooking information adopted in the Private Securities Litigation Reform Act of 1995
does not extend to financial statement disclosures.
Nonpublic companies should consider making the disclosures that a comparable
public company would make.

4.2.05
Financial Statements. Paragraph 51(g) of FASB Statement No. 141 requires
disclosure of the amount of purchased R&D assets acquired and written off in the period
in which a material business combination is completed and the line item in the income
statement in which amounts written off are aggregated. For each acquisition having an
associated material IPR&D charge, best practices suggest that an acquiring company
disclose the following in the footnotes to the financial statements (both in the interim
period of acquisition and in the annual financial statements of the year of acquisition):

•
•

The portion of the purchase price assigned to each individually material project
The technique used in each acquisition to value material assets acquired to be used
in R&D activities

4.2.06
The task force developed the following sample footnote disclosures as an
illustration of the disclosure requirements of paragraph 51 (e) and (g) of FASB
Statement No. 141 and best practices for a significant acquisition. (Appendix C of FASB
Statement No. 141 provides illustrations of some of its disclosure requirements.)
NOTE WW. SIGNIFICANT ACCOUNTING POLICIES—RESEARCH AND
DEVELOPMENT EXPENSES
Company A incurred research and development expenses of $X, $Y,
and $Z million in 2000, 1999, and 1998, respectively, including amounts
assigned to acquired in-process technology of $200 million in 2000. The value
assigned to acquired in-process technology was determined by identifying
those acquired specific in-process research and development projects that
would be continued and for which (a) technological feasibility had not been
established at the acquisition date, (b) there was no alternative future use, and
(c) the fair value was estimable with reasonable reliability.
NOTE XX. ACQUISITIONS
On October 5, 2000, Company A consummated its acquisition of Company X in a
transaction accounted for as a business combination. Company X was engaged in

55

licensing, implementing, and supporting business network software systems, and
had a well-established global service and support team. The aggregate purchase
price of $1 billion for Company X’s equity consisted of approximately $400 million
in cash and the issuance of 4 million shares of Company A common stock with a
market value of approximately $600 million. In addition, short-term liabilities with a
fair value of $300 million and long-term liabilities with a fair value of $700 million
were assumed by Company A. The results of operations of Company X and the
estimated fair value of the assets acquired and liabilities assumed are included in
Company A’s financial statements from the date of acquisition.
The purchase price was allocated to the tangible and intangible assets
acquired and liabilities assumed based on Company A’s estimates of fair value
at the acquisition date. The purchase price exceeded the amounts allocated to
the tangible and intangible assets acquired and liabilities assumed by $785
million, and this excess was classified as goodwill.
The following table shows the allocation of the purchase price for the
acquisition of Company X:
Value Assigned to Assets & Liabilities
Balance Sheet Category (in millions)
Current assets
Property, plant and equipment
Acquired in-process R&D
Intangible assets:
Developed technology
Customer list
Trademarks
Goodwill
Other assets
Short-term liabilities
Long-term liabilities
Net assets

Acquired
$ 100
650
200
175
25
40
785
25
(300)
(700)
$ 1,000

Approximately $200 million of the purchase price represents the estimated fair
value of acquired in-process R&D projects that had not yet reached
technological feasibility and had no alternative future use. Accordingly, this
amount was immediately expensed in the Consolidated Statement of Income
upon the acquisition date. The value assigned to purchased in-process
technology comprises the following projects: Project A ($100 million), Project B
($70 million), and others ($30 million).
The estimated fair value of these projects was determined by employment of a
discounted cash flow model. The discount rates used take into account the
stage of completion and the risks surrounding the successful development and
commercialization of each of the purchased in-process technology projects
that were valued.
[Note: Required pro forma disclosures have been omitted.]
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4.2.07
MD&A. The task force notes that the objectives and requirements of MD&A
as stated in the instructions in Regulation S-K include the following:

•

•

The purpose of MD&A is to provide to investors and other users information relevant
to an assessment of the financial condition and results of operations of the registrant
as determined by evaluating the amounts and certainty of cash flows from
operations and from outside sources. The information provided need only include
that which does not clearly appear in the registrant’s financial statements.
MD&A should focus specifically on material events and uncertainties known to
management that would cause reported financial information not to be necessarily
indicative of future operating results or of future financial condition. This would
include descriptions and amounts of (a) matters that would have an impact on
future operations and have not had an impact in the past, and (b) matters that have
had an impact on reported operations and are not expected to have an impact
upon future operations.

Registrants are encouraged, but not required, to supply forward-looking information.
This is to be distinguished from presently known data that will affect future operating
results, such as known future increases in costs. This latter data may be required to be
disclosed. Any forward-looking information supplied is expressly covered by the safe
harbor rule for projections.
4.2.08
The task force also notes the following considerations that could influence
management’s consideration of disclosures to be included in MD&A regarding IPR&D:

•
•
•
•
•
•

IPR&D charges may materially affect the total amount of R&D expense, income from
continuing operations, or trends in those amounts.
IPR&D charges may cause reported financial information not to be necessarily
indicative of future operating results.
Purchased R&D projects represent a known event that may produce uncertainty that
could reasonably be expected to materially affect future operating results, due to
additional R&D expenses expected to be incurred to complete the projects and
changes in revenue and profitability from changes in the product sales mix.
Purchased R&D projects may represent a material demand on liquid resources to
fund completion of the projects.
Qualitative information about management’s objectives in material acquisitions of
businesses and intangibles may be helpful in understanding the financial statements
“through the eyes of management.”
The SEC staff informed the task force that the staff believes that the letter to
selected public company chief financial officers (see paragraph 4.2.03) continues to
be relevant. That letter does not specify which of the commonly requested
disclosures should appear in MD&A as opposed to the financial statements.
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CHAPTER 5
VALUATION OF ASSETS ACQUIRED
5.1

INTRODUCTION AND OVERVIEW

5.1.01
Acquiring assets in a business combination requires ascertaining the cost of
the acquired company (that is, purchase price) and assigning that cost to the assets
acquired and liabilities assumed. The acquiring company should assign a portion of the
purchase price to the assets acquired and liabilities assumed usually equal to their fair
values at the date of acquisition. Tangible and intangible assets that meet the criteria in
paragraph 39 of Financial Accounting Standards Board (FASB) Statement No. 141,
Business Combinations, for separate recognition apart from goodwill should be
assigned an amount; assets acquired to be used in research and development (R&D)
activities generally represent intangible assets that also should be assigned a portion of
the purchase price based on their fair values if they meet that criterion. Examples of
assets acquired to be used in R&D activities include patents, software copyrights, base
(or core) technology, developed product technology, specific in process R&D (IPR&D)
projects, and technical drawings or manuals.1 The acquiring company undertakes
procedures to specifically identify and value assets acquired to be used in R&D
activities if either of the following conditions exists at the date of acquisition:

•
•

The acquired company was conducting R&D activities.
The acquired company has other assets that will be used in R&D activities by the
combined enterprise.

5.1.02
Valuations may be used as an aid in determining the fair values of assets
acquired and liabilities assumed. A valuation specialist, engaged to perform a valuation
of assets acquired in a business combination for the purpose of assisting management
of the combined enterprise in the allocation of purchase price, should consider the best
practices set forth in this Practice Aid. This chapter of the Practice Aid provides best
practices related to the valuation of assets acquired in a business combination, with an
emphasis on the valuation of assets acquired to be used in R&D activities, including
specific in-process R&D (IPR&D) projects.
5.1.03
The section of this chapter starting with paragraph 5.2 sets forth what the
IPR&D Task Force believes are best practices in the acceptance, administration, and
reporting of a valuation engagement in connection with the allocation of purchase price
pursuant to generally accepted accounting principles (GAAP). The objective of that
valuation is to estimate the fair value (as that term is defined by GAAP—see chapter 1)
of the assets acquired and liabilities assumed, including assets acquired resulting from
and to be used in R&D activities. The valuation specialist should perform appropriate
procedures to estimate the fair value.
1 The Financial Accounting Standards Board (FASB) recently issued FASB Statement of Financial Accounting
Standards No. 141, Business Combinations, which provides guidance on which intangible assets should be
recognized apart from goodwill in the allocation of purchase price in a business combination.
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5.1.04
The section of this chapter starting with paragraph 5.3 sets forth best
practices on the application of the multi-period excess earnings methodology. The multiperiod excess earnings methodology is the most common method used by valuation
specialists in estimating the fair value of assets acquired to be used in R&D activities,
including specific IPR&D projects.

5.2

PROCEDURES TO BE FOLLOWED BY VALUATION SPECIALISTS

5.2.01 An acquiring company initially should decide whether it possesses sufficient
expertise in-house to appropriately identify and value the assets acquired. In many
cases, the expertise may not be available in-house, resulting in the need for the
acquiring company to engage an independent valuation specialist to perform the
valuation of the assets acquired. An acquiring company that engages an independent
valuation specialist to perform a valuation would expect that the valuation specialist’s
work will comply with the requirements of Statement on Auditing Standards (SAS) No.
73, Using the Work of a Specialist (AICPA, Professional Standards, vol. 1, AU sec.
336), so that the independent auditor may rely on the work of the independent valuation
specialist. See chapter 6 of this Practice Aid for guidance on using the work of a
specialist pursuant to SAS No. 73. Whether the valuation is prepared in-house or by an
independent valuation specialist, the task force believes that the valuation specialist
should follow the best practices set forth in this Practice Aid.
5.2.02

Acceptance of Engagement

5.2.03
The valuation specialist should consider several factors before accepting or
performing a valuation engagement. These factors include the following:

•

•

The purpose of the valuation. The valuation specialist should consider the purpose
of the engagement. The valuation methods employed by the valuation specialist will
be determined by the reasons for the engagement because certain concepts,
approaches, and standards of value may be required for certain types of
engagements. For example, engagements that entail the valuation of assets
acquired in a business combination are engagements to provide asset valuations
that assist in forming the basis for purchase price allocations pursuant to FASB
Statement No. 141, FASB Interpretation No. 4, Applicability of FASB Statement No.
2 to Business Combinations Accounted for by the Purchase Method, and related
guidance. Therefore, the valuation specialist should be familiar with, and his or her
valuation report should be consistent with, the authoritative accounting literature as it
relates to assets acquired in a business combination.
The valuation specialist’s competency to perform the engagement. The person
performing the valuation should have demonstrated competence to perform the
valuation. This competence is demonstrated by the valuation specialist’s prior
experience in performing asset valuations (including assets acquired to be used in
R&D activities), in connection with purchase price allocations pursuant to FASB
Statement No. 141. The valuation specialist also would be expected to possess an
appropriate understanding of the—
 Industry in which the acquired company operates and its trends and conditions.
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 Operations of the acquired and acquiring companies (including their products,

marketing and distribution channels, technologies, and manufacturing processes).
 Market participants (see paragraphs 1.1.04 and 1.1.05 for guidance on the
effects of market participants on the valuation).

•

•

•
•

•

•

Willingness to be identified as an expert. Valuation specialists often undertake
engagements for public registrants and render reports summarizing their findings and
conclusions. These engagements may cause valuation specialists to be considered
“experts” in the meaning of Section 7 of the Securities Exchange Act of 1933 (the 1933
Act). In current practice, when work is performed solely to assist company management
in estimating the fair value of assets acquired in a business combination, and neither
the valuation specialist’s name nor his or her work is referred to in a 1933 Act filing, the
valuation specialist generally would not be referred to in the filing as an expert.
Therefore, the valuation specialist would not sign a consent as an expert. However, on
occasion, the Securities and Exchange Commission (SEC) staff has requested
valuation specialists to be referred to as experts in filings with the SEC. The task force
believes that valuation specialists, in the case of engagements with public companies,
should be prepared to support their valuation study in discussions with the SEC staff
and willing to be referred to as an expert in filings with the SEC before accepting and
completing a valuation engagement.
The proper identification of the assets to be valued. An important consideration in
the valuation process is the identification of what will be valued. Therefore, the
valuation specialist should be familiar with, and the valuation report should be
consistent with, the criteria in paragraph 39 of FASB Statement No. 141 for separate
recognition apart from goodwill. Valuation engagements that entail the valuation of
assets acquired to be used in R&D activities would identify the specific assets and
IPR&D projects to be valued along with all the contributing assets. See paragraph
5.3.33 for guidance on the characteristics and attributes of assets acquired to be
used in R&D activities and paragraph 5.3.54 for guidance on contributory assets.
The proper date at which to value the assets. In this case, the assets acquired
resulting from and to be used in R&D activities are valued as of the acquisition date,
as defined in paragraph 48 of FASB Statement No. 141, of the business combination.
See paragraph 4.1.03 for guidance on the definition of the acquisition date.
The appropriate premise or standard of value to be used. In the context of allocating
purchase price to assets acquired in a business combination, the valuation of assets
acquired to be used in R&D activities, including specific IPR&D projects, should be
consistent with the concept of fair value as that term is defined by GAAP. See
chapter 1 of this Practice Aid for guidance on the GAAP concept of fair value.
The appropriate approaches and methodologies for estimating value. The task force
believes that this chapter sets forth best practices in the use of appropriate valuation
methodologies to be applied in the valuation of assets acquired to be used in R&D
activities, including specific IPR&D projects. See chapter 2 of this Practice Aid for a
general discussion of valuation approaches to estimating fair value of assets acquired.
The relevant valuation standards and codes of ethics. Independent valuation
specialists are subject to the standards and codes of ethics set forth by numerous
professional organizations to which they belong. If valuation specialists hold
themselves out as certified public accountants (CPAs) or partners, principals, or staff
of AICPA member firms, they also should follow rules governing CPAs (particularly
the Consulting Standards found in Professional Standards, vol. 2, CS sec. 100.).
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•

•

The type of report to be issued. The results of the valuation of assets acquired to be
used in R&D activities, including specific IPR&D projects, should be documented in a
written report, supported by appropriate exhibits and appendixes. A key requirement
of a report prepared by an independent valuation specialist is that it contain sufficient
information so it can be subjected to audit procedures outlined in SAS No. 73 (see
chapter 6 of this Practice Aid). A limited scope valuation engagement or calculation is
where the prospective financial information is not investigated by the valuation
specialist in determining its propriety for use in the valuation. The task force believes
that a limited scope valuation engagement or calculation would not be sufficient for the
independent auditor to reduce the nature, timing, and extent of his or her audit
procedures relating to the valuation of the assets acquired. See paragraph 5.2.06 for
guidance on the contents of a valuation report.
The possibility of a conflict of interest or the appearance of a conflict of interest. A
conflict of interest or the appearance of a conflict would include situations in which the
client has the ability or appearance of an ability (through employment, ownership,
contractual right, family relationship, or otherwise) to directly or indirectly control or
significantly influence the valuation specialist. For example, the task force believes that
a direct financial interest by a valuation specialist (or his or her firm, or principal owners
of the firm) in the acquiring company or the acquired company would constitute a
conflict of interest, which would necessitate disclosure in the valuation report. The task
force believes that a valuation report prepared by a valuation specialist who is the
subject of an actual or perceived conflict of interest may be precluded from being
treated as the work of a specialist, as that term is used in SAS No. 73 (see paragraphs
6.3.28 through 6.3.32). (Also see Discussion Memorandum 99-3, Appraisal and
Valuation Services, issued by the Independence Standards Board.)

5.2.04

Engagement Letters

5.2.05
The task force believes that independent valuation specialists should be
engaged by clients using some form of written agreement (that is, an engagement letter).
An engagement letter is a document that defines the terms and scope of the valuation
engagement as agreed upon with the client. The engagement letter helps avoid
misunderstandings and, therefore, is in the interests of both the independent valuation
specialist and the client. An engagement letter usually would include the following:

•

•
•
•
•

The objective or purpose of the valuation engagement. In this case, the objective of
the valuation engagement is the performance of a valuation of assets acquired with
the resultant fair value used to assist management of the acquiring company in the
allocation of purchase price pursuant to FASB Statement No. 141, FASB
Interpretation No. 4, and related guidance.
The date of the valuation. In this case, the assets acquired to be used in R&D
activities are valued as of the acquisition date, as defined in paragraph 48 of FASB
Statement No. 141, of the business combination.
The nature and scope of the procedures to be performed.
An identification of the assets to be valued.
A definition of the premise or standard of value (it is also customary to include the
definition in the final written report). In this case, the premise/standard of value is fair
value, as that term is defined by GAAP. See chapter 1 of this Practice Aid for
guidance on the GAAP concept of fair value.
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•
•
•
•

•
•

The form of the report to be delivered.
The timing of the engagement.
The fees to be charged for the engagement.
A list of limiting conditions and restrictions on the use of the report by the party or
parties that it is intended for. Valuation specialists would be expected to make the
valuation report and the related supporting documentation available to the acquiring
company’s independent auditors in connection with their audit of the allocation of
purchase price.
An outline of what will be expected of the client in the engagement, such as providing
the valuation specialist with the appropriate prospective financial information, and
signing a representation letter at the conclusion of the engagement.
Other terms and conditions, as necessary.

5.2.06

Contents of a Valuation Report

5.2.07
The following discussion outlines the task force’s conclusions regarding the
content of a well-documented valuation report. The valuation specialist’s report would
not constitute an examination, compilation, or an agreed-upon procedures assignment
as described in Statement on Standards for Attestation Engagement No. 10, Revision
and Recodification (AICPA, Professional Standards, vol. 1, AT sec. 301, “Financial
Forecasts and Projections”). Nonetheless, the valuation specialist will perform
procedures necessary to satisfy himself or herself that prospective financial
information (that is, a forecast of expected future cash flows, or PFI) is objectively
verifiable (as evidenced by validating procedures), reliable, relevant, and useful to the
valuation process. Best practices suggest (and some valuation standards of practice
require) that the valuation specialist state in the report that he or she does not provide
assurance on the achievability of the prospective results because events and
circumstances frequently do not occur as expected; differences between actual and
expected results may be material; and achievement of the prospective results is
dependent on actions, plans, and assumptions of the responsible party (that is, the
acquiring company’s management).
5.2.08
Transmittal or cover letter. This section of the report (if prepared in this
format) usually would include a signature of the valuation firm or individual. It would
summarize the engagement, including information contained in the engagement letter,
such as—

•
•
•
•
•
•
•

Objective of the valuation.
Purpose and function of the valuation.
Date as of which the assets are valued.
Premise or standard of value.
Summary description of the assets valued.
Scope of the assignment.
Any limiting conditions relating to the performance of the engagement, the use of the
report, or both.

Additional language may include a summary of findings or conclusions and a reference
to the attached valuation study. The task force believes that there should not be any
language in the report that is contradictory to the performance of best practices set forth
in this Practice Aid. For example, PFI provided by management that is accepted by the
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valuation specialist without having been subjected to validating procedures by the
valuation specialist would contradict the performance of best practices set forth in this
Practice Aid. Examples of validating procedures are outlined in paragraph 5.2.19. See
Exhibit 5-2.1 for an example of a transmittal letter.
Table of contents and list of exhibits/appendixes. These typically are provided
5.2.09
for ease of use by the reader.
Certification. Most valuation standards of practice require that the valuation
5.2.10
specialist provide a signed certification. For example, for those specialists subject to
Uniform Standards of Professional Appraisal Practice (USPAP), Standard 10, Business
Appraisal, Reporting, provides appropriate wording for the certification.
Limiting conditions. Most standards of practice require a statement of those
5.2.11
conditions that limit the activities of the valuation specialist and the use of the ultimate
report. For example, section 8.3 of the American Society of Actuaries (ASA) Code of
Ethics and Principles of Appraisal Practice lists mandatory limiting conditions; many
valuation specialists have added language based on specific issues.
Introduction or executive summary. This is an optional section used to
5.2.12
increase the user-friendliness of the report; it often repeats a summary of findings or
conclusions as well as other details mentioned in the Transmittal or Cover Letter
section, as discussed in paragraph 5.2.08. See Exhibit 5-2.2 for an example of an
introduction or executive summary.
5.2.13

The objective or purpose of the valuation engagement. See paragraph 5.2.05.

History and nature of the company’s business and its assets. This is a
5.2.14
background section that demonstrates the valuation specialist’s knowledge of the
acquired company and identifies the assets to be valued. A description of the subjects
that would be covered in this section includes the acquired company’s business; key
events affecting the acquired company; competition, including identification of key
markets and market participants; technology; management; structure of the acquired
company; organization of the acquired company; ownership; and physical facilities of
the acquired company.
Analysis of the company’s industry. This section demonstrates the valuation
5.2.15
specialist’s knowledge of the industry in which the acquired company participates and it
identifies the key markets and market participants whose data will be used in analyzing
the PFI. Key sources of industry data would be listed in this section. Competition would
be a key topic of discussion in this section. This section is sometimes merged with the
section described in paragraph 5.2.13. See Exhibit 5-2.3 for an example of an analysis
of the company’s industry.
Analysis of the local, regional, and national economy affecting the company. This
5.2.16
section demonstrates that the valuation specialist has an awareness of the current economic
trends and conditions that may affect the acquired company’s operations. Some of the issues
that are discussed in this section include: economic growth, interest rates, manufacturing
capacity utilization, product demand, labor, and local and regional conditions.
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Financial analysis of the company. This section demonstrates the valuation
5.2.17
specialist’s knowledge of the historical financial performance of the acquired company.
This section serves, in part, as a basis for review of the PFI for the acquired company.
Generally, an analysis of three to five years of historical financial data is summarized,
including growth trends, ratio analysis, and common-sizing of selected financial data.
See Exhibit 5-2.4 for an example of the financial analysis of the company.
General description of valuation approaches/methodologies. This section
5.2.18
provides an overview of the valuation methods to be applied and demonstrates that
the valuation specialist understands the applicable approaches and methodologies
and best practices outlined in this Practice Aid. Generally, an overall description of
the cost, market, and income approaches is provided, as well as specifics of the
methods used for the valuation of assets acquired, including assets acquired to be
used in R&D activities. In all but very rare circumstances, the multi-period excess
earnings or another commonly accepted discounted cash flow methodology would
be used for the valuation of intangible assets acquired to be used in R&D activities,
including specific IPR&D projects. See Exhibit 5-2.5 for an example of a general
description of valuation approaches.
Valuation analysis. This is the most important section of the report and would
5.2.19
expand on the background sections described above. This section would include a
discussion of the following:

•
•

A description of the process used to identify assets for valuation and methodologies
to be employed. See exhibit 5-2.5 for an example of a description of assets valued.
A description of how assets acquired to be used in R&D activities are classified into
appropriate subcomponents (for example, base [or core] technology, developed product
technology, and IPR&D projects). Sufficient, objective, verifiable evidence would be
presented to demonstrate that the valuation specialist has considered the relevant
accounting guidance on assets acquired to be used in R&D activities regarding—







Control.
Economic benefit.
Measurability.
Substance.
Incompleteness.
Alternative future use.

This evidence would be derived from review of factual data and interviews with
management and market experts. Chapter 3 of this Practice Aid describes these
bulleted items.

•

A listing of company data sources; documents received, read, and analyzed;
interviews performed; and industry data sources used, if not mentioned elsewhere,
and those market participants considered in the development of assumptions. This
section’s purpose is to demonstrate that the valuation specialist has considered the
appropriate data and has the necessary supporting documents in his or her work
files. The supporting documentation and work files would be made available to
management or the independent auditor upon request.
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•

For each asset valued, the following topics would be covered:
 Assets valued pursuant to a cost approach. Sources of data (for example,

acquiring company, acquired company, market participants), nature of costs
(reproduction versus replacement), method of cost aggregation (that is, actual
application of approach), treatment of obsolescence, treatment of taxes,
treatment of amortization tax benefit, and circumstances that lead to selection of
the cost approach as opposed to other approaches. The task force notes that the
cost approach is rarely used in the valuation of intangible assets acquired to be
used in R&D activities.
 Assets valued pursuant to a market approach. Sources of comparable data
(acquiring company, acquired company, market participants), adjustments
to comparable data, application of actual method, discounts or adjustments
to value indications, and circumstances that lead to selection of the market
approach as opposed to other approaches. The task force notes that with
the exception of certain assets within limited industries (for example,
pharmaceuticals), the market approach is rarely used in the valuation of
intangible assets.

•

Assets valued pursuant to an income approach. In the case of the multi-period
excess earnings or another commonly accepted discounted cash flow methodology:
 Sources of PFI (acquiring company, acquired company, financial advisers, or

market participants)
Procedures performed to allow the valuation specialist to rely on and use the PFI
Adjustments made to PFI
Procedures performed (such as revenue splitting)
Sources of data and procedures performed to reflect technology migration and
the existence and separate valuation of base (or core) technology and other
contributory assets
 Development of appropriate tax rates, discount rates, and contributory asset charges
 Actual application of the method, including calculation of the amortization tax benefit





See exhibit 5-2.6 for an example of assets valued pursuant to an income approach.
In the case of the relief from royalty method (the task force notes that the use of this
method in valuing specific IPR&D projects should be rare, as discussed in paragraph
2.1.15):
 Revenue forecasts (acquiring company, acquired company, financial advisers, or

market participants)
 Procedures performed to allow the valuation specialist to rely on the revenue forecasts
 Sources of royalty or license rates (for example, internal company comparable

data, external market comparable data, and publicized sources)
 Development of discount rates and tax rates

•

An affirmation that the valuation will be used in the allocation of purchase price in
accordance with GAAP.
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5.3 APPLICATION OF MULTI-PERIOD EXCESS EARNINGS METHOD TO
ACQUIRED INTANGIBLE ASSETS
5.3.01

Overview

5.3.02
The multi-period excess earnings method is the most common method used
by valuation specialists in estimating the fair value of intangible assets acquired to be
used in R&D activities, including specific IPR&D projects, for purposes of allocating
purchase price pursuant to FASB Statement No. 141, FASB Interpretation No. 4, and
related guidance.
5.3.03
The principle behind the multi-period excess earnings method is that the
value of an intangible asset is equal to the present value of the incremental after-tax
cash flows attributable only to that intangible asset.
5.3.04
The application of the multi-period excess earnings method generally involves
the following overall steps:
1. Select the PFI that best reflects the final purchase price.
2. Evaluate and document the key assumptions relating to the elements that make up
3.

4.
5.
6.
7.
8.
9.

10.

the PFI and ascertain that the PFI reflects management’s good-faith best estimates.
Eliminate synergies (that is, acquiring company and acquired company assumptions
that are not consistent with assumptions used by market participants) from the
selected PFI resulting in the “adjusted PFI.” Also see paragraph 1.1.15.
Identify assets acquired, including assets to be used in R&D activities.
Confirm the existence of assets acquired to be used in R&D activities, including
specific IPR&D projects.
Eliminate effects of non-IPR&D activities from the PFI resulting in the “final PFI.”
Apply contributory asset charge for assets that contribute to the generation of the cash
flows (that is, apply contributory asset charges to the cash flows).
Calculate the present value of the cash flows using a discount rate appropriate for the
specific asset acquired being valued.
Compute the related income tax benefits resulting from the amortization of the asset
acquired for income tax purposes.
Evaluate the overall reasonableness of the asset’s fair value relative to the other
assets acquired and the overall purchase price.

5.3.05
To summarize the multi-period excess earnings method, the fair value of an
intangible asset acquired is estimated by deducting expected costs, including income
taxes (as described in paragraph 5.3.97), from expected revenues attributed to that
asset to arrive at after-tax cash flows. Such revenues and costs should reflect the
assumptions that would be used by market participants. From after-tax cash flows,
after-tax contributory asset charges are deducted (see paragraph 5.3.54) to arrive at
incremental after-tax cash flows. These remaining cash flows are discounted to present
value (see paragraph 5.3.68) and then summed. The calculation of the value of the
amortization tax benefit (see paragraph 5.3.97) is added to the sum of the present
values of incremental after-tax cash flows to arrive at the fair value of the intangible
asset acquired. See exhibit 5-2 for a comprehensive example of a valuation analysis of
intangible assets acquired to be used in R&D activities. The final step is the
determination of the overall reasonableness of the asset’s fair value.
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5.3.06
Step 1—Select the Prospective Financial Information That Best Reflects
the Final Purchase Price
5.3.07
Before consummation of a business combination, various PFI alternatives
frequently are prepared. From the perspective of the acquired company, PFI often exist
as a result of reports and analyses that management had prepared as part of ongoing
management of technology projects and overall business operations. PFI also may
have been prepared by the acquired company or its advisers as part of the selling effort
(for example, offering memoranda). From the perspective of the acquiring company, PFI
may have been prepared as part of due diligence procedures or as part of an overall
process to determine acceptable purchase price ranges. The PFI may encompass
various alternatives, including optimistic, base case, pessimistic scenarios, or all three.
All PFI produced by parties to the transaction (as well as by their advisers) should be
evaluated by the valuation specialist to understand the underlying assumptions and the
differences between the sets of assumptions.
5.3.08
The PFI alternative that best reflects the final purchase price is the logical
starting point for the valuation specialist. The valuation specialist should prepare an
information request to assist in evaluating which PFI alternative best represents the
alternative that was used in negotiating the final purchase price. The following
information, for example, would be requested:

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•

Historical financial statements of the acquired company for an appropriate period of
time (for example, the most recent five years)
Transaction documents (that is, the purchase agreement and related exhibits)
Press releases and other public disclosures of the transaction
PFI prepared by the acquired company
PFI prepared by the acquired company’s advisers
PFI prepared by the acquiring company
PFI prepared by the acquiring company’s advisers
PFI prepared for lenders
Reports of outside analysts, market experts, governmental agencies, or other third
parties, that relate to the transaction
Board of directors’ presentations prepared for the acquired company
Board of directors’ presentations prepared for the acquiring company
Technical analysis that relates to the acquired company’s products or technologies
(whether it be prepared by the acquiring company, acquired company, or a third party)
Sales or marketing materials used to sell the acquired company’s products and services
Data on patents held by the acquired company
Acquired company’s analysis of its specific IPR&D projects, including analysis
supporting management’s approval of the projects and periodic status reports
R&D budget of the acquired company
Historical R&D expenditures by the acquired company
Product road map or other similar detail of the acquired company’s expected evolution
from current products and technologies to future products and technologies
Licensing agreements that exist for either the development of technologies or
ultimate marketing of product manifestations
Identification of market participants and relevant market participant data
Government or industry publications
Market surveys
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•
•
•
•
•

Engineering studies
General economic indicators
Industry statistics
Trends and patterns developed from the acquired company’s operating history (for
example, life cycles of prior generations of products and rate of changes in average
selling prices)
Internal data and analyses, accompanied by their supporting objective evidence

5.3.09
Not all of these data sources will be available in a given transaction. At a
minimum, the valuation specialist should collect data that would have been considered
by the acquiring company and acquired company in performing their due diligence and
agreeing upon a final purchase price. The valuation specialist also would consider
significant changes that may have occurred between the date when the acquiring
company and acquired company came to final terms and the acquisition date of the
business combination. Upon collecting the relevant data, the valuation specialist should
interview appropriate members of the acquiring and acquired companies’ management
teams (if relevant and applicable). Management should be in a position to state its
reliance on such data when corroborative or explain its lack of reliance when contrary.
The functional departments represented in such queries would include: scientific (that
is, R&D), marketing, sales, finance, accounting, and operations. See paragraph 5.3.26
for additional information to be obtained during these interviews with management.
5.3.10
The valuation specialist should understand and document the process by
which the PFI was prepared. To the extent that management or its advisers have a
process for preparing PFI, the valuation specialist will be able to readily find the support
for the PFI and determine its suitability for use in the valuation analysis. Best practices
suggest that significant differences (and their underlying reasons) between the PFI used
in the valuation of the acquired company and the final PFI that was presented to the
acquiring company’s board of directors or management (as appropriate) by the
acquiring company, acquired company, or their financial advisers should be
documented and reconciled. The task force believes that the valuation specialist should
select the PFI that best represents the alternative that was used in negotiating the final
purchase price and, therefore, is most representative for purposes of determining the
fair value of the acquired company.
5.3.11
The task force believes that management of the acquiring company should
take responsibility for the completeness and accuracy of the PFI alternative selected for
use in the valuation analysis. Management would represent to the valuation specialist
that the PFI represents management’s best estimate of the most likely expected
outcome of the economic benefits resulting from the assets acquired. Management also
would be expected to provide the valuation specialist with data supporting the key
assumptions used in the preparation of the PFI, including identification of any expected
synergies. The valuation specialist does not simply accept PFI from management
without investigating its suitability for use in the valuation analysis. The valuation
specialist is responsible for evaluating the methodology and assumptions used by
management in preparing the PFI and concluding whether the PFI is appropriate for use
in valuing the assets acquired.
5.3.12
At this point, the valuation specialist and management should reach
agreement on the PFI alternative that best represents the alternative that was used in
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negotiating the final purchase price and, therefore, is most representative for purposes
of determining the fair value of the acquired company. If the valuation specialist and
management cannot agree on the appropriate PFI alternative, the valuation specialist
would disclose the nature of its disagreement in its valuation report and the effect, if
quantifiable, on the value assigned to the assets acquired. Pursuant to some
professional standards of conduct, the valuation specialist also would need to consider
the possibility of resigning from the engagement if the valuation specialist concludes
that the management-prepared PFI is not appropriate.
5.3.13
Step 2—Evaluate and Document the Key Assumptions Relating to the
Elements That Make Up the PFI and Ascertain That the PFI Reflects
Management’s Good-Faith Best Estimates
5.3.14
The next step for the independent valuation specialist would be to evaluate
the methodology and assumptions used by management in preparing the PFI and
concluding whether the methodology and assumptions are appropriate for use in the
valuation analysis. The following represents specific elements of PFI for the valuation
specialist to verify and suggested sources of objective evidence that support each
material assumption underlying the specific elements of PFI:

•

•

•

Revenue. The valuation specialist’s assessment of PFI begins with an analysis of
the key assumptions related to revenue from current products and revenue that is
expected to result from both specific IPR&D projects and R&D projects not yet
commenced, including estimated number of units expected to be sold, estimated
selling prices throughout the selling period, estimated market penetration, and
estimated market share. Year-over-year unit growth (or decline) rates over the
product(s) life cycle(s) (that is, the period of years over which revenue is expected to
be received for a given technology or related product offering) and the
reasonableness of average per-unit selling prices during the period should be
evaluated by the valuation specialist, giving due consideration to expected
competitors’ reactions, anticipated technological developments, and historical trends.
Historical financial data of the acquired company is a common source of objective
evidence to support the assumptions in the PFI regarding revenue. Industry data,
data from public filings of market participants, and reports generated by market
research firms and industry analysts also may be sources of objective evidence to
support revenue assumptions in PFI. Once these key assumptions relating to
revenue are understood by the valuation specialist, management should be queried
on its support for material assumptions.
Costs of sales. Historical financial data of the acquired company is a common source of
objective evidence to support the assumptions in the PFI regarding cost of sales.
Industry data, data from public filings of market participants, and reports generated by
market research firms and industry analysts also may be sources of objective evidence
to support cost of sales assumptions in PFI. Valuation specialists should understand the
difference between company-wide costs of sales and specific product-by-product costs
of sales because costs of sales may change over a product’s life cycle and likely will
differ from product to product. Valuation specialists should query management about
past experience with prior product offerings and compare the trend of costs of sales for
prior product offerings with those contained in the PFI.
Sales and marketing expense. Historical financial data of the acquired company is a
common source of objective evidence to support the assumptions in the PFI
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•

•

•

•
•

•

•

regarding sales and marketing expense. Industry data, data from public filings of
market participants, and reports generated by market research firms and industry
analysts also may be sources of objective evidence to support sales and marketing
expense assumptions in PFI. Product launch costs should be included in PFI if
product development activities are expected to lead to the introduction of new
product offerings. Product launch costs commonly are incurred during the
introduction of new product offerings and can differ dramatically from routine sales
and marketing expense. Objective evidence may be gathered from the acquired
company’s prior experience with previously launched product offerings or from
industry and market participant’s data.
General and administrative expense. Historical financial data of the acquired
company is a common source of objective evidence to support the assumptions in
the PFI regarding general and administrative expense. Industry data, data from
public filings of market participants, and reports generated by market research firms
and industry analysts also may be sources of objective evidence to support general
and administrative expense assumptions in PFI.
Technical support expense. Historical financial data of the acquired company is a
common source of objective evidence to support the assumptions in the PFI
regarding technical support expense. Industry data, data from public filings of market
participants, and reports generated by market research firms and industry analysts
also may be sources of objective evidence to support technical support expense
assumptions in PFI.
R&D expense. Historical financial data of the acquired company is a common source
of objective evidence to support the assumptions in the PFI regarding R&D expense.
Industry data, data from public filings of market participants, and reports generated
by market research firms and industry analysts also may be sources of objective
evidence to support R&D expense assumptions in PFI.
Tax expense. See paragraph 5.3.97 for guidance on the impact of income taxes on
the determination of fair value of assets acquired.
Required levels of net working capital. PFI may include expectations regarding
working capital needs for the acquired company. Historical levels of working capital,
combined with industry experience available from the public filings of market
participants, typically serve as the best evidence of required levels of working
capital. Such levels will further serve as an input to the calculation of future
contributory asset charges in the valuation analysis. See paragraph 5.3.54 for
guidance on contributory asset charges.
Required levels of tangible assets. PFI may include expectations regarding tangible
asset needs for the acquired company. Historical levels of tangible assets, combined
with industry experience available from the public filings of market participants, typically
serve as the best evidence of required future levels of tangible assets. Such levels will
further serve as an input to the calculation of contributory asset charges in the valuation
analysis. See paragraph 5.3.54 for guidance on contributory asset charges.
Required levels of intangible assets. PFI typically does not include expectations
regarding intangible asset needs for the business in aggregate because companies
often do not budget purchases of intangible assets. Levels of other intangible assets
calculated as a result of the valuation process associated with allocating the
purchase price, combined with industry experience available from the public filings of
market participants, typically serve as the best evidence of required levels of
intangible assets. Such levels will further serve as an input to the calculation of

73

contributory asset charges in the valuation analysis. See paragraph 5.3.54 for
guidance on contributory asset charges.
5.3.15
To the extent that the valuation specialist, in his or her judgment, does not
receive sufficient support for particular PFI assumptions, the valuation specialist should
investigate other client records as well as external sources in an effort to locate
corroborating objective support for each material assumption. If conflicting data exists,
the task force believes that the valuation specialist should challenge management to
further support its assumptions or change those assumptions to be consistent with the
objective evidence.
5.3.16
At this point the valuation specialist would have completed his or her
evaluation of the methodology and assumptions used by management in the
preparation of the PFI that best reflects the final purchase price. The valuation specialist
and management should reach agreement on the methodology and assumptions used
in the preparation of the PFI alternative that best reflects the final purchase price. If the
valuation specialist and management cannot agree on the appropriate methodology and
assumptions used in the preparation of the selected PFI, the valuation specialist would
disclose the nature of the disagreement in the valuation report and the effect, if
quantifiable, on the value assigned to the assets acquired. Pursuant to some
professional standards of conduct, the valuation specialist also would need to consider
the possibility of resigning from the engagement if the valuation specialist concludes
that the management-prepared PFI is not appropriate.
5.3.17
Step 3—Eliminate Synergies From the Selected PFI, Resulting in the
Adjusted PFI2
5.3.18
At this point in the valuation process, the assumptions used in the preparation
of the selected PFI may include assumptions that are specific to the acquiring company
and not necessarily those of market participants. Therefore, the next step in the multiperiod excess earnings analysis is to remove from the selected PFI the cash flows
attributed to synergies.3 Valuation methods for measuring assets should be consistent
with the objective of measuring fair value, as that term is defined by GAAP. Those
methods would incorporate assumptions that market participants would use in their
estimates of values, future revenues, and future expenses. If the acquiring company
pays the owners of the acquired company any significant consideration for synergistic or
strategic benefits in excess of those expected to be realized by market participants, the
valuation specialist would identify those excess benefits and remove them from the
selected PFI. (Those excess benefits ultimately will be included in the portion of the
purchase price allocated to goodwill.) The ultimate assumptions included in the selected
PFI that are used to assign cost to the assets acquired should reflect the best estimate
of how market participants would benefit from use of the assets acquired. Also see
paragraph 1.1.15 for guidance on strategic or synergistic value.

2

Synergies are acquiring company and acquired company assumptions that are not consistent with assumptions
used by market participants.
3 Paragraph B174 of FASB Statement No. 141 provides that an entity may use its estimates of cash flows if
market participant assumptions are not available without undue cost and effort.
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5.3.19
During the data collection and management interview process, the valuation
specialist should identify, document, and evaluate the reasonableness of the synergistic
revenues and cost savings identified by management of the combined enterprise.
Management of the combined enterprise should be queried on what unique operating
efficiencies or revenue enhancements are expected to be experienced by the combined
enterprise that would not be expected to be experienced by market participants. Once
identified, those synergistic revenues (that is, revenue enhancements) and cost savings
should be eliminated from the selected PFI.
5.3.20
Synergies unique to the combined enterprise should not be used in estimating
the fair value of any asset acquired. Adjustments to the selected PFI can be
accomplished by revising the revenue growth or cost savings rates from those used in
the selected PFI to those of market participants.
Example–eliminating cost synergies. Company A acquired Company X in a
5.3.21
business combination. Selling costs for Company X are 40 percent of revenues, and the
rate representative of performance of market participants is 30 percent of revenues.
Due to the unique size and efficiency of its distribution channel, selling costs for
Company A are 20 percent (also the rate used by Company A in its PFI alternative that
was used to negotiate the final purchase price). Selling costs in the PFI would be
adjusted up to 30 percent, the rate representative of market participants, to eliminate a
synergy specific to the acquiring company.
Example–eliminating revenue synergies. Company A acquired Company X in a
5.3.22
business combination. Company X’s product complements Company A’s product. Upon
acquisition, Company A’s combined product offering will be unique in the market, and
Company A believes that it can derive 10 percent more in revenues from both products
than it or market participants could if they were to sell either product on a separate standalone basis. The PFI should exclude all revenues attributable to Company A’s preexisting
product, and the incremental 10 percent increase in revenues derived from Company X’s
product, which resulted from having a combined product offering.
Example–eliminating income tax synergies. Company A acquired Company X
5.3.23
in a business combination. Company A currently does not pay income taxes because of
net operating loss carryforwards. Company A does not expect to pay income taxes in
the foreseeable future due to the size of the net operating loss carryforwards. In the PFI
that Company A provides to the valuation specialist for use in valuing certain assets
acquired to be used in R&D activities, management of Company A does not include any
expected income tax payments resulting from the cash flows attributable to the acquired
assets. In other words, in the PFI prepared by Company A’s management, the present
value of the expected future cash flows attributed to the acquired assets is the same on
a pretax basis as on an after-tax basis because no income tax payments are expected.
5.3.24
The valuation specialist would adjust the PFI to include an estimate of the
expected tax payments that market participants would be expected to pay on the
expected future cash flows attributable to the acquired assets. The “favorable” tax
attributes of Company A is a synergy and, therefore, is eliminated from the PFI used to
value the acquired assets. See paragraph 5.3.97 for guidance on the impact of income
taxes on the multi-period excess earnings method.
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5.3.25
At this point the valuation specialist would have adjusted the selected PFI so
the assumptions underlying the selected PFI would reflect the assumptions expected to
be experienced by market participants (adjusted PFI). The next step in the analysis is to
identify which assets acquired are to be valued by the valuation specialist.
5.3.26
Step 4—Identify Assets Acquired, Including Assets to Be
Used in R&D Activities
5.3.27
At the outset of the valuation analysis, the valuation specialist and
management should identify all assets acquired that can be subjected to valuation
procedures (including all contributory assets, as discussed in paragraph 5.3.54). Many
assets already will be identifiable from the balance sheet of the acquired company
based on historical transactions. These assets typically include working capital items,
such as cash, accounts receivable, inventory, and prepaid expenses. Also, tangible
assets commonly appear on historical balance sheets at historical cost less
accumulated depreciation. Intangible assets appear less frequently because they
typically result from prior business combinations or asset acquisitions by the acquired
company. Historical balance sheets often do not include intangible assets that were
developed internally by the acquired company. All assets acquired will require analysis
to determine their fair value in the current transaction.
5.3.28
During the analysis of historical financial data, the valuation specialist would
interview management of the acquiring and acquired companies, including those
responsible for marketing and technology development. During those interviews, the
valuation specialist would collect company data relating to product offerings, channels
of distribution, facilities, operations of the acquired company, and R&D efforts underway
by the acquired company. The purpose of those interviews would be to ascertain the
existence of other intangible assets not readily apparent from a reading of the historical
financial data. The valuation specialist generally would have made reference to a list of
potential intangible assets, such as that referenced in paragraph 5.3.60 (which
references appendix A of FASB Statement No. 141) of this Practice Aid, in conducting
the interviews of management. A common inquiry to management is “What is your
perception of the assets you acquired?” or, alternatively, “What is your perception of the
assets you sold?”
5.3.29
In the context of an acquisition of a technology-based company, assets
acquired to be used in R&D activities often are part of the finalized list of assets to be
valued. Therefore, the valuation specialist’s inquiry of management also would include a
discussion regarding the identification and classification of assets acquired to be used in
R&D activities. The valuation specialist also would review the following information in
evaluating management’s identification and classification of assets acquired to be used
in R&D activities:

•
•
•
•
•
•
•

Presentations to the board of directors
Offering memoranda
Due diligence reports
Press releases (including those of the acquired company before the business combination)
Web site materials
Analysts reports
Industry reports
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5.3.30
Ultimately, the valuation specialist should agree with management on a
specific listing of assets to be valued, based on the facts and circumstances of the
specific transaction, and the experience of management and the valuation specialist.4
5.3.31
The remainder of this chapter will focus on estimating the fair value of assets
acquired to be used in R&D activities, including specific IPR&D projects, using the multiperiod excess earnings methodology.
5.3.32
Step 5—Confirm the Existence of Assets Acquired to Be Used in R&D
Activities, Including Specific IPR&D Projects
5.3.33
Once the existence of assets acquired to be used in R&D activities has been
preliminarily established, the valuation specialist should evaluate and document his or her
conclusion that the identified assets meet the definition of assets acquired to be used in
R&D activities. Considerations in reaching such a conclusion would include an analysis of
the characteristics and attributes of assets to be used in R&D activities, including specific
IPR&D projects, which are discussed in detail in chapter 3 of this Practice Aid.

•
•

Scope of IPR&D projects. An IPR&D project is the result of activities undertaken
before the acquisition date, the costs of which qualify as R&D costs pursuant to
FASB Statement No. 2, Accounting for Research and Development Costs, and
related guidance. See paragraph 3.3.01 for guidance on the scope of R&D activities.
Control. The valuation specialist should conclude and document that the acquiring
company has purchased assets to be used in R&D activities that the acquiring
company obtains the benefit of and controls others’ access to. See paragraphs
3.2.02 and 3.3.13 for guidance on the definition of control. Evidence that indicates
that the acquiring company has met the control characteristic would include—
 Existence of patents, software copyrights, or regulatory approval.
 Ability to sell, lease, license, franchise, or use the assets.
 Qualitative data that indicates that the company has what it believes are

defendable intellectual proprietary rights to the assets.

•

4

Economic benefit. The valuation specialist should conclude that the assets acquired
to be used in R&D activities are anticipated to produce an economic benefit. See
paragraphs 3.2.02 and 3.3.17 for guidance on the definition of economic benefit.
Evidence to be considered includes the existence of the acquired company’s
business plans for commercial exploitation of the technology through product
offerings that were developed when it initially considered funding the project and
thereafter when considering whether to continue funding the project, forward-looking
statements made by management regarding anticipated economic benefits of the
technology, and external market or industry data that support the significance of the
potential economic benefits or substantiates the existence of an unserved or
underserved market for product offerings related to the technology project. Parallel
efforts to develop similar technologies by competitors also would corroborate the
existence of anticipated economic benefit.

See footnote 1.
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•

•

Measurability. The valuation specialist should conclude and document that the value of
the assets acquired to be used in R&D activities is estimable with reasonable reliability.
See paragraphs 3.2.03 and 3.3.22 for guidance on the definition of measurability. The
valuation specialist generally would review the business plans that address the
exploitation of the technology through product offerings. These business plans should be
supportable by historical data of the acquired company, other current company records,
opinions of market experts either internal or external to the company, external
publications, the opinion of external industry analysts, or a combination of these. The fact
that assets acquired to be used in R&D activities are anticipated to have economic benefit
does not, in and of itself, indicate that such benefit is estimable with reasonable reliability.
Sufficient objective, verifiable evidence to support the assumptions used in the
measurement process must exist to compute a reasonably reliable estimate of the fair
value to be assigned to the assets acquired to be used in R&D activities.
Substance. The valuation specialist should conclude and document that an R&D
project has been advanced to a sufficient stage to be deemed to have substance.
See paragraphs 3.2.04 and 3.3.45 for guidance on the definition of substance.
Evidence to be considered includes—
 The stage of completion of the project as evidenced in the acquired company’s

records, such as periodic status reports of specific IPR&D projects.
 The treatment and emphasis given to the project in the company’s product road










•

map for the technology.
The acquired company’s R&D budget.
The acquired company’s R&D planning documents and related status reports.
R&D costs incurred by project and estimated costs to complete the project.
Press releases by the acquired company.
Presentations to the board of directors.
Offering memoranda.
Due diligence reports.
Web site materials.
Assessments made by market research firms and industry analysts.

Incompleteness. The valuation specialist should conclude and document that the
technology project is incomplete as of the acquisition date. See paragraphs 3.2.04
and 3.3.54 for guidance on the definition of incompleteness. Evidence to be
considered includes—
 The stage of development as indicated by the development milestones attained





and yet to be reached.
Remaining technological, engineering, or regulatory risks to be overcome.
Remaining development costs to be incurred.
Remaining time to be spent to reach completion.
Probability of successful completion.

Such analysis also will be useful in determining the impact of stage-of-completion on
the selection of an appropriate discount rate under the traditional approach. (See
paragraph 5.3.81 for guidance on selection of an appropriate discount rate.)

•

Alternative future use. The valuation specialist should conclude and document
whether the assets acquired to be used in R&D activities have an alternative future
use. See paragraphs 3.2.06 and 3.3.69 for guidance on the definition of alternative
78

future use. If assets acquired to be used in R&D activities (recognized separate and
apart from goodwill) have an alternative future use, the allocated fair value of those
assets would be accounted for pursuant to FASB Statements No. 141 and No. 142,
Goodwill and Other Intangible Assets. If assets acquired to be used in R&D activities
(recognized separate and apart from goodwill) do not have an alternative future use,
the allocated fair value of those assets would be charged to expense as of the date
of acquisition.
5.3.34
Once the existence of assets acquired to be used in R&D activities
(recognized separate and apart from goodwill) has been established, the valuation
specialist should remove from the adjusted PFI activities unrelated to assets acquired to
be used in R&D activities, including ancillary revenues. Once removed, the remaining
cash flows included in the adjusted PFI will represent the expected future cash flows to
be used as the basis for estimating the fair value of assets acquired to be used in R&D
activities, including specific IPR&D projects.
5.3.35
Step 6—Eliminate Effects of Non-IPR&D Activities From the PFI
Resulting in the Final PFI
5.3.36 If cash flows attributable to activities that are unrelated to assets acquired to be
used in R&D cannot be removed from the adjusted PFI (because those cash flows are
not largely independent of the cash flows attributable to assets acquired to be used in
R&D activities), a contributory asset charge would be used to remove the benefits of net
after-tax cash flows associated with the activities that are unrelated to assets acquired
to be used in R&D. Maintenance, consulting, service, and other ancillary revenues and
costs also would be eliminated from the adjusted PFI at this step. The task force
believes that ancillary revenues and costs should be excluded from the valuation
analysis of assets acquired to be used in R&D activities because ancillary revenues and
costs do not represent cash flows resulting directly from the assets acquired to be used
in R&D activities. Ancillary revenues and costs are an indirect benefit. While there might
be a conceptual basis for including the ancillary revenues and costs in the valuation
analysis, the task force believes that it is unlikely that the ancillary revenues’
contribution to the value of the assets acquired to be used in R&D activities would be
significant, after taking into consideration assumptions used by market participants and
applying appropriate expenses and contributory asset charges.
Example—IPR&D bundled with non-IPR&D. Company A acquired Company
5.3.37
X in a business combination. At the acquisition date of the business combination,
Company X was developing a software product. Company A plans to sell a solution that
will bundle the software product (IPR&D) under development acquired from Company X
with computer hardware (non-IPR&D) purchased from a third party. The solution is
expected to be sold for a single price, and Company A concludes that it cannot reliably
remove the revenues and costs associated with reselling the computer hardware from
the PFI attributable to the software product under development. Using an estimate of
the value of identifiable assets committed to the hardware reselling business (including
net working capital, tangible assets, and intangible assets), a contributory asset charge
is calculated and charged against the combined after-tax cash flow of the solution for
the use of those assets representing the business of hardware resale. The remaining
after-tax cash flows would be attributable to the software product under development.
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5.3.38
At this point, the remaining cash flows included in the adjusted PFI represent the
expected future cash flows that will be used as the basis for estimating the fair value of
assets acquired to be used in R&D activities, including specific IPR&D projects (final PFI).
PFI attributable to assets acquired to be used in R&D activities. The forecast of
5.3.39
future expected revenues and expenses included in the final PFI would extend only for the
estimated useful life of the related assets acquired. Thus, the fair value of assets acquired to
be used in R&D activities should not include the value inherent in gaining a market position
that may be retained after the value of the assets acquired to be used in R&D activities has
been exhausted. Except for a few specific industries (for example, pharmaceutical), best
practices suggest that the estimated life typically would be presumed to not extend beyond
five to seven years, unless there is objectively verifiable evidence to support a longer life for
the technologies. In many cases, the estimated life would be shorter than five to seven years,
which should be considered an outer limit for software and hardware technologies. However,
for pharmaceutical industries, the life of a patent compound that will be marketed as a drug
upon successful completion of development generally would be the patent life or the period of
market exclusivity, if longer. The pattern of cash flows (for example, growth rates and
profitability) would follow patterns that would be expected by market participants.
5.3.40
The final PFI should be further allocated into various subcomponents of the
assets acquired to be used in R&D activities. These subcomponents of the assets acquired
to be used in R&D activities may include patents, software copyrights, base (or core)
technology, developed product technology, specific IPR&D projects, technical drawings or
manuals, and general intellectual know-how. Each subcomponent generally would be
separately identified and valued (provided that subcomponent meets the criteria in
paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill).
5.3.41
A current product’s attributes and characteristics (known as functionality) are a
result of the functionality of prior versions or releases of the product (referred to as base or
core technology) and the functionality that was added as a result of the release of the current
product (referred to as developed product technology). As future versions of the products are
released, the revenue generated by those future products also will be a result of research
and development that is undertaken in the future (referred to as future R&D or future
technology). The forecast of expected future revenue is based on sales of products. At times,
there is a direct correlation between a technology project and a new product offering. When
the subcomponents of assets acquired to be used in R&D activities are used by many
product offerings, or when the subcomponents will be used over numerous
generations of product offerings, the valuation specialist should go through a process
of assigning a portion of the revenue stream from each product offering to the
subcomponents. The allocation of the cash flows to the subcomponents would consider
the relative contribution of developed product technology, current R&D projects, future
technology, and base (or core) technology over successive releases of products that
incorporate these subcomponents (the process of allocating the cash flows is referred to
as technology migration). The contribution of each subcomponent of technology will be
based on the specific facts and circumstances. The following factors would be
evaluated in determining the contribution of each subcomponent of technology:

•
•
•

Historical cost to develop the subcomponent
Dates that the development of the subcomponent began and was completed
Economic useful life of the subcomponent
80

•
•
•
•
•

Relative complexity of technical issues addressed and resolved by the subcomponent
Whether the subcomponent represents unique or proprietary technology, or an
alternative solution to other technologies in the marketplace
Whether the subcomponent is (or could be) protected by patents
Difficulty of designing around the patented technology of the subcomponent
Whether the technology in the subcomponent allows the company to charge
premium prices for the product

5.3.42
Figure 5.3.42 illustrates the contribution of the technology subcomponents to
the forecast of expected future revenue included in the final PFI. In year 1 (the year
immediately following the acquisition), a significant portion of the forecasted expected
future revenue is attributed to the developed product technology (that is, the products that
existed at the date of acquisition) with assistance from the base (or core) technology,
whereas in year 5, a significant portion of the forecasted expected future revenue is
attributed to R&D that is expected to be performed subsequent to the date of acquisition.

5.3.43
The allocation of value to the subcomponents (that is, technology migration)
may be reflected in the final PFI as either—

•
•

Adjustments to revenues and costs to eliminate everything but revenues and costs
associated with a specific IPR&D project (known as revenue splitting).
Contributory asset charges related to developed product technology and base (or
core) technology (charges that decrease over time) and future technology (charges
that increase over time).

5.3.44
The revenue-splitting method may be appropriate in circumstances where a
company has numerous separable businesses; products or services; or in the case of
technology, numerous subcomponents, such as base (or core) technology, developed
product technology, in-process technology, and future technology. When the assets
acquired (or some subset thereof) produce measurable economic benefit only in
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combination with one another, the task force believes that the best way to isolate
individual asset values is through a revenue splitting exercise. The splitting of revenues
in this fashion for technology may be a preferable alternative to applying contributory
asset charges (or economic rents) for the use of base (or core) or developed
technologies. Contributory asset charges can be used in situations where the fair value
of contributory assets can be separately estimated.
Example—technology migration. Company A acquired Company X in a
5.3.45
business combination. Company X releases annually a major new version of its
software products. At the acquisition date of the business combination, Company X has
under development the second release of a software product (that is, Version 2 or V2).
Historically each release has doubled the functionality of the product, and Company A
expects this to continue. The relative contributions over multiple releases (that is, the
technology migration) are estimated as follows:
PFI Year
1

2

3

100%

50%

25%

12.5%

6%

In-process technology (Version 2)

0%

50%

25%

12.5%

6%

Future technology

0%

0%

50%

75%

88%

100%

100%

100%

100%

100%

Developed product technology
(Version 1)

4

5

5.3.46
Upon acquisition, Company A concludes that Version 2 qualifies as an IPR&D
project. Accordingly the percentage of annual forecasted revenues attributable to the
IPR&D subcomponent of the project (that is, Version 2) would be only 50 percent of the
forecasted revenues for year 2 (the year in which Version 2 is initially released), 25
percent of the forecasted revenues for year 3, and so on. In the example above, the
revenue split does not include an allocation to base (or core) technology; therefore, the
cash flows attributable to the R&D project would include a contributory asset charge
associated with the base (or core) technology used by or incorporated in the R&D
project. A number of factors would need to be considered in estimating the relative
contributions of the subcomponent technologies, including the number of lines of code
added or changed, and the functionality of the product that was added or changed by
each subcomponent. The valuation specialist gathers the underlying support for the
percentage allocations based on interviews with management from various departments
including R&D, marketing and sales, finance, and operations. Outside verification is
obtained through industry data and the valuation specialist’s experience with similar
companies and technologies.
5.3.47
The terms base technology and core technology are often used
synonymously. The basic definition reflects the existence of underlying technology that
has value through its continued use or re-use in many products or many generations of
a singular product (that is, a product family). This base (or core) technology of a
company may be represented by, for example, a portfolio of patents, a library of
potential candidates for therapeutic drugs, or a superior manufacturing capability. The
existence of base (or core) technology is dependent on facts and circumstances. In
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some cases, companies “in-license” technology that serves as a core or base for their
product development efforts. In other cases, base (or core) technology may not exist at
all, as each new product is developed from a new or novel technology platform.
5.3.48
The concept of technology migration also indicates technology re-use from
one generation of a product to the next. In that circumstance where technology
migration is present, some would describe today’s developed product technology (that
is, technology manifested in current product offerings) as tomorrow’s base (or core)
technology (through its re-use in future product offerings). In this circumstance,
especially when the re-usable technology has a one-to-one correspondence to a
product family, the delineation between what may be referred to as developed product
technology and base (or core) technology may blur.
5.3.49
Even when using a valuation model that splits revenues or profits, it may be
necessary to set up a separate category for base (or core) technology because it
derives its economic value from its use with many products or product families, as well
as ongoing developmental efforts. It no longer exhibits, strictly speaking, the one-toone correspondence that a single-product technology migration model might indicate.
The consideration of a simulated royalty is one alternative to a “revenue split” model,
as it effectively “profit-splits” the income stream. That royalty also can be applied
against future revenues to capture continued re-use of the base (or core) technology.
It is important to note that, in a valuation model that splits revenues or profits, care
must be taken to ensure that proper consideration is given to all completed
technology, both base (or core) and developed product technology. If the split includes
a category that properly comprises both base (or core) and developed product
technology, no further disaggregation is necessary. However, if the split of revenue or
profits considers only the migration of developed product technology, it is necessary to
provide for a separate category comprising base (or core) technology to the extent
that base technology exists.
5.3.50
From a GAAP perspective, the use of two categories of technology
(base/developed and in-process) versus three categories of technology (base,
developed, and in-process) is significant if the categories of base and developed
product technology exhibit different amortizable useful lives (because the value of both
technologies is capitalized and amortized, provided each category meets the criteria in
paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill).
However, if the useful lives are the same, developed product technology and base (or
core) technology may be combined into one category in a valuation model which “splits”
revenues or profits.
5.3.51
The remainder of this section of the chapter focuses on the application of the
multi-period excess earnings method in the valuation of a specific IPR&D project.
Revenue attributable to the IPR&D subcomponent. At this point the valuation
5.3.52
specialist has become satisfied that the revenue expectations specifically attributable to
a specific IPR&D project have been isolated on an appropriate basis.
Expenses attributable to the IPR&D subcomponent. Expenses to be attributed to
5.3.53
the IPR&D subcomponent should include costs of sales, selling and marketing expenses,
general and administrative expenses, maintenance R&D costs (including only ongoing
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charges to debug or maintain technology, once completed), costs to complete technology,
any one-time roll-out or launch costs, contributory asset charges, and income taxes.
Unrelated expenses, including costs of financing, should not be deducted in arriving at
after-tax cash flows. All expense levels should reflect that which would be expected to be
experienced by market participants, as opposed to a specific party to the transaction.

•

•

•

Technical support expense attributable to IPR&D. In many industries, technical
support is provided as part of product sales or in exchange for product maintenance
fees. To the extent that such fee revenues are appropriately not included in the
expected future cash flows attributable to specific IPR&D projects, it would not be
appropriate for the associated expense to be included in the expected future cash
flows. If, however, such technical services are incapable of being unbundled from
the product sale, the appropriate level of expense should be reflected in the PFI.
See paragraph 5.3.35 for guidance on the elimination of non-IPR&D activities,
including ancillary revenues.
R&D expense attributable to IPR&D. In the case of a project that is categorized as an
asset to be used in R&D, there is generally a significant up-front expense related to R&D
costs to complete. Also, there are typically ongoing expenses that may be incurred by the
R&D staff, subsequent to project completion that may relate to maintenance, debugging,
post-market approval surveillance, and other activities. The product roadmap of the
acquired company, combined with R&D budgeting documents, will serve as primary
source material evidencing appropriate levels of costs to complete and ongoing
expenditures. A useful cross-check is to sum all project costs-to-complete and ongoing
expenditures per year and compare to the total R&D budget or R&D expense as a
percentage of sales historically for the acquired company, acquiring company, or both,
and for the market participants, when relevant data is available.
Tax expense attributable to IPR&D. Objective evidence to support particular
assumptions used in the PFI include historical financial data, industry data, and
statutory rates. Care should be taken not to reflect specific tax circumstances of the
acquired company, acquiring company, or both, in choosing the effective tax rate,
such as net operating loss carry-forwards, penalties, and special payments. Industry
data demonstrating the effective tax rate experienced by market participants should
be carefully considered and compared with company-specific data and statutory
rates. See paragraph 5.3.97 for guidance on the impact of income taxes on the
determination of fair value of assets acquired.

5.3.54
Step 7—Apply Contributory Asset Charge for Assets That Contribute to
the Generation of the Cash Flows
5.3.55
As noted previously, the application of the income approach to the valuation
of intangible assets acquired typically is performed using the multi-period excess
earnings method. The fundamental premise of the multi-period excess earnings
method is that the value of an intangible asset is equal to the present value of the net
cash flows attributable to the subject intangible asset. The net cash flows attributable
to the subject asset are those in excess of fair returns on all the assets that are
necessary to the realization of the cash flows. These assets include not only assets
purchased in the instant transaction, but all assets required to realize the cash flows.
The acquiring company already may own some of these assets or may need to
purchase them in a separate transaction, if they are necessary to generate the
expected future cash flows in the aggregate. The contributory asset charges would be
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based on the fair value of the contributing assets (for example, fixed assets and
customer list). After-tax cash flows of each intangible asset are charged after-tax
amounts representing a return of and a return on these contributory assets based on
the fair value of such contributory assets.
5.3.56
These fair returns are frequently called contributory asset charges, capital
charges, or economic rents. They represent the contribution of other assets to the
overall value realized for a particular intangible asset (for example, an IPR&D project).5
5.3.57
The principle behind a contributory asset charge is that each IPR&D project
“rents” or “leases” from a hypothetical third party all the assets it requires to produce the
cash flows resulting from its development, that each project rents only those assets it needs
and not the ones that it does not need, and that each project pays the owner of the assets a
fair return on (and of, when appropriate) the fair value of the rented assets. Thus, any net
cash flows remaining after such charges are attributable to the subject IPR&D project.
5.3.58
For self-constructed assets, such as customer lists, the cost to replace them
(that is, the return of value) typically is included in normal operating costs and, therefore,
already is factored into the PFI as part of the operating cost structure. Likewise, the return
of fixed assets can be included in a cost structure as depreciation or amortization.
Because this component of return is already deducted from the subject revenues, the
returns charged for these assets would include only the required return on the investment
and not the return of the investment in those assets. Where returns of the asset are not
included in the operating cost structure, a return on and of value would be charged.
Types of contributory assets.6 Capital charges should be made for all assets
5.3.59
(including elements of goodwill) that contribute to the realization of the expected future cash
flows. Similarly, capital asset charges would not be made for assets that do not contribute to
the expected future cash flows (for example, land held for investment should not be considered
as a basis for a charge if it is not necessary for the generation of expected future cash flows).
5.3.60
Assets make a contribution to the expected future cash flows by supporting
the realization of those cash flows. Examples of assets that may be charged for and the
type of contributions that they make include—

•

Working capital—Realizing cash flows from the commercialization of a new product
or service requires working capital for investment in receivables, inventory, and other
short-term assets. Whereas certain projects may have negative working capital
balances, the expectation is that a positive working capital balance is associated
with each project over the medium to long term. Working capital makes a
contribution to the project by allowing and supporting the normal business cycle.

5 See

Gooch & Grabowski, 1976, and Gooch, 1993.
The word asset is used loosely in the context of contributory assets. The task force recognizes that FASB
Statement No. 141 results in no allocation of purchase price to intangibles that do not meet the criteria in paragraph
39 of FASB Statement No. 141 for separate recognition apart from goodwill (some of which are described here as
“contributory assets”). Regardless of whether an intangible is a separately recognized asset for financial reporting
purposes, best practices suggest that “contributory asset” charges include charges for certain intangibles that do not
meet the criteria in paragraph 39 of FASB Statement No. 141 for separate recognition apart from goodwill.
6
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•

•

Fixed assets—Fixed assets allow for the physical production of products; the
workspace for the marketing, sales, and logistics functions for both tangible and
intangible products; and the facilitation of general management functions and corporate
overhead. Although the exact nature of the contribution of a particular desk to a specific
IPR&D project is most likely unknowable, a reasonable estimation would be used (for
example, an allocation of fixed asset charges on the basis of revenue).
Intangible assets—In addition to the above, business combinations may include other
assets. Paragraph A14 of FASB Statement No. 141 lists examples of intangible assets that
meet the criteria for recognition as a separate asset apart from goodwill, including:
marketing-related intangible assets; customer-related intangible assets; artistic-related
intangible assets; contract-based intangible assets; and technology-based intangible
assets. In addition, certain intangibles may make a contribution to expected future cash
flows even if they are not recognizable under FASB Statement No. 141. For example—
 Workforce-based assets—Intangibles that relate to the value of the established

employees or workforce of a company:
SAssembled workforce and trained staff
SNonunion status, strong labor relations, and favorable wage rates
SSuperior management or other key employees
STechnical expertise
SOngoing training and recruiting programs
5.3.61
As with working capital and fixed assets, a return should be charged for the use of
each asset as appropriate. However, a careful analysis would be made to determine
which assets contribute to which projects. Many contributory assets benefit most or all
projects, including current technologies. The total return earned by an asset should be
spread over the projects that benefit from that asset. The aggregate return calculated
for a contributory asset should be allocated to the individual projects acquired. A project
that uses twice as much of a contributory asset than another project should incur twice
the capital charge. When objective use information is available, it forms the basis of a
capital charge allocation. In the absence of reliable data, a reasonable assumption is
used. Capital charges generally are allocated to projects based on the relative revenue
of each project. When an asset is not expected to contribute to a particular project, its
return is not charged against that project (its return is, however, charged against all of
the projects to which it does make a contribution).
5.3.62
Basis for determining charges. Contributory asset charges should be based
on the concept that the owner of that asset should reasonably expect to get a return on
and of the fair value of the asset that is commensurate with the risk of that asset and the
returns earned by market participants on similar assets. The fair value of the asset may
not be the same as the current carrying value or the value recorded in the allocation of
the purchase price.
5.3.63
The fair value of contributory assets may be expected to change over time. For
example, working capital may be assumed to remain a constant percentage of sales and,
therefore, would be expected to change as the estimate of future sales changes. It should
be noted that a technology-based business may have high scalability relative to working
capital, fixed assets, and possibly other assets (for example, a software company may be
able to grow revenue ten-fold without significantly increasing its fixed assets).
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5.3.64
The following table provides examples of assets typically charged for and the
basis for determining the fair return, and it presumes the return of the asset is reflected in
the operating costs when applicable (for example, depreciation expense). The capital asset
charge is the product of the asset’s fair value and the required rate of return on the asset.
Basis of Charge

Asset
Working capital

Short-term lending rates for market
participants (for example, working capital
lines or short-term revolver rates)

Fixed assets (for example, property,
plant, and equipment)

Financing rate for similar assets for market
participants (for example, terms offered by
vendor financing), or rates implied by
operating leases, capital leases, or both
(typically segregated between returns of [that
is, recapture of investment] and returns on).

Workforce (which is not recognized
separate from goodwill), customer lists,
trademarks, and tradenames

Weighted average cost of capital (WACC)
for young, single-product companies (may
be lower than discount rate applicable to a
particular project—see paragraph 5.3.90).

Patents

WACC for young, single-product companies
(may be lower than discount rate applicable
to a particular project—see paragraph
5.3.90). In cases where risk of realizing
economic value of patent is close to or the
same as risk of realizing a project, rates
would be equivalent to that of the project.

Other intangibles, including base (or
core) technology

Rates appropriate to the risk of the subject
intangible. When market evidence is
available it should be used. In other cases,
rates should be consistent with the relative
risk of other assets in the analysis and
should be higher for riskier assets.

Contribution for unallocated purchase price.7 The general principle of
5.3.65
contributory asset charges is to provide a return on the fair value of all assets necessary
for the realization of the cash flows. In deciding whether a contributory charge for
elements of goodwill is appropriate, the valuation specialist first would determine if the
other assets, including intangibles, represent all the assets necessary to support those
particular cash flows. Generally, the allocation of value to acquired intangibles and the
consideration of other intangibles (that is, intangibles from sources other than the
subject purchase, such as the acquiring company’s existing intangibles) would provide
all of the necessary contributory asset charges.

7

See footnote 4.
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5.3.66
However, if the identification of other assets explains only a small portion of
the consideration, further analysis is required. The valuation specialist should
determine the likely sources of the unidentified value and their relationship to the
subject asset. Significant unidentified value may be attributable to a synergistic or
market premium paid by the buyer (this value would not, under the fair value premise,
be associated with the individual assets). If the valuation specialist believes that the
unidentified amount is a synergistic premium, it is not an asset that is required to
realize the subject cash flows.
Period of charge. Returns should be charged over the period that the subject
5.3.67
project requires such assets. In the case where a project requires an asset that has an
economic life of three years but the project has a life of six years, the capital asset
charge would be over the entire six years. The assumption is that the investment in that
asset is replaced over time as the asset is amortized and that the subsequent new
investment requires the same type of return that the original investment required. It
should be noted that the continuation of charges over the life of the project (versus the
asset life) prevents the unreasonable situation where the later project cash flows are
“free” money (that is, are not reduced by capital charges).
5.3.68
Step 8—Calculate the Present Value of the Cash Flows Using a Discount
Rate Appropriate for the Specific Asset Acquired Being Valued
5.3.69
As noted previously, the most common method used by valuation
specialists to estimate the fair value of an intangible asset is the multi-period
excess earnings method. Under this method, the future after-tax net cash flows
expected to arise from the ownership of an identified intangible asset are
discounted to their present value using an after-tax discount rate. In applying the
multi-period excess earnings method, valuation specialists most often rely on a
best estimate of future cash flows, which are discounted at a single, all-in interest
rate. An issue addressed by the task force is whether this technique for estimating
fair value is acceptable under GAAP.
5.3.70
Before FASB Concepts Statement No. 7, Using Cash Flow Information and
Present Value in Accounting Measurements, guidance about the appropriate use of
present value techniques in accounting was limited and not always consistent.
5.3.71
The task force observes that the technique typically used in the application of
the multi-period excess earnings method is similar to the traditional approach, as
described in FASB Concepts Statement No. 7. The acceptability of the traditional
approach from the viewpoint of GAAP is found in several references in the accounting
literature. Although perhaps more suited for measuring the fair value of assets with
contractual cash flows, the task force notes that the traditional approach is one
measurement alternative described in FASB Statement No. 121, Accounting for the
Impairment of Long-Lived Assets and for Long-Lived Assets to Be Disposed Of. That
Statement provides guidance about estimating the fair value of long-lived assets,
including intangible assets, following a determination that an impairment in an asset
should be recognized. Specifically, paragraph 7 of FASB Statement No. 121 notes that
in the absence of a market price for a long-lived asset:
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The estimate of fair value shall consider prices of similar assets and the
results of valuation techniques to the extent available in the circumstances.
Examples of valuation techniques include the present value of estimated
future cash flows using a discount rate commensurate with the risks involved,
option-pricing models, matrix pricing, option-adjusted spread models, and
fundamental analysis. [Emphasis added]
5.3.72
Paragraph 9 of FASB Statement No. 121 provides guidance about
estimating cash flows for purposes of measuring impairment, requiring that it should
be the “best estimate based on reasonable and supportable assumptions and
projections.” The FASB acknowledged in paragraph 89 of that Statement that the
language in paragraph 9 allows the use of either a single most likely estimate or a
range that considers the probability of possible outcomes. The latter alternative
(described in FASB Concepts Statement No. 7 as the expected cash flow approach)
is discussed more fully in the following paragraphs. In reaching this conclusion, the
FASB determined that it was more useful to permit techniques that were currently
available and to allow for the use of new techniques that may be developed in the
future rather than to prescribe specific techniques.
5.3.73
The task force reasoned that if the traditional approach was acceptable in
estimating the fair value of similar assets under FASB Statement No. 121, the income
approach used by valuation specialists was an acceptable technique to estimate the fair
value of intangible assets acquired in a business combination accounted for under
FASB Statement No. 141.8
5.3.74
In FASB Concepts Statement No. 7, the FASB concludes that fair value is
the objective in using present value in measurements at initial recognition and fresh
start measurements of assets. Although acknowledging that the simplicity of the
traditional approach has caused it to enjoy a broad acceptance in practice, the
FASB describes the expected cash flow approach as generally a superior
measurement technique. This approach uses expected cash flow measurements
discounted at the risk-free rate of interest. The FASB notes that the improvement in
the measurement capabilities of the expected present value (which is the result of
the expected cash flow approach) is particularly true in situations involving the
complexities encountered in measuring the fair value of nonfinancial assets,
including intangible assets.
5.3.75
Expected cash flow is defined as “the sum of probability-weighted
amounts in a range of estimated amounts; the estimated mean or average.” For
example, if the population of future cash flow outcomes was $10, $100, and
$1,000, which had probabilities of occurring of 10 percent, 40 percent, and 50
percent, respectively, the expected cash flow is $541 ([$10 x 10%] + [$100 x 40%]
+ [$1,000 x 50%]). If it is assumed for the purposes of this example that all the
outcomes would occur one year from today, the expected present value of the
cash flow is $515.24 using a discount rate (risk-free rate of return) of 5 percent
8

The proposed FASB Statement, Accounting for the Impairment or Disposal of Long-Lived Assets and for
Obligations Associated with Disposal Activities, addresses the appropriate use of present value techniques when
measuring the fair value of an asset or asset group. The task force recommends that entities follow the
developments of that proposed Statement.
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($541/[1 + .05]). Note that in this example, the best estimate of future cash flow
as is used in the traditional approach is $1,000 because it is the most likely
outcome based on probabilities. To arrive at the same present value amount (that
is, $515.24) using the traditional approach, the rate necessary to discount the best
estimate of $1,000 would be approximately 94 percent. This example illustrates
one of the principal differences between the traditional approach and the expected
cash flow approach. That is, the expected cash flow approach focuses on the
variations in the amount and timing of estimated cash flows and their relative
probability of occurrence, whereas the traditional approach attempts to capture
those same factors by focusing on the selection of an interest rate that is
commensurate with the risk. To employ the latter approach requires that a similar
asset with similar cash flow characteristics exists in the marketplace and the rate of
return implicit in its market price may be measured. For many unique nonfinancial
assets, including IPR&D, the task force observes that comparable items in the
market may be very difficult to identify.
5.3.76
FASB Concepts Statement No. 7 notes that the following five elements of a present
value measurement, taken together, capture the economic differences between assets:
a.
b.
c.
d.
e.

An estimate of the future cash flow, or in more complex cases, series of future cash
flows at different times
Expectations about possible variations in the amount or timing of those cash flows
The time value of money, represented by the risk-free rate of interest
The price for bearing the uncertainty inherent in the asset or liability
Other, sometimes unidentifiable, factors including illiquidity and market imperfections

5.3.77
In selecting a discount rate to determine the present value of future cash
flow under the expected cash flow approach, in theory, only the third element (riskfree rate of return) is needed because elements b, d, and e are incorporated in the
cash flows. In practice, it may be more practical to adjust the risk-free rate of return
to compensate for systemic risks (see paragraph 69 of FASB Concepts Statement
No. 7) rather than attempting to adjust estimates of future cash flows for these risks.
Adjustments to the discount rate are needed for elements b, d, and e in applying the
traditional approach.
5.3.78
The FASB notes that many CPAs routinely do not use the expected cash flow
approach and, therefore, may be reluctant to depart from the apparent simplicity of the
traditional approach, arguing the high level of subjectivity involved in assigning
probabilities to cash flow outcomes. However, the FASB observes that the subjectivity is
no greater than that involved in selecting a discount rate under the traditional approach.
The FASB also notes the explicit assessment of the probabilities associated with the
possible cash flow outcomes provides computational transparency compared with
selecting a discount rate commensurate with the risks.
5.3.79
The task force notes that the use of probability-adjusted cash flows is more
commonplace in the pharmaceutical, insurance, natural resource, and other industries
in which management has developed a reasonable basis for estimating relative
probabilities. Accordingly, the task force believes the expected cash flow approach
should be used by companies with relevant historical experience to estimate the fair
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value of intangible assets, including IPR&D. Exhibit 5-1 includes an example of the
application of the expected cash flow approach in a pharmaceutical setting.
5.3.80
The task force notes that FASB Concepts Statement No. 7 states, “Like
any measurement, the application of an expected cash flow approach is subject to
a cost-benefit constraint. In some cases, an entity may have access to
considerable data and may be able to develop more than general statements about
the variability of cash flows without incurring considerable cost.” The task force
expects that, in practice, the traditional approach will continue to serve as the
method that often will be used to estimate the fair value of an intangible asset
acquired, including assets acquired to be used in R&D activities. Nevertheless, the
task force encourages the discipline embodied in explicitly addressing the
variability in the timing and amount of cash flows.
Selection of discount rates. The following paragraphs describe the process for
5.3.81
selecting discount rates for valuing specific IPR&D projects under the traditional approach.
5.3.82
GAAP prescribes that, under the traditional approach, the appropriate
discount rate used to determine present value is the rate commensurate with the risk.
That is, in addition to the time value of money (risk-free rate of return), the discount rate
should include the premium that market participants command for bearing the
uncertainties in the estimates of future cash flows from the IPR&D project.
5.3.83
Estimates of future cash flows from new product launches are subject to a
variety of risks or uncertainties, including—

•
•
•
•
•
•

Time to market.
Market and customer acceptance.
Viability of technology.
Regulatory approval.
Competitor response.
Price/performance characteristics.

5.3.84
Unlike business investment projects involving the launch of previously
developed products, the cash flow estimates for an IPR&D project have the added
uncertainty associated with the completion of the development effort (that is, whether
the development effort will result in the new knowledge or technology that is a
necessary first step to achieving the cash flows anticipated from its commercialization).
In addition, the relative success of the development effort and the timing of the
development project’s completion have a significant effect on the subsequent risks and
uncertainties associated with its commercialization. Accordingly, the task force believes
that risk premiums for IPR&D projects should be significantly higher than projects
involving the application of existing knowledge or technology.
5.3.85
The task force believes that the risk premium should decrease as a project
successfully proceeds because the uncertainty about accomplishing the necessary first
step, and as a result each subsequent step, diminishes. Accordingly, the uncertainty
about the cash flows that are estimated to arise from commercialization of a successful
project should decline as the project proceeds. Unfortunately, observable markets for
the risk premiums that are charged by market participants to fund IPR&D projects do
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not exist, let alone provide insight on how those premiums are likely to vary as progress
to completion of projects is made. In the absence of a market, identification of
observable rates charged in similar or comparable risk situations is the next best
approach. Many times, however, the search for specific comparables may prove
unsatisfactory. It is in this context that valuation specialists often find themselves when
valuing specific IPR&D projects acquired as part of a business combination.
5.3.86
The task force concluded that practice could be improved by providing fences
(or ranges) within which discount rates for specific IPR&D projects are presumed to fall.
Where the selected rate falls in that range is influenced by the stage of completion of
the project. The task force cautions valuation specialists that very early stage projects
may not have progressed to the point that reasonably reliable estimates of cash flows
from the commercial exploitation of the development effort can be made. The task force
believes that valuation specialists should be skeptical about whether the fair value of
acquired IPR&D projects that have had only limited activity can be estimated with
reasonable reliability.
5.3.87
For acquired IPR&D projects that the valuation specialists have
concluded are estimable with reasonable reliability, the task force observed that the
projects often have risk profiles similar to early stage development enterprises
funded by venture capital financing. The task force noted that venture capital
continues to be an important source of R&D funding. As such, it provides an
observable market for the cost of capital used to fund R&D activities. The task
force noted that venture capital financing was better characterized as equity
financing, because commercial lending, at least in the early stages of development,
is unlikely.
5.3.88
The task force identified two publications that provide guidance about the
rates of return commanded by venture capital investors at various stages of an entity’s
development. A summary is set forth in table 5.3.88.
Table 5.3.88
Rates of Return
Stage of Development

Plummer 9

Scherlis and Sahlman10

Start-up

50%–70%

50%–70%

First Stage or “Early Development”

40%–60%

40%–60%

Second Stage or “Expansion”

35%–50%

30%–50%

Bridge/IPO

25%–35%

20%–35%

9 Plummer,

James L., QED Report on Venture Capital Financial Analysis (Palo Alto: QED Research, Inc., 1987).
Scherlis, Daniel R. and William A. Sahlman, A Method for Valuing High-Risk, Long Term, Investments: The
Venture Capital Method (Boston: Harvard Business School Publishing, 1987).
10
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5.3.89
As described in the publications referenced in table 5.3.88, start-up stage
investments typically are made in companies that are less than a year old. The
venture funding is to be used substantially for product development, prototype testing,
and test marketing. Early development stage investments are made in companies that
have developed prototypes that appear viable and for which further technical risk is
deemed minimal, although commercial risk may be significant. Companies in the
expansion stage have usually shipped some product to customers (including beta
versions). Bridge/IPO stage financing covers such activities as pilot plant construction,
production design and testing, as well as bridge financing in anticipation of a later
initial public offering.
5.3.90
The task force concluded that in developing a range of discount rates to
be used in valuing IPR&D under the traditional approach, the rate of return
expected for start-up investments could be used as the upper boundary for the
selection of a discount rate for early stage IPR&D projects. The task force
concluded that, once an IPR&D project is complete, a premium over the weighted
average cost of capital (WACC) observable for young, single-product companies in
the acquired company’s industry segment could be used to approximate a market
discount rate for projects with similar risks. For practical purposes, the task force
observes that the use of the WACC without the premium may be a reasonable
approach. These rates would serve as the lower boundary for discount rates used
for completed R&D projects (that is, developed product technology). The task force
noted that young, single-product companies in the same industry segment are
more likely to exhibit risk characteristics similar to completed IPR&D projects. The
task force believes that an IPR&D project should be thought of as an early stage
entity, even if it is actually being conducted by an established or diversified entity.
Therefore, the best way to estimate an appropriate discount rate for assets to be
used in R&D activities, including specific IPR&D projects, would be to determine
the WACC of several early stage entities that intend to provide the same or similar
products or services. The task force noted that it was inappropriate to use the
WACC of a large or diversified entity for valuing IPR&D because the goal of
valuation is to approximate the rates of returns required by market participants on
the project assets. Entities whose value is based partially on such items as
established brand names, significant financial resources, or a diversified (and thus
less risky) product line will generally have a lower WACC, reflecting these less
risky operations.
5.3.91
The task force also observed that the WACCs for such young, single
product companies are not unlike the rates commanded by venture capital investors
for bridge/IPO investments. In developing anecdotal evidence for this observation,
the task force considered WACCs for young, public companies (market capitalization
less than $250 million) in industry segments for which IPR&D projects are often
identified (that is, Internet software and services, biotechnology, and networking and
communication devices). The results of this test (which may change as market
conditions change in the future) are shown in table 5.3.91.
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Table 5.3.91.
Weighted Average Cost of Capital in Young, Public Companies
Number of
Companies

Expected Returns*
Trimmed
Mean
Mean**

Median

Networking and Communication
Devices

25

19.9%

19.5%

19.6%

Biotechnology

62

19.3%

19.3%

19.2%

Internet Software and Services

20

29.3%

28.1%

25.6%

* The returns computations use a size-adjusted capital asset pricing model,11 assuming a risk-free rate of
6%, a market premium of 7.8%, and size adjustment of 3.3%. Betas were retrieved from Hoover’s Online
by selecting all companies in the indicated sub-industry with a market capitalization less than or equal to
$250 million. The capital asset pricing model and basic input data (long-term treasury rate, MRP, size
adjustments) were taken from Ibbotson Associates: Stocks, Bonds, Bills, and Inflation 1998 Yearbook:
Market Results for 1926-1997, pp.162–165.
** Excludes the smallest and largest 5% of observed returns from the computation.

11

In developing the statistics in this table, the task force made use of the size-adjusted Capital Asset
Pricing Model (CAPM). CAPM is one of several asset return models. The use of the CAPM in the task
force’s report is not intended to proscribe the use of other widely accepted approaches to estimating an
entity’s cost of equity capital. Rather, the task force chose to use a version of the CAPM to illustrate the
goals of arriving at an estimated weighted average cost of capital (WACC) when valuing in-process
research and development because of its broad acceptance in the finance community. The task force
notes that debt financing is not commonly used to finance the entities that the task force believes are
appropriate proxies. This simplifies the WACC estimation to estimating the required return on equity of
proxy entities. The formula used, together with an explanation of the variables used, is as follows:
Ke = rf + β x (rm - rf) + P
Each of these inputs is discussed in further detail below.
Risk-free Rate (rf): The risk-free rate is the return on government securities with a term similar to that of the
investment being valued.
Market Risk Premium (MRP = rm – rf): The market risk premium (MRP), also known as the equity risk premium,
is defined as the additional rate of return over the risk-free rate that is expected by investors from
investments with systematic risk equal to the “market” portfolio. The market portfolio can be thought of as
a broadly diversified investment portfolio, often thought of as the return on an index such as the S&P 500.
Beta (ß): The theory and application of beta as a modifier of the MRP are well documented and widely
accepted. Beta is a measure of the risk of an entity’s stock relative to the risk of a diversified portfolio (the
MRP). Rather than explain the nature of how to estimate beta, the task force notes that there are many
available sources of betas. Because the estimation procedure is not controversial, those sources may
normally be relied on.
Size Premium (P): Research has shown that small companies have larger betas than large companies.
The adjustment is necessary because small stocks outperform large stocks, even after adjusting for the
systematic risk (beta) of small stocks. This phenomenon is widely known as the size effect.
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5.3.92
The task force’s conclusions about the expected behavior of discount rates
over the life of an IPR&D project and the presumed lower boundary from which discount
rates may be selected for young, single-product companies are illustrated in figure 5.3.92.

5.3.93
Paragraph 39 of FASB Statement No. 2 states, “There is normally a high
degree of uncertainty about the future benefits of individual research and development
projects, although the element of uncertainty may diminish as a project progresses
[emphasis added].” Accordingly, the selection of the discount rate in the range between
the upper and lower boundary would be based in part on stage of completion. That is,
earlier stage projects would be closer to the upper boundary, whereas a project nearing
completion would be expected to be closer to the lower boundary. As progress toward
completion is made, the task force expects discount rates would behave in a “step”
fashion, reflecting the reduction of risk as progress is achieved. That is, even though
development activities may be taking place, technological or engineering risk may not
be reduced until a particular hurdle has been accomplished.
5.3.94
One reasonable approach to determine the point in the range of discount
rates that would be selected for a particular project would be to analyze each
performance step, milestone, or task in the project and assign a weight to those steps,
milestones, or tasks based on their relative technical complexity. It would not be
expected that each step or task would necessarily reduce technological risk in the same
proportion. If, for example, the cumulative weighting for steps or tasks completed at the
acquisition date indicates that half of the technological complexity had been solved, the
rate to be selected should fall at or above the rate in the midpoint of the range for stage
of completion.
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5.3.95
Paragraph 47 of Statement of Position (SOP) 81-1, Accounting for
Performance of Construction-Type and Certain Production-Type Contracts, notes that
stage of completion (or progress toward completion) generally is best measured by
output measures in circumstances in which a reliable measure can be established.
Output measures (for example, milestones, units produced or delivered, and value
added) measure progress directly. Where output measures are not reliable, input
measures or efforts expended should be used as an indirect measure of progress.
5.3.96
As figure 5.3.92 also illustrates, discount rates may vary for reasons other
than stage of completion (that is, at each stage of completion there may be a range of
discount rates). Where in this range of discount rates a particular IPR&D project falls
requires the consideration of a variety of factors and ultimately, the application of
judgment. Some of the factors that should be considered and their impact, at least
directionally, on the judgment reached are as follows:

•

•
•
•
•

Industry segment. Industries or subsegments within an industry may be characterized by,
for example, rapid technological or competitive change. The task force believes that the
discount rates for companies in those industries or subsegments would be at the higher
range of possible rates. For example, within the software industry, products of enterprise
software developers may be characterized by structured development projects for software
that are expected to have long useful lives (for example, five to seven years). In contrast,
products of Internet software developers would be expected to have shorter useful lives. A
discount rate selected for IPR&D projects of enterprise software developers would be
expected to be lower than Internet software developers.
Nature of expected product, service, or process to be developed. The development of a
new product, service, or process would be expected to have greater commercial risks
than a significant improvement to a product that has achieved commercial success.
Length of time to complete the project. The longer the development horizon, the greater
the risk that the expected market for the new product, service, or process will change.
History of the company bringing products to commercial success. The more experience
the company has with successfully completing development of products and bringing
those products to market, the lower the risks about the company’s ability to assess the
status of the project and the greater the likelihood of commercial success.
Competitive position. If the IPR&D project is expected to introduce a product that will
be the first to market, expectations about commercial success may be higher than a
project that will result in a follow-on product.

5.3.97
Step 9—Compute the Related Income Tax Benefits Resulting From the
Amortization of the Asset Acquired for Income Tax Purposes
5.3.98
The task force believes that the valuation of an intangible asset would include
(a) the expected tax payments resulting from the cash flows attributable to the intangible
asset and (b) the tax benefits resulting from the amortization of that intangible asset for
income tax purposes.12 Including the tax effects in the valuation is common in the
12

As noted in paragraph 41 of FASB Concepts Statement No. 7, Using Cash Flow Information and Present
Value in Accounting Measurements, “interest rates used to discount cash flows should reflect assumptions that
are consistent with those inherent in the estimated cash flows.” That is, assumptions about taxes and discount
rates should not result in double counting their effects.

96

income and cost approaches. It is not typical in the market approach because any tax
benefits already would be factored into the quoted market price through the negotiation
of market participants during the bid-and-ask process.
5.3.99
When the business combination is structured as an asset sale for tax
purposes (as opposed to a stock sale), practice typically includes the associated tax
benefits in the valuation of the assets acquired because it is assumed that the assets
acquired will be amortized for both book and tax purposes. When a stock sale occurs
without a corresponding change in the bases of assets acquired and liabilities assumed
for tax purposes, some have argued that no tax benefit should be included in the
valuation of the intangible assets acquired because the buyer will not amortize the
intangible assets acquired for income tax reporting purposes.
5.3.100 Before FASB Statements No. 96 and No. 109, Accounting for Income Taxes,
the net-of-tax approach was used in assigning values to assets acquired and liabilities
assumed in a business combination. Under the net-of-tax approach, the future tax
effects of differences between fair values and tax bases and timing of those tax effects
(that is, discounting) were considered in assigning values to assets acquired and
liabilities assumed. Thus, before FASB Statements No. 96 and No. 109, deferred tax
assets and liabilities were not recognized in a business combination.13 FASB Statement
No. 109 prohibits the net-of-tax approach and requires assets acquired and liabilities
assumed to be recorded at their “gross” fair value.
5.3.101

Paragraph 129 of FASB Statement No. 109 states:

Paragraph 89 of APB Opinion 16 stated that “. . . the fair value of an asset to
an acquirer is less than its market or appraisal value if all or a portion of the
market or appraisal value is not deductible for income taxes.” The Board
believes that the net result is the same whether amounts assigned to the
individual assets acquired and liabilities assumed are pretax or net-of-tax. For
example, assume that the (a) pretax market or appraisal value of depreciable
assets acquired in a purchase business combination is $1,000, (b) tax basis of
those assets is zero, and (c) enacted tax rate is 40 percent for all years. If netof-tax, the assigned value of those assets would be $600. If pretax, the
assigned value of those assets would be $1,000, and there would be a $400
deferred tax liability. Under either approach, the net result of allocating the
purchase price is the same. The Board concluded that the amounts assigned
to assets and liabilities in a purchase business combination should not be net
of any related deferred tax liability or asset.
In either case, the acquired intangible asset in this example would be assigned a cost of
$1,000 for financial reporting purposes.
5.3.102 This issue should not be confused with the need to apply taxes to pretax income
streams to apply a particular valuation method, such as a discounted cash flow method. A
willing buyer would factor into the amount that it would be willing to pay the seller to acquire
13

See EITF Issue No. 96-7, “Accounting for Deferred Taxes on In-Process Research and Development Activities
Acquired in a Purchase Business Combination.”
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the seller’s business all incremental cash flows that inure to the benefit of that buyer. Those
incremental cash flows would be reduced by expected income tax payments using
appropriate tax rates. The task force believes that the determination of fair value would take
into account future income taxes that a market participant purchasing the asset would be
expected to pay, without regard to how the transaction is structured for income tax reporting
purposes (that is, whether the transaction is structured to result in a change in bases of
assets acquired and liabilities assumed for income tax reporting purposes). The task force
also believes that the fair value of an intangible asset would include the value of the tax
benefit resulting from the amortization of that asset because FASB Statement No. 109
requires that the cost assigned to an acquired intangible asset be the same whether the
asset is acquired piecemeal or in a nontaxable business combination in which the asset
had no corresponding tax basis. If the value of the tax benefit resulting from the
amortization of that asset were not included in the fair value of the intangible asset, it would
have the impact of stating that asset on the balance sheet “net of tax.” The task force
believes that only after the fair value is determined would the asset’s assigned value be
subjected to the deferred tax accounting requirements of FASB Statement No. 109. That is,
the deferred tax calculation is performed only after the determination of fair value is made.
5.3.103 Question 1: If Company A acquires the assets of Company X in a transaction
structured as an asset acquisition for income tax reporting purposes, and the allocation
of purchase price for financial reporting purposes includes an intangible asset that is
valued using a discounted cash flow method, would the expected future income taxes to
be paid resulting from the pretax expected future cash inflows to be generated by the
acquired intangible asset be deducted from the pretax cash flows in calculating the fair
value of the acquired intangible asset?
5.3.104 Answer: Yes. As discussed in paragraph 5.3.102, the application of the
discounted cash flow method would capture after-tax cash flows resulting from
ownership of the subject asset being valued.
5.3.105 Question 2: Assume the same set of facts as in 5.3.103. In addition, the
acquired intangible asset is deductible for income tax reporting purposes on a straightline basis over a fifteen-year life. Company A values the acquired intangible assets
using a discounted cash flow technique with a 45 percent discount rate. Because the
transaction was structured as an asset acquisition, there is a change in the bases of the
assets acquired for income tax reporting purposes. Further assume the following
regarding the acquired intangible asset:
Year 1
Estimated:
Pre-tax cash flows

Year 2

Year 3

$1,000

$1,000

$1,000

Income taxes @40%

400

400

400

After-tax cash flows

600

600

600

.6897

.4756

.3280

414

285

197

Present-value factor @45%
Present value of estimated after-tax cash flows
Sum

$ 896
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The estimated income tax benefit that results from amortization of the intangible asset for
income tax reporting purposes is $381 ([$896+381]*40%), using a market participant
assumed 40 percent income tax rate. The present value of those estimated income tax
benefits is $56, using a discount rate of 45 percent and a fifteen-year life for income tax
reporting purposes. Should the fair value allocated to the intangible be $896, representing
its value before consideration of tax deductibility, or $952, representing the value assuming
the acquired intangible asset is amortizable for income tax reporting purposes?
5.3.106 Answer: $952. As discussed in paragraph 5.3.98, the valuation of an
intangible asset would include the tax benefits resulting from the amortization for
income tax reporting purposes of that intangible asset.
5.3.107 Question 3: Assume the same facts as paragraphs 5.3.103 and 5.3.105,
except that the transaction was structured as a stock acquisition for income tax
reporting purposes (that is, a nontaxable business combination). Because the
transaction was structured as a stock acquisition instead of an asset acquisition, no
change occurs in the bases of the assets acquired for income tax reporting purposes.
The specific intangible asset under analysis has no tax basis. Should the fair value
allocated to the intangible asset be $896, representing its value without assuming tax
deductibility (that is, reflecting that no tax benefits will result from the asset), or $952,
representing the value assuming the acquired intangible asset is amortizable for income
tax reporting purposes irrespective of the asset’s actual tax attributes?
5.3.108 Answer: $952. As discussed in paragraph 5.3.98, the valuation of an
intangible asset would include the tax benefits resulting from the amortization of that
intangible asset for income tax reporting purposes. In addition, as discussed in
paragraph 5.3.102, the tax benefits associated with the amortization of that intangible
asset would be included in the valuation of the intangible asset without regard to
whether the transaction was structured as a taxable (that is, change in tax bases of
assets acquired) or nontaxable business combination (that is, no change in tax bases of
assets acquired).
5.3.109 Step 10—Evaluate the Overall Reasonableness of the Asset’s Value
Relative to the Other Assets Acquired and the Overall Purchase Price
5.3.110 The valuation specialist should reconcile the individual asset valuations to an
overall business enterprise valuation of the acquired company to ensure consistency of
assumptions. Feedback should be solicited from management and their advisers to
establish that the valuation analysis “hangs together.” To the extent that differences of
opinion exist, they should be reconciled and documented in an objective and
supportable fashion.
5.3.111 A business enterprise valuation assists the valuation specialist in concluding
on the appropriateness of PFI. The determination of business enterprise value is
beyond the scope of this Practice Aid.
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EXHIBIT 5-1
Pharmaceutical IPR&D Valuation Example: Expected Cash Flow Approach∗
Pharma Inc. acquired ABC Company, a developer, manufacturer, and marketer of
pharmaceutical products. One of the assets acquired in the business combination was a
research and development (R&D) project involving a compound that has possible
application in the treatment of certain cancers. At the acquisition date, the compound
was entering Phase II Clinical Testing in preparation for possible approval by the U.S.
Food and Drug Administration. Two possible indications (tumor types) for the
compound, that is, colorectal and prostate, were under development. The probabilities
of success at each phase based on historical experience are given in the following
table. The probability of success for each indication is independent of the probability of
success for the other, and neither indication has an alternative future use.
Probability of Advancing

Development Phase
Phase II

15%

Phase III

75%

Based on these indicators, the probabilities of reaching a commercial launch for each
indication is 11.25 percent (15% x 75% = 11.25%).
The after-tax development costs for each indication are $5 million for Phase II and $50
million for Phase III. It is estimated that it will take one year to complete each phase,
with all costs assumed to occur at the beginning of the period. The estimated cash flows
following a commercial launch for the two indications (assuming an eight-year
commercial life) are summarized in the following table. All amounts are in millions of
dollars after income taxes. The computation of the net present value (NPV) of those
cash flows is discounted using the risk-free rates of return applicable to the period (for
simplicity, this has been assumed to be a single rate of 6 percent throughout the yield
curve).1 The NPV amounts are computed to the start date of the remaining development
effort. For each indication, the probability of a high market potential is 30 percent and a
low market potential is 70 percent. The estimates for the probability of success were
based on historical experience with similar compounds.

∗ As mentioned in paragraph 5.3.79.
1

The use of the risk-free rates in this example is not intended to imply that the price for bearing uncertainty is
captured solely in the expected cash flows. As discussed in paragraph 62 of Financial Accounting Standards
Board (FASB) Concepts Statement No. 7, Using Cash Flow Information and Present Value in Accounting
Measurements, the estimate of fair value should include the price that market participants are able to receive for
bearing the uncertainty of the cash flows.
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Post-Launch Year
1

2

3

4

5

6

7

8

NPV

High

-61

43

122

195

281

305

329

342

975

Low

-50

35

80

100

160

180

190

190

554

High

-68

47

135

217

311

339

366

379

1082

Low

-56

39

90

105

166

190

205

210

593

Colorectal

Prostate

The following tree diagrams show the present value of the cash flows and related
probabilities for each indication:
Colorectal Tree
Fail
p=0.85
Cost = -5

Fail
p=0.25

p=0.15
Succeed
Cost = -47

Low
p=0.70

p=0.75
Succeed

p=0.30
High
Phase 2

Phase 3

Post-launch NPV = 554

Post-launch NPV = 975

Commercial
outcome

The probability-weighted present value of cash flows for the colorectal indication equals
$64.5 million.
Prostate Tree
Fail
p=0.85
Cost = -5

Fail
p=0.25

p=0.15
Succeed
Cost = -47

Low
p=0.70

p=0.75
Succeed

p=0.30
High
Phase 2

Phase 3

Commercial
outcome
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Post-launch NPV = 593

Post-launch NPV = 1082

The probability-weighted present value of cash flows for the prostate indication equals
$71.2 million.
Because the probabilities and values associated with the two indications are
independent of one another, the expected present value for the compound is the sum of
the expected present value for each indication, or $135.7 million.
An example of the computations associated with the amounts determined here are as
follows for the colorectal indication.
Commercial outcome—Low:

$554x.70x.75x.15

=

$43.63

Commercial outcome—High:

$975x.30x.75x.15

=

$32.91

Cost for Phase III:

-$47x.15

=

-$7.05

Cost for Phase II:

-$5x1.00

=

-$5.00
$64.50 rounded
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EXHIBIT 5-2.1
Sample Valuation Report—Transmittal Letter
March 31, 2002
Acquiring Company
Address
City, State, Zip code
In accordance with your authorization, we have made an investigation and valuation of
the intangible assets of
Target Company
headquartered in Mountain View, California, and hereby submit our findings in this report.
The purpose of this valuation is to provide an opinion as of January 21, 2002 (also
referred to as the acquisition or valuation date) of the fair value of the intangible assets,
in connection with the acquisition by Acquiring Company (Acquiror) of the stock of
Target Company (Target) for approximately $50 million. It is understood that our
findings will serve to assist management in their allocation of the purchase price to the
intangible assets acquired by Acquiror for financial reporting purposes under U.S.
generally accepted accounting principles (GAAP). This valuation report is intended
solely for the information and use of the managements of Acquiror and Target,
Acquiror’s independent auditors, and the respective companies’ legal counsel. It is not
to be used, circulated, quoted, or otherwise referred to for any other purpose, including,
but not limited to, the registration, purchase, or sale of securities, nor is it to be filed with
or referred to, in whole or in part, in a registration statement or any other document,
except that reference may be made to it in documents filed with the Securities and
Exchange Commission upon our express written consent.
For financial reporting purposes, the fair value of an asset is defined as the amount at
which the asset could be bought or sold in a current transaction between willing parties,
that is, other than in a forced or liquidation sale. Quoted market prices in active markets
are the best evidence of fair value and would be used as the basis for the
measurement, if available. If a quoted market price is not available, the estimate of fair
value should approximate the price at which the asset would be expected to be bought
or sold in a current transaction between a willing buyer and seller and would be based
on the best information available in the circumstances. The estimate of fair value should
consider prices for similar assets and the result of valuation methods to the extent
available in the circumstances. The method selected to determine fair value should be
consistent with the definition of fair value, as defined by GAAP. The method should
incorporate assumptions that market participants would use in their estimates of fair
values, future revenues, future expenses, and discount rates (if applicable).
Historical and prospective financial data furnished to us by management was subjected
to procedures consistent with the AICPA Practice Aid titled Assets Acquired in a
Business Combination to Be Used in Research and Development Activities, and the
data was deemed to represent business operations and conditions.
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Our report consists of the following:
1.
2.

3.

4.

This letter, identifying the assets valued, stating the objective and extent of the
valuation, and presenting the conclusions of fair value.
A narrative report, setting forth the purpose and scope of the valuation, the history
and nature of the business, economic perspectives, industry conditions, a
description of the assets valued, a presentation and correlation of the valuation
techniques employed, and the conclusion of fair value, including associated
exhibits, assumptions (including related support) and limiting conditions, certificate
of appraiser, and general service conditions.
Exhibits, comprising—
a. Exhibit A
Valuation Summary
b. Exhibit B
Business Enterprise Value (BEV)
c. Exhibit C
Existing Technology—Product PT
d. Exhibit D-1–D-4
Technologies Under Development
e. Exhibit E
Stage of Completion Analysis
f. Exhibit F
Tax Benefit Amortization Calculation
Statements of Assumptions and Limiting Conditions, Certificate of Appraiser, and
General Service Conditions. (Note to reader: these are not provided in this
Practice Aid.)

Working papers underlying the valuation are retained by the valuation specialist and are
available upon request and acquiror consent.
The intangible assets valued include the existing software technology, which includes
base (or core) technology and developed technology; technologies under development;
three noncompete agreements; an established trademark/trade name; and an installed
customer base.1 All current assets, tangible assets, other assets, and goodwill
associated with the product and professional services businesses were not subject to
independent valuation in this report. However, many of those assets were incorporated
into the valuation of the intangible assets through contributory asset charges. In
addition, the effects of the professional services business (activities that are not inprocess research and development [IPR&D]) were eliminated from the prospective
financial information used to value acquired IPR&D (see exhibit B to this report).
For the purpose of this valuation, audited historical financial statements, unaudited
financial information, other records and documents, and prospective financial
information (PFI) pertaining to the business operations and assets valued were
furnished. We make no representations about the achievability of this PFI. Actual results
may differ, and these differences could be material. We have not performed agreedupon procedures, a compilation, or an examination of the PFI as contemplated by the
AICPA standards covering such matters. However, we have performed certain
procedures to test the reasonableness of this PFI for use in the valuation process.
These procedures include, among others: (1) comparison of changes in unit volumes
and average selling prices over the life cycle of the technology with historical changes
1 The FASB recently issued FASB Statement No. 141, which provides guidance on determining which intangible
assets should be recognized apart from goodwill in the allocation of purchase price in a business combination.
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experienced by the Target, Acquiror, and the industry (per analysts’ reports); (2)
comparison of expected costs as a percent of revenue with historical results for the
Target, Acquiror, and the industry comparables; (3) changes in unit prices over the life
cycle of the technology with historical changes experienced by the Target, Acquiror, and
the industry (per analysts’ reports); and (4) preparation of a business enterprise value
that compares the PFI, in aggregate, to the purchase price paid. Explanations were
obtained for differences identified in these comparisons and the reasonableness of the
explanations was investigated. Based on these procedures, we have determined that
the PFI are reasonable and appropriate for use in reaching a conclusion of fair value for
the intangible assets.
Based on the investigation and analysis outlined above and on the valuation
approaches, methods, and techniques employed, it is our opinion that, as of January
21, 2002, the fair value of the acquired intangible assets2 of Target, is reasonably
represented in the aggregate amount of $18,493,600, distributed as follows:

Existing technology

6,398,100

Technologies under development

7,892,100

Noncompete agreements

1,849,200

Trademark/trade name

546,200

Customer list

1,808,000

Total

$18,493,600

A valuation summary is provided as exhibit A to this report.
Respectfully submitted,

Valuation Specialist or Firm

2

See footnote 1.
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EXHIBIT 5-2.2
Sample Valuation Report—Introduction
1. The purpose of this valuation is to provide an opinion as of January 21, 2002 (also
referred to as the acquisition or valuation date) of the fair value of the intangible assets, in
connection with the acquisition by Acquiring Company (Acquiror) of the stock of Target
Company (Target). It is understood that our findings will serve to assist management in
their allocation of the purchase price to the intangible assets acquired by Acquiror for
financial reporting purposes under U.S. generally accepted accounting principles (GAAP).
This valuation report is intended solely for the information and use of the management of
Acquiror and Target, Acquiror’s independent auditors, and the respective companies’ legal
counsel. It is not to be used, circulated, quoted, or otherwise referred to for any other
purpose, including, but not limited to, the registration, purchase, or sale of securities, nor is
it to be filed with or referred to, in whole or in part, in a registration statement or any other
document, except that reference may be made to it in documents filed with the Securities
and Exchange Commission upon our express written consent. Furthermore, it is
understood that financial accounting and reporting for the acquisition includes consideration
of the following accounting pronouncements and guidance:3

•
•
•
•
•

Financial Accounting Standards Board (FASB) Statement of Financial Accounting
Standards No. 141, Business Combinations
FASB Statement No. 142, Goodwill and Other Intangible Assets
FASB Statement No. 2, Accounting for Research and Development Costs
FASB Interpretation No. 4, Applicability of FASB Statement No. 2 to Business
Combinations Accounted for by the Purchased Method
AICPA Practice Aid Assets Acquired in a Business Combination to be Used in
Research and Development Activities

2. For financial reporting purposes, the fair value of an asset is defined as the amount at
which the asset could be bought or sold in a current transaction between willing parties,
that is, other than in a forced or liquidation sale. Quoted market prices in active markets are
the best evidence of fair value and would be used as the basis for the measurement, if
available. If a quoted market price is not available, the estimate of fair value should
approximate the price at which the asset would be expected to be bought or sold in a
current transaction between a willing buyer and seller and would be based on the best
information available in the circumstances. The estimate of fair value should consider
prices for similar assets and the result of valuation methods to the extent available in the
circumstances. The method selected to determine fair value should be consistent with the
definition of fair value, as that term is defined by GAAP. The method should incorporate
assumptions that market participants would use in their estimates of fair values, future
revenues, future expenses, and discount rates (if applicable).

3 See footnote 1. In addition, FASB Interpretation No. 6, Applicability of FASB Statement No. 2 to Computer
Software, and Statement of Position 98-1, Accounting for the Costs of Computer Software Developed or
Obtained for Internal Use, should be considered, if applicable.
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3. The intangible assets valued include the existing software technology, which includes
base (or core) technology and developed technology; technologies under development;
three noncompete agreements; an established trademark/trade name; and an installed
customer base.4 All current assets, tangible assets, other assets, and goodwill associated
with the product and professional services businesses were not subject to independent
valuation in this report. However, many of those assets were incorporated into the valuation
of the intangible assets through contributory asset charges. In addition, the effects of the
professional services business (activities that are not in-process research and development
[IPR&D]) were eliminated from the prospective financial information used to value acquired
IPR&D (see exhibit B to this report).
4. Historical and prospective financial data furnished to us by management were
subjected to procedures consistent with the AICPA Practice Aid titled Assets Acquired in a
Business Combination to Be Used in Research and Development Activities, and the data
were deemed to represent business operations and conditions.
5. For the purpose of this valuation, audited historical financial statements, unaudited
financial information, other records and documents, and prospective financial information
(PFI) pertaining to the business operations and assets valued were furnished. We make no
representations about the achievability of this PFI. Actual results may differ, and these
differences could be material. We have not performed agreed-upon procedures, a
compilation, or an examination of the PFI as contemplated by the AICPA standards
covering such matters. However, we have performed certain procedures to test the
reasonableness of this PFI for use in the valuation process. These procedures include,
among others: (a) comparison of changes in unit volumes and average selling prices over
the life cycle of the technology with historical changes experienced by the Target and the
industry (per analysts’ reports); (b) comparison of expected costs as a percent of revenue
with historical results for the Target and its industry comparables; (c) changes in unit prices
over the life cycle of the technology with historical changes experienced by the Target and
the industry (per analysts’ reports); and (d) preparation of a business enterprise value that
compares the PFI, in aggregate, to the purchase price paid. Explanations were obtained for
differences identified in these comparisons and the reasonableness of the explanations
was investigated. Based on these procedures, we have determined that the PFI are
reasonable and appropriate for use in reaching a conclusion of fair value for the intangible
assets.

4

See footnote 1.
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EXHIBIT 5-2.3
Sample Valuation Report—Industry Conditions (Internet)
6. The Internet market is a constantly evolving and highly volatile market, characterized
by rapid technology developments and frequent new product introductions. The needs of
the graphics professional are rapidly changing to encompass online publishing as well as
print-based publishing. The consumer software market, which is focused on digital imaging
and Web publishing, is characterized by intense competition, price sensitivity, brand
awareness, and strength in retail distribution. The dynamic media market is an increasingly
competitive market as professionals, enthusiasts, and home users migrate away from
analog video tools toward digital camcorders and digital video production.
7. The success of the Internet in streamlining business-to-consumer commerce is
encouraging companies to seek similar efficiencies in their transactions with other
businesses. Companies are increasingly using the Internet to enter new markets, improve
supply chains, and meet the challenges of increased competition and global markets.
Forrester Research estimates that U.S.-based Internet commerce between companies will
grow from $109 billion in 1999 to $1.3 trillion in 2003. Forrester Research further estimates
that by 2003 this market for business-to-business transactions will be more than ten times
larger than the related business-to-consumer transactions market.
8. Initial efforts by businesses to reduce transaction costs and increase commerce
efficiency focused on automating supply chains, particularly for the purchase and sale of
raw materials, unfinished items, and other direct goods. Most large companies have
historically relied upon enterprise resource planning (ERP) and supply chain automation
systems to increase the efficiency of their internal procurement processes for direct goods.
These systems are based on complex client-server architectures that are designed to be
used by a relatively small number of sophisticated users. In addition, since ERP solutions
do not typically tie the corporation with its suppliers or customers, they do not address any
transaction costs or inefficiencies that are external to the organization.
9. A variety of point-to-point solutions have been developed to address procurement
cycle inefficiencies for both buyers and suppliers. The most successful of these has been to
integrate electronic data interchange (EDI) into existing ERP systems. EDI has gained wide
acceptance in automating the sale and procurement of selected direct goods, principally in
environments characterized by high-dollar-volume transactions with a few suppliers.
However, because EDI relies on the execution of certain predefined transactions, it typically
is not well suited for situations involving many buyers and suppliers, a wide variety of goods
and services, or numerous low-dollar-volume transactions. Moreover, EDI does not support
real-time interactions between trading partners, making it difficult for buyers to obtain up-todate supplier information about price, availability, and order status. Finally, the expense and
complexity associated with licensing, implementing, and managing both ERP and EDI
solutions makes them unsuitable for all but the largest organizations.
10. Similar efforts have been made to improve the procurement process for indirect goods
and services, which include information technology and telecommunications equipment,
office equipment and supplies, travel and entertainment, professional services, and other
repeat purchase items. The purchase and sale of these goods constitute a large portion of
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business-to-business transactions. The process of procuring these goods often involves
thousands of internal users, as numerous work groups, departments, and divisions within
an enterprise are involved in the purchase of indirect goods and services. As a result, the
indirect goods procurement process is also mired in several inefficiencies, including high
purchasing costs (as paper-based, manual processes still dominate this process), wasted
time on low-value activities within purchasing departments, and poor communication
between buyers and suppliers.
11. A number of desktop-based requisitioning solutions have been introduced to focus on
automating the indirect goods and services procurement processes within the enterprise.
These solutions serve to enforce purchasing policies and improve the efficiency of supplier
management, buying authorization, approval routing, and order processing. However,
these buyer-focused approaches offer limited ability to address the costs and inefficiencies
associated with the supplier side of the transaction. They also typically lack the interactivity
users need to check prices, availability, and order status, while they also generally fail to
provide a mechanism to automatically update supplier information relating to these areas.
Consequently, both internal users and suppliers must still rely upon costly, manual phoneand fax-based processes to interact and conduct commerce.
12. Accompanying the growth in the use of the Web has been a trend toward customer
self-service. Just as consumers have extensively used automated teller machines rather
than using the services of a bank teller, the Web now allows a wide range of businesses
the ability to offer electronic self-service to their customers. For example, consumers are
now shopping for goods and services and seeking answers to customer service questions
on their own from their computers at any hour of the day. The Gartner Group estimated that
by 2001 companies would receive 25 percent of all customer contacts and inquiries over
the Web, through e-mail messages and other Web-based forms. Companies are using this
Web-based customer interaction to augment more traditional means of handling customer
service and commerce, such as telephone-based customer service. Rather than replacing
the technology systems designed to support telephone-based customer service,
companies are actively seeking ways to integrate their various forms of customer
interaction, such as Web communications, e-mail, and the telephone. Businesses are
seeking solutions such as Target’s products to coordinate these various media and present
a consistent interface to their customers for service and commerce.
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EXHIBIT 5-2.4
Sample Valuation Report—Historical Financial Analysis

INTRODUCTION
13. Target, a California-based software and professional services company, has brought
historic photographic shots and technology together by creating digital catalogs and
portfolios. These relational databases, filled with digitized photographs of historical
significance, allow Target’s customers to browse through thousands of historical shot
pieces on their own time. Target’s Web-enabled solutions provide the support that editorial
teams need. Target’s customer list includes many of the nation’s leading newspapers and
magazine publishing companies.
14. Target grew from a start-up with five people in 1995 to a company employing fifty-four
people and on track for over $30 million in revenue for fiscal year 2002. Target’s sales are
derived only from the U.S. market. Target’s existing product offering was introduced in 1999
and is nearing the end of its life cycle.
15. The digital imaging industry is subject to rapid and significant technological change,
and frequent introductions of new competitive products. To remain competitive, Target will
be required to continue to invest substantially in research and development, enhance its
existing products, introduce new competitive products, and maintain price/performance
advantages in its selected markets.
16. Target’s research and development programs are focused on advancing digital
imaging software technologies that strengthen its core product and service offerings. Target
devotes substantial resources to ensure that its evolving technology roadmap is aligned
with the technology direction of industry-leading vendors. This is evidenced by Target’s
current research and development of its next generation software technologies, all of which
are discussed in detail in this report.

SOFTWARE GROUP
17. Target’s Web-ready software solutions reduce costs, increase sales, and maximize
the customer’s technology investment. Product PT, a high-performance publishing tool,
connects management, sales, customer service, and production teams simply and
efficiently, enhancing relationships with customers and partners at every point of contact.
Whether for a small publishing group or multinational enterprise, Target has the solutions
for today’s business needs.
18. Product PT combines digital images and company data in powerful, simple-to-use
applications. The users can create targeted material in seconds. Preformatted layouts
make it easy to produce custom layouts, visual portfolios, and merchandised assortments.
Web capabilities link everyone in the user’s supply chain in one collaborative environment.
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PROFESSIONAL SERVICES
19. Target’s professional services group provides consulting, training, and installation
services to help customers maximize their use of software products. Services are provided
in time and material arrangements.
20. The historical financial statements of Target were analyzed to understand Target’s
past performance and operating trends. Target management provided audited financial
statements for the fiscal years ended December 31, 2000 (fiscal 2000) and December 31,
2001 (fiscal 2001). The following is extracted from the historical financial statements:

•
•
•
•
•
•
•
•

Net sales: For the twelve months ended December 31, 2001, net sales of Target
were approximately $25 million. This represents a 25 percent compound annual
growth rate from fiscal 1999.
Operating expenses: During the years ending 1999 through 2001, cost of sales
averaged 15 percent of net sales. During that same period, sales and marketing
expenses averaged 30 percent of net sales, general and administrative expenses
averaged 22 percent of net sales, and R&D expenses averaged 12 percent of net sales.
Operating income: During the years ending 1999 through 2001, operating income
averaged 21 percent of net sales. During that same time period, operating income
increased from about $2 million to $5 million.
Return on equity: During the years ended 2000 and 2001, Target generated return
on equity of 21 percent and 20 percent, respectively.
Shareholders’ equity: From December 31, 2000 to December 31, 2001, total
shareholders’ equity increased from $25 million to $30 million.
Current ratio: Target’s average current ratio during 2000 and 2001 was 3.2x, indicating
that the Target had $3.20 in current assets for every $1.00 in current liabilities.
Leverage ratio: For the year ended December 31, 2001, Target’s debt level was nominal.
Target’s five-year historical information:
Years Ended December 31
1997

Revenue
Operating expenses
EBITDA
Depreciation
Pre-tax income
Income taxes
Net income

1998

1999

$0

$5,100

$9,920

$19,840

$24,800

5,000

7,000

7,936

15,475

19,592

(5,000)

(2,000)

1,984

4,365

5,208

200

200

300

400

500

(5,200)

(2,200)

1,684

3,965

4,708

0

0

0

0

1,351

($5,200)

($2,200)

$1,684

$3,965

$3,357
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EXHIBIT 5-2.5
Sample Valuation Report—Valuation Analysis and Valuation Approaches

DESCRIPTION OF ASSETS VALUED
Overview
21. The valuation of intangible assets of acquired technology-based companies is
particularly important since the most valuable assets of this type of company generally are
not recorded on the balance sheet before acquisition. Intangibles that may exist at the time
of the acquisition include: (a) base (or core), developed, and in-process technologies; (b)
customer-related intangibles (such as a distribution network or a customer base); (c)
trademark(s), trade name(s), and related intellectual property; and (d) covenants not-tocompete.5 In the determination of the fair value for each intangible asset, each assessment
should consider specific factors to the asset, including (but not limited to)—

•
•
•

The value of economic or monetary benefit to market participants.
The remaining economic life.
The relative risk profile.

Summary of Intangible Assets Under Consideration
22. With respect to Target, all intangible assets that may have existed at the date of
valuation were initially considered in the valuation analysis. Potential intangible assets were
identified through an assessment of the economics of the transaction, a review of all
supporting documents and materials, and discussions with Target management. (Step 4 in
chapter 5 of the AICPA Practice Aid identifies many of the materials reviewed). As a
result of our review, five intangible asset categories (which meet the criteria for separate
recognition apart from goodwill; see paragraph 39 of FASB Statement No. 141) were
identified for our analysis: (a) existing technology, (b) technologies under development,
(c) noncompete agreements, (d) trademark and tradename, and (e) customer list. Please
see the following description of intangible assets for all of Target’s divisions and entities.
Technology Accounting Considerations
23. To determine whether a technology was complete or under development, FASB
Statement No. 2 and FASB Interpretation No. 4 guidelines were reviewed.

5 This list is not all-inclusive; intangible assets listed above are for illustrative purposes only. The identification of
intangible assets is specific to each transaction and depends on the facts and circumstances surrounding the
acquisition. Also, see footnote 1.
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24. Published in October 1974, FASB Statement No. 2 provides accounting guidelines for
research and development (R&D) with the objective of reducing the number of reporting
practices previously employed. The statement is broken into four specifications concerning
R&D: activities identified, elements of cost, accounting for, and disclosure of.
25. FASB Statement No. 2 identifies R&D activities using the following definitions:

•

•

Research is defined as a planned search or critical investigation aimed at discovery
of new knowledge with the hope that such knowledge will be useful in developing a
new product or service (hereinafter, “product”) or a new process or technique
(hereinafter, “process”) or in bringing about a significant improvement to an existing
product or process.
Development is defined as the translation of research findings or other knowledge
into a plan or design for a new product or process or for a significant improvement to
an existing product or process, whether intended for sale or use. It includes the
conceptual formulation, design, and testing of product alternatives, construction of
prototype, and operation of pilot plants. It does not include routine or periodic
alterations to existing products, production lines, manufacturing processes, and
other ongoing operations, even though alterations may represent improvements, and
it does not include market research or market testing activities.

26. Elements of R&D cost include personnel cost for those employed in R&D activities;
materials, equipment, and facilities that have no alternative future use; and intangible
assets purchased from others that have no alternative future use and, therefore, no
separate economic values.
27. According to FASB Statement No. 2, accounting for R&D costs requires charging
them to expense when incurred. Appropriate disclosure in financial statements is then
required.
28. FASB Interpretation No. 4, issued in February 1975, addresses the accounting
treatment for assets to be used in R&D activities acquired in a business combination. More
specifically, FASB Interpretation No. 4 makes a distinction between those assets resulting
from R&D activities of the acquired enterprise and those to be used in R&D activities of the
combined enterprise. It indicates that, according to APB Opinion No. 16 (which is
superseded by FASB Statement No. 141), the costs assigned to assets either resulting
from or to be used in R&D projects are determined from the amount paid by the acquiring
enterprise and not from the original cost to the acquired enterprise. It also confirms that,
according to FASB Statement No. 2, the costs assigned to assets to be used in R&D
projects that have no alternative future use are charged to expense.
29. In November of 1998, the AICPA convened a task force to identify best practices with
regard to the accounting for, valuation of, and auditing of acquired in-process research and
development (IPR&D). The AICPA published a Practice Aid titled Assets Acquired in a
Business Combination to Be Used in Research and Development Activities.
30. The information in this report has been subjected to procedures consistent with the
AICPA Practice Aid.
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31. The technologies under development were reviewed as of the valuation date to
determine their stages of completeness and the specific stages achieved; discussions also
were held with Target and Acquiror management concerning the scheduled release dates
of the products employing the technologies. After considering all of the guidance and facts
outlined in this report, a decision was made about whether the technologies were complete
or under development.
32. On the basis of discussions with Target and Acquiror management and a review of
the appropriate accounting literature addressing the identification and valuation of
intangible assets, as well as their classification as completed technology or technologies
under development, the categories of Target technology as of the valuation date were
identified as described in the following sections.
Existing Technologies
33. Product PT, a high-performance publishing tool, combines digital images and
company data in powerful, simple-to-use applications, creating targeted material in
seconds. Preformatted layouts make it easy to produce custom layouts, visual portfolios,
and merchandised assortments. Web capabilities link everyone in the supply chain in one
collaborative environment. Combination of the functionality of a database with a Web
browser allows for instant worldwide access to the client’s Product PT solution.
34. Product PT was developed in fiscal years 1998 and 1999, introduced in June 1999,
and is expected to be sold through the remainder of 2002. The developed technology
embodied within Product PT also will be present in Software A and D. The fair value of
the developed technology, therefore, is represented by the excess earnings of Product
PT and a portion of the projected operating income of Products A and D, expressed as
a base (or core) technology charge to cash flows.
Technologies Under Development
35. Software A—When developed, Software A will incorporate two modules into the basic
product. Design Module will add 100 new layouts and the ability to add thousands more.
Slides Module will create freestanding CD-ROM or e-mail-based slide shows (runtimes) for
customer distribution.
36. Software B—The Software B Suite program will be customized to create LAN and
Web-based all-encompassing shop creation tools for the publishing industry. Graphics
personnel will use these tools to maintain the image on the shop floor to maximize selling to
consumers and save hundreds of thousands of dollars in shop development costs.
37. Software C—Software C Suite, a workgroup-centric planning and selling technology,
will replace spreadsheets into a networkable, business-rule, scalable solution for
merchandising, production, retail and wholesale planning, sales, and management. When
developed, this tool is intended to increase sales by 10 percent, lower costs by 45 percent,
and increase productivity by 145 percent.
114

38. Software D—Software D is a Web-based digital asset management and
workflow management tool for content creation and photo studios. It will be designed for
keeping track of hundreds of thousands of digital images and coordinating of the
photography, editing, and information regarding their styling, editing, and use. Software D
also will track shipments of goods to be digitized, where goods are loaded, who shoots
them in what bay, and who edits them. When developed, this tool will report on planned
versus actual productivity, manage the original and edited version, allow the customer to
review images, and give Web-based styling and editing notes. In addition, the tool will allow
for the creation of a copy to be included on e-commerce Web sites and interfaces
with customers’ legacy systems.
39. For each technology under development, we have analyzed the stage of
completion to adjust the discount rate to include the risk associated with the completion
effort. We obtained information about the accumulated costs incurred through the
valuation date, the estimated cost to complete, and the total estimated development
costs to compute the stage of completion based on costs incurred. We also have
discussed with management the technical issues that were overcome before the
valuation date, as well as those to be resolved. We concluded on a stage of completion,
as shown in exhibit E.
Noncompete Agreements
40. The fair value of a noncompete agreement stems from the protection afforded to the
acquirer from competition from key management. Such competition could significantly
erode the value of the acquired assets. As of the valuation date, three-year noncompete
agreements were entered into with three key personnel. [For purposes of the sample
valuation report, the fair value of this intangible is stated without related details because that
determination is beyond the scope of this Practice Aid.]
Trademark/Trade Name
41. Target’s name is well known in the marketplace and Acquiror intends to continue
using that name in the marketplace. End-user recognition and acceptance of a
trademark/trade name may be a valuable asset that can be separated from other
intangible assets. A trademark is a letter, word, symbol, or design, or any combination
thereof, used by a company to identify its products and to distinguish them from those
of its competitors. The history of continued use of its products is essential to the
maintenance of trademark rights. A trade name, as defined herein, includes not only
the legal trademark but also the presentation and image that this intangible asset
infers. [For purposes of the sample valuation report, the fair value of this intangible is
stated without related details because that determination is beyond the scope of this
Practice Aid.]
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Customer List
42. Target’s customer accounts numbered approximately 100 at December 31, 2001.
Customer accounts are very important assets of this business because of the
propensity of the customers to generate revenue for Target beyond the initial sale is the
underlying worth of the customer accounts. Acquiror will not have to duplicate historical
marketing, training, and start-up expenses to develop a customer base to the same
level. [For purposes of the sample valuation report, the fair value of this intangible is
stated without related details because that determination is beyond the scope of this
Practice Aid.]

VALUATION INTRODUCTION
43. The designated assets have been valued on the basis of their fair value, which has
been defined in the introduction of this report.
44. Certain of the historical financial analyses of Target and a capsule description of the
business operations and the assets valued are presented in this report. Expected operating
results of Target were analyzed and current and estimated cash flows were discussed with
members of Target and Acquiror management and were determined to be reasonable for
use in the valuation.
45. Before arriving at the opinion of fair value of the intangible assets, the following, as
well as other relevant factors, were considered:

•
•
•
•

The extent, character, and utility of the intangible assets
The income-generating or cost-savings attributes of the intangible assets
The nature and timing of the functional or economic obsolescence of each intangible asset
The relative risk and uncertainty associated with an investment in intangible assets

46. The acquired technologies under development were reviewed for alternative future
use, other than those described herein, in accordance with the AICPA Practice Aid.
The research and development process at Target is a focused effort to deliver new
products with certain well-defined characteristics. It was concluded that the technologies
under development have no alternative future use other than the objective of the
current project.
47. The methods used in determining fair value of the intangible assets included
consideration of the three traditional approaches to value: market, income, and cost.
48. The market approach considers prices recently paid for similar assets with
adjustments made to the indicated market prices to reflect the condition and utility
of the analyzed asset relative to market comparatives. As intangible assets
typically are exchanged only in the context of the purchase of a business, this
approach was not employed.
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49. In an income approach, fair value is dependent on the present value of future
economic benefits to be derived from ownership of an asset. Central to this approach is an
analysis of the earnings potential represented by the asset and of the underlying risks
associated with obtaining those earnings. Value indications are developed by discounting
future net cash flows available for distribution to their present value at market-based rates
of return. Based on the analysis performed, we have concluded that the future cash flows
used result in a reasonably reliable estimate of fair value. Accordingly, the income
approach has been employed to value the existing technology, the technologies under
development, the noncompete agreements, and the trademark/trade name. The income
approach was not selected to value the customer list since the amount of income directly
attributable to this asset cannot be separately measured.
50. The cost approach, as applied in the valuation of intangible assets, establishes fair
value based on the cost of reproducing or replacing the assets, less depreciation for
functional or economic obsolescence. Valuation results derived using the cost approach
can be viewed as an upper limit of value in cases where the asset is easily replaced or
reproduced since no prudent investor would purchase an existing asset for more than it
would cost to create a comparable asset. This approach has been employed to value the
customer list.
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EXHIBIT 5-2.6
Sample Valuation Report—Income Approach

VALUATION OF EXISTING TECHNOLOGY AND TECHNOLOGIES UNDER
DEVELOPMENT
51. The fair values for the existing technology and technologies under development were
estimated by discounting cash flows to be derived from the sales of these products to
present value.
52. The discounted net cash flow method of the income approach explicitly recognizes
that the current value of an asset is premised upon the expected receipt of future economic
benefits such as cost savings, periodic income, or sales revenue. Indications of value are
developed (under what many view as a traditional approach) by discounting future net cash
flows to their present value at a rate that reflects both the current return requirements of the
market and the risks inherent in the specific investment.
53. Management provided us with forecasts of (a) net sales for products employing the
existing technology and (b) net sales of products expected to employ the technologies
under development. The forecasts were reviewed for reasonableness, and are included in
our valuation models. Management also provided us with forecasts of the operating
expenses related to cost of sales, selling and marketing, and general and administrative for
the products employing the existing technologies and for the products expected to employ
the technologies under development. The forecasted operating expenses were compared
to historical levels of operating expenses and the cost structure of comparable companies,
and the forecast was determined to be reasonable.
54. Management also provided us with their estimate of the costs to complete the R&D
for each technology under development. The estimated costs to complete were added
to R&D expenses incurred prior to the valuation date, and were compared to data on
costs incurred to develop similar products. The estimated costs to complete were
determined to be reasonable, and are reflected in the valuation models as additional
operating expenses.

EXISTING TECHNOLOGY
55. Existing technology consists of the current release of Product PT, which is expected to
be sold for the remainder of the year 2002 and then replaced with Software A. Revenues
are expected to be $9 million for fiscal year 2002 based on an expected growth rate over
2001 revenues, adjusted downward for the expected release of Software A in late 2002.
Expense expectations were based on historical experience combined with market
participant data.
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56. Existing technology also will be leveraged in the development of Softwares A and D.
The contributions of existing technology are expected to last through 2006, indicating a
remaining useful life of approximately five years. This fact has been accounted for through
the imputation of a royalty (or contributory asset) charge to the forecasted operating income
of the technologies under development.
57. To estimate an appropriate charge, the operating margin for these technologies was
analyzed. In an article published in The Encyclopedia of Patent Practice and Invention
Management, author Albert S. Davis, Jr., states the following:
Analysis of a great number of cases, both bargained-out and imposed as
damages by the courts, makes it clear that a royalty rate of 25 to 33 1/3 per
cent of the anticipated profit is about the average, with many exceptions
outside this range.
58. Considering the profit margin expected and the amount of base (or core)
technology being employed by the technologies under development, a royalty rate at
the upper end of the observed range was deemed to be reasonable. Therefore, a
royalty rate of 33 percent of operating profit was selected. This 33 percent was
deducted from the individual cash flows of the technologies under development that
leverage existing technology, tax-effected, and discounted to present value. This value
has been added to the value of existing technology and represents the contribution of
base (or core) technology inherent in the technologies under development. See exhibit
C for specific valuation calculations for existing technology.

TECHNOLOGIES UNDER DEVELOPMENT
59. For all technologies under development, revenue expectations, derived from
management’s “base case” forecast, were based upon experience with prior releases,
combined with expected industry growth as indicated in industry source document, number
of other competitors, and estimated share of the market. In addition, expenses are
expected to track historical experience because the sales, marketing, and management of
the product is expected to be similar to past experience. The expectations of revenue and
expenses are consistent with market participant data.
Software A
60. Software A is the next release of Product PT, scheduled for availability in late 2002.
This release is a new technology platform that relies, in part, on the contribution of the
existing technology. Revenues are expected to ramp up from $4,000,000 in 2002,
reaching a peak of $40,000,000 in 2004, declining to $20,000,000 in 2006 when future
releases and/or competition are expected to supplant this release and the technology
underlying it. Expense expectations were again based on historical experience
combined with market participant data. This technology is 90 percent complete as of the
valuation date, based on cost, time, and complexity factors. See exhibit D-1 for specific
valuation calculations for Software A.
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Software B
61. Software B represents a new technology designed to support Web-based publishing
activities. As such, it represents a new source of income that does not rely on existing or
core technology. Revenues are expected to grow from a base of $1,500,000 in late 2002,
when introduced, peaking at $3,000,000 in 2004, and dropping to $1,500,000 in 2005 when
new products and technologies are expected to replace Software B. This technology is 70
percent complete as of the valuation date, based on cost, time, and complexity factors. See
exhibit D-2 for specific valuation calculations for Software B.
Software C
62. Software C represents a new technology for sales management and productivity
enhancement. As such, it also represents a new source of income that does not rely on
core or existing technology. Revenues are expected to grow from a base of $2,500,000 in
2003, to a peak of $5,000,000 in 2005, dropping to $2,500,000 in 2007, when new products
and technologies are expected to replace Software C. This technology is 50 percent
complete as of the valuation data, based on cost, time, and complexity factors. It is not
expected to be released until late 2003, in contrast to Software A and B, which are
expected to be released in late 2002 (due to their more advanced stage of completion).
See exhibit D-3 for specific valuation calculations for Software C.
Software D
63. Software D is a Web-enabled asset management workflow module that is being
designed to be an add-on to Product PT. As such, Software D relies on the contribution of
the existing technology. Revenues are expected to grow from $750,000 in 2003, to a peak
of $3,000,000 in 2005, dropping to $1,500,000 in 2006. This technology, although having
significant substance in terms of progress, is only 30 percent complete as of the valuation
date based on cost, time, and complexity factors. This product is not expected to be
released until late 2003. See exhibit D-4 for specific valuation calculations for Software D.

TAX RATES AND CONTRIBUTORY ASSET CHARGES
64. The expected operating profit forecasted for each intangible asset valued under the
income approach was then tax-effected at the industry (or market participant) rate of 38
percent. The net income ascribable to the technologies under development was then reduced
by a fair return on the required tangible assets and intangibles, including property, plant, and
equipment; assembled workforce; trademark/trade name; customer list; and the required
working capital. The chart in paragraph 5.3.64 of the AICPA Practice Aid was used as a basis
for determining the contributory asset rate. A required return of 10.0 percent was calculated for
working capital, a return on tangible assets was computed at 12.9 percent; a return of 19.0
percent was used as the required return on the workforce and other intangible assets.
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DISCOUNT RATES
65. The discount rate used for the valuation of the completed technology was 19.0
percent. The discount rate determination considered that the existing technology is both
complete and has been in the marketplace since 1999, and it also considered the
calculated weighted average cost of capital (WACC) for companies deemed comparable to
Target as of the valuation date. A rate of 16.5 percent was concluded in the WACC. [For
purposes of the sample valuation report, the WACC is stated without related details
because that determination is beyond the scope of this Practice Aid.] In approximating the
purchase price in the BEV (refer to analysis in exhibit B) a 19.0 percent discount rate was
indicated as being more reflective of the Target and its reliance on technologies under
development to produce a majority of its future cash flows. Therefore, the 19.0 percent rate
was used as the discount rate for current technologies. A premium was added to the
WACC to reflect the risk associated with investing in technologies under development.
66. The incomplete technology represents a mix of near-term and mid-term prospects for
the business and imparts a level of uncertainty to its prospects. It is the nature of the
business to be constantly developing new technology for future product releases.
Therefore, a reasonable expectation of return on the incomplete technology would be
higher than the WACC.
67. To estimate what the relative risk/return should be for the incomplete technology, an
analysis of the work effort already completed compared to what was needed to complete
the project was undertaken. In general, the earlier in the development process, the higher
the risk of successfully completing the project and realizing the expected revenue and
profit. The closer a project is to completion, the lower the risk of completion and the
associated future expectations. The following chart summarizes this relation and the
resulting discount rate for each of the incomplete technology:

Product

Percent
Premium to Existing
Complete Technology Discount Rate

Concluded
Discount Rate

Product PT

100%

19%

Software A

90%

3%

22%

Software B

70%

12%

31%

Software C

50%

21%

40%

Software D

30%

31%

50%

TAX AMORTIZATION BENEFITS
68. One additional adjustment to the indicated values derived above using the income
approach is required to reflect the hypothetical tax benefits associated with amortizing the
asset for income tax purposes.
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69. When a business combination is structured as a stock purchase for income tax
purposes, there generally is not a corresponding change in the tax basis of assets
acquired. That is, the tax basis of the intangible assets generally carries over from Target.
Historically, valuation practice would dictate that no tax benefit should be included in the
valuation of the intangible assets acquired because the buyer would not be able to amortize
the intangible assets acquired for income tax reporting purposes, and thus would not
benefit from the tax savings associated with amortization of the assets.
70. However, the value of tax amortization benefits associated with intangible assets,
including IPR&D assets, should be recognized when the purpose of the valuation is to
estimate fair value as that term is defined under U.S. generally accepted accounting
practices, including for transactions where the buyer will not be allowed to gross up and
amortize the value of purchased intangible assets for income tax purposes (that is,
nontaxable business combinations rather than asset purchases). FASB Statement No. 109,
Accounting for Income Taxes, prohibits the net-of-tax approach and requires assets
acquired and liabilities assumed to be recorded at their “gross” fair value. In accordance
with paragraph 5.3.102 of the AICPA Practice Aid, the fair value of the intangible assets
includes the value of the tax benefit resulting from the amortization of those assets. The
benefits of amortizing the values of the assets are shown in exhibit F and are added to the
values previously determined.

CONCLUSION
71. Based on the investigation and analyses outlined above and on the valuation
approaches, methods, and techniques employed, it is concluded that, as of January 21,
2002, the fair value of the designated intangible assets6 of Target is reasonably
represented in the amount of $18,493,600, distributed as follows:
Existing technology

6,398,100

Technologies under development

7,892,100

Non-compete agreements

1,849,200

Trademark/trade name

546,200

Customer list

1,808,000

Total

6

$18,493,600

See footnote 1.
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EXHIBIT A
Target
Valuation Summary
Valuation Date: January 21, 2002
Value
Existing technology:
Product PT
Total existing technology:

6,398,100
6,398,100

Technologies under development:
Software A
Software B
Software C
Software D
Total technologies under development:

6,968,700
621,400
0
302,000
7,892,100

Other assets
Noncompete agreements
Trade name
Customer list
Total other assets

1,849,200
546,200
1,808,000
4,203,400
Total all assets:
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18,493,600

EXHIBIT B
Target
Business Enterprise Value (see paragraph 5.3.111)
Valuation Date: January 21, 2002
For Fiscal Years Ending,
Professional services
Existing technology
Technologies under development
Future development
Total revenue

2002
12,000
9,000
9,500
500
31,000

2003
22,000
0
35,500
1,000
58,500

2004
40,000
0
54,000
10,750
104,750

($000's)
2005
60,000
0
39,500
57,625
157,125

Total expenses (services)
Total expenses (existing)
Total expenses (IPR&D)
Total expenses (future)
Total expenses

9,000
6,390
9,151
259
24,800

18,500
0
24,788
4,682
47,970

36,200
0
40,500
15,480
92,180

54,300
0
29,625
54,345
138,270

67,875
0
16,875
88,087
172,837

71,269
0
0
110,210
181,479

6,200

10,530

12,570

18,855

23,569

24,747

736

1,388

2,486

3,728

4,660

4,893

5,464

9,142

10,084

15,127

18,908

19,854

2,076

3,474

3,832

5,748

7,185

7,544

Debt-free net income

3,388

5,668

6,252

9,379

11,723

12,309

Add: depreciation expense
Less: capital expenditures
Less: working capital requirements

736
1,700
1,900

1,388
1,700
2,750

2,486
1,700
4,625

3,728
1,700
5,238

4,660
1,700
3,928

4,893
4,893
982

Net cash flow

524

2,606

2,413

6,169

10,755

11,327

Partial period adjustment

0.94

1.00

1.00

1.00

1.00

1.00

Adjusted net cash flow

491

2,606

2,413

6,169

10,755

Discount period

0.46

1.42

2.42

3.42

4.42

0.9234

0.7816

0.6568

0.5519

0.4638

453

2,037

1,585

3,405

4,988

EBITDA
Depreciation expense
Net income
Estimated income taxes @

Discount rate WACC @

38%

10%

19%

Present value
Present value of interim cash flows

Terminal value calculations
Capitalized stabilized annual net
cash flow @14%: WACC 19% less

2006
Stabilized Period
75,000
0
22,500
98,906
196,406
206,226

12,468

5%

Terminal
Cash Flow

Terminal
Value

Present
Value @
19%

11,327

80,909

37,526

VALUATION SUMMARY

Based on:
Capitalized final year DFNCF
at WACC less g (h)

PV of
Interim
Cash Flows

PV of
Terminal
Value

12,468

37,526
Indicated Value(rounded):

Indicated
Value

49,994 *
50,000

* The indicated value approximates the purchase price of $50,000,000, and no additional reconciliation was performed
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EXHIBIT C
Target
Existing Technology—Product PT
For Fiscal Years Ending
2002

2003

2004

2005

2006

Revenue

9,000

0

0

0

0

Operating expenses

6,390

0

0

0

0

Operating income

2,610

0

0

0

0

0

0

0

0

0

2,610

0

0

0

0

992

0

0

0

0

1,618

0

0

0

0

90
45
147
76
18

0
0
0
0
0

0
0
0
0
0

0
0
0
0
0

0
0
0
0
0

1,242

0

0

0

0

0.94

1.00

1.00

1.00

1.00

1,164

0

0

0

0

0.46

1.42

2.42

3.42

4.42

0.9234

0.7816

0.6568

0.5519

0.4638

1,075

0

0

0

0

Research & development
EBIT
Estimated income taxes @

38%

Net income
Contributory charges:
Working capital @
Trade name
Customer list
Workforce
Fixed assets

10%

Net cash flow
Partial period adjustment
Adjusted net cash flow
Discount period
Discount rate WACC @

19%

Present value
Present value of interim cash flows

1,075

Value indication: product sales
core technology charge - see below

1,075
4,461
5,536
862
6,398

benefits of tax amortization - see exhibit F
Total

2002
Software A
Software D
Core technology royalty

Contributory Charges - Core Technology
2003
2004
2005

2006

766
0
766

3,062
158
3,221

3,630
248
3,878

2,228
495
2,723

1,403
248
1,650

291

1,224

1,473

1,035

627

Net income

475

1,997

2,404

1,688

1,023

Partial period adjustment

0.94

1.00

1.00

1.00

1.00

Adjusted net income

445

1,997

2,404

1,688

1,023

Discount period

0.46

1.42

2.42

3.42

4.42

0.9041

0.7323

0.5877

0.4717

0.3786

402

1,462

1,413

796

387

Estimated income taxes @

Discount rate @
Present value

38%

24.6%

Present value of interim cash flows

4,461
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EXHIBIT D-1
Target
Technology Under Development—Software A
For Fiscal Years Ending
2002

2003

2004

2005

2006

Revenue

8,000

29,000

44,000

27,000

17,000

Operating expenses

5,680

19,720

33,000

20,250

12,750

Operating income

2,320

9,280

11,000

6,750

4,250

Cost to complete (R&D)

500

0

0

0

0

Contributory charge - core technology

766

3,062

3,630

2,228

1,403

1,054

6,218

7,370

4,523

2,848

401

2,363

2,801

1,719

1,082

654

3,855

4,569

2,804

1,765

171

EBIT

Estimated income taxes @

38%

Net income

Contributory charges:
80

291

442

271

Trade name

Working capital @

10%

40

138

115

47

24

Customer list

131

453

378

155

78

Workforce

68

235

196

80

40

Fixed assets

16

55

46

19

9

319

2,684

3,393

2,232

1,443

Net cash flow

Partial period adjustment

0.94

Adjusted net cash flow

1.00

299

Discount period

0.46

Discount rate @

22%

Present value

Present value of interim cash flows
Benefits of tax amortization - see exhibit F
Fair value

1.00

2,684

1.42

1.00

3,393

2.42

1.00

2,232

3.42

1,443

4.42

0.9129

0.7545

0.6184

0.5069

0.4155

273

2,025

2,098

1,131

600

6,127
842
6,969
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EXHIBIT D-2
Target
Technology Under Development—Software B
For Fiscal Years Ending
2002

2003

2004

2005

2006

Revenue

1,500

2,500

3,000

1,500

0

Operating expenses

1,065

1,700

2,250

1,125

0

Operating income

435

800

750

375

0

Cost to complete (R&D)

305

0

0

0

0

0

0

0

0

0
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800

750

375

0

49

304

285

143

0

81

496

465

233

0

15

25

30

15

0

7

12

8

3

0

Contributory charge - core technology
EBIT
Estimated income taxes @

38%

Net income

Contributory charges:
Working capital @

10%

Trade name
Customer list

25

39

26

9

0

Workforce

13

20

13

4

0

3

5

3

1

0

18

395

385

201

0

Fixed assets

Net cash flow
Partial period adjustment

0.94

Adjusted net cash flow

1.00
17

Discount period

0.46

Discount rate @

31%

Present value

1.00
395

1.42

1.00
385

2.42

1.00
201

3.42

0
4.42

0.8836

0.6821

0.5207

0.3975

0.3034

15

269

200

80

0

Present value of interim cash flows

564

Benefits of tax amortization - see exhibit F

57

Fair value

621
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EXHIBIT D-3
Target
Technology Under Development—Software C
For Fiscal Years Ending
2002

2003

2004

2005

2006

Revenue

0

2,500

4,000

5,000

2,500

Operating expenses

0

1,700

3,000

3,750

1,875

Operating income

0

800

1,000

1,250

625

1,500

648

0

0

0

0

0

0

0

0

-1,500

152

1,000

1,250

625

-570

58

380

475

238

-930

94

620

775

388

0

25

40

50

25

Cost to complete (R&D)
Contributory charge - core technology
EBIT
Estimated income taxes @

38%

Net income

Contributory charges:
Working capital @

10%

Trade name

0

12

10

9

3

Customer list

0

39

34

29

11

Workforce

0

20

18

15

6

Fixed assets

0

5

4

3

1

-930

-7

513

669

340

Net cash flow

Partial period adjustment

0.94

Adjusted net cash flow

1.00
-872

Discount period

0.46

Discount rate @

40%

Present value

1.00
-7

1.42

1.00
513

2.42

1.00
669

3.42

340
4.42

0.8571

0.6208

0.4435

0.3168

0.2263

-747

-4

227

212

77

Present value of interim cash flows

-174*

Benefits of tax amortization - see exhibit F

0

Fair value

0

* The negative present value suggests a fair value of $0.
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EXHIBIT D-4
Target
Technology Under Development—Software D
For Fiscal Years Ending
2002

2003

2004

2005

2006

Revenue

0

1,500

3,000

6,000

3,000

Operating expenses

0

1,020

2,250

4,500

2,250

Operating income

0

480

750

1,500

750

101

0

0

0

0

0

158

248

495

248

-101

322

503

1,005

503

-38

122

191

382

191

-63

199

312

623

312

0

15

30

60

30

0

7

8

10

4

Cost to complete (R&D)
Contributory charge - core technology
EBIT
Estimated income taxes @

38%

Net income
Contributory charges:
Working capital @

10%

Trade name
Customer list

0

23

26

34

14

Workforce

0

12

13

18

7

Fixed assets

0

3

3

4

2

-63

139

231

496

255

Net cash flow
Partial period adjustment

0.94

Adjusted net cash flow

1.00
-59

Discount period

0.46

Discount rate @

50%

Present value

1.00
139

1.42

1.00
231

2.42

1.00
496

3.42

255
4.42

0.8304

0.5630

0.3754

0.2502

0.1668

-49

78

87

124

43

Present value of interim cash flows

283

Benefits of tax amortization - see exhibit F

19

Fair value

302
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EXHIBIT E
Target
Stage of Completion Analysis

Software
A

Product
Software
Software
B
C

Software
D

Cost-based
Incurred to date
To complete
Percent complete

$4,500
500
90%

$1,220
305
80%

$2,148
2148
50%

$67
101
40%

Time-based (months)
Time from start to date
To complete
Percent complete

8
2
80%

6
4
60%

6
6
50%

2
8
20%

Complexity-based
Management estimate
of tasks completed
weighted by complexity

95%

70%

60%

30%

Conclusion

90%

70%

50%

30%
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EXHIBIT F
Target
Tax Benefit Amortization Calculation
$000s
Sample present value of tax benefits table
# of Months
Period

Year

Fraction

Years to

of Year

Midpoint

Product PT
Annual

19.00%

PV of Tax

Amortization %

Tax Rate

PV Factor

Benefits

1

2002

0.000

0.000

0.00%

38.00%

1.0000

0.0000

2

2003

1.000

0.500

6.67%

38.00%

0.9167

0.0232

3

2004

1.000

1.500

6.67%

38.00%

0.7703

0.0195

4

2005

1.000

2.500

6.67%

38.00%

0.6473

0.0164

5

2006

1.000

3.500

6.67%

38.00%

0.5440

0.0138

6

2007

1.000

4.500

6.67%

38.00%

0.4571

0.0116

7

2008

1.000

5.500

6.67%

38.00%

0.3841

0.0097

8

2009

1.000

6.500

6.67%

38.00%

0.3228

0.0082

9

2010

1.000

7.500

6.67%

38.00%

0.2713

0.0069

10

2011

1.000

8.500

6.67%

38.00%

0.2280

0.0058

11

2012

1.000

9.500

6.67%

38.00%

0.1916

0.0049

12

2013

1.000

10.500

6.67%

38.00%

0.1610

0.0041

13

2014

1.000

11.500

6.67%

38.00%

0.1353

0.0034

14

2015

1.000

12.500

6.67%

38.00%

0.1137

0.0029

15

2016

1.000

13.500

6.67%

38.00%

0.0955

0.0024

16

2017

1.000

14.500

6.67%

38.00%

0.0803

0.0020

Totals

15.000

100.00%

0.1347

Calculation
Assets:
Indicated Value**

Discount Rate

PV of Tax Benefits

Tax Benefit*

Adjusted Value

Concluded Value

Product PT

5,535,968

19.0%

0.1347

862,119

6,398,087

6,398,100

Software A

6,127,169

22.0%

0.1208

841,559

6,968,729

6,968,700

Software B

564,302

31.0%

0.0919

57,129

621,431

621,400

Software C

0

40.0%

0.0745

0

0

0

Software D

283,252

50.0%

0.0620

18,713

301,965

302,000

* Sample calculation: 5,535,968/(1-0.1347)=6,398,087; 6,398,087-5,535,968=862,119 (rounded)
** From exhibits C and D-1 through D-4
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CHAPTER 6
AUDITING ACQUIRED IPR&D ESTIMATES
6.1

INTRODUCTION AND OVERVIEW

6.1.01
Business combinations often result in material amounts of the purchase
price attributed to goodwill or other long-lived intangible assets. In many situations,
valuation specialists are engaged to perform a valuation of the assets acquired,
including assets acquired to be used in research and development (R&D) activities
(which includes specific in-process R&D [IPR&D] projects, referred to in this chapter
as acquired IPR&D), and issue a report that sets forth, among other things, the
results of the valuation study. As with any material accounting estimate, the auditor
designs audit procedures to test the reasonableness of the amount allocated to the
acquired IPR&D.
6.1.02
Chapter 3 identifies best practices concerning the definition of assets
acquired that are to be used in R&D activities and chapter 4 provides accounting and
disclosure best practices. Chapters 2 and 5 set forth best practices for the valuation
specialist to follow in performing a valuation to be used in connection with the allocation
of the purchase price in conformity with generally accepted accounting principles
(GAAP). The IPR&D Task Force believes that the auditor should review the best
practices presented in those chapters.
6.1.03
Given the complexity of the valuation process and the myriad of estimates
and judgments that must be made, the development of the estimated fair value of the
acquired IPR&D often is performed by persons having special skills and training, that
is, valuation specialists. While an acquiring company may have persons with the
requisite skills in its employ, in many instances, it engages the services of an outside
valuation specialist. The auditor’s support for his or her conclusions about the
reasonableness of the amount allocated to acquired IPR&D will be derived from the
substantive audit procedures applied in evaluating the work of the valuation specialist.
The guidance that follows is intended to assist the auditor in determining the nature,
extent, and timing of the substantive audit procedures to be applied in the evaluation
to reach a conclusion as to the reasonableness of the amount of the purchase price
allocated to acquired IPR&D.
6.1.04
This Practice Aid focuses on the software, electronic devices, and
pharmaceuticals industries; however, modification of the guidance may be necessary in
response to the specific circumstances of each acquisition. The nature and extent of the
modifications may be influenced by the business, legal, and regulatory environments in
which both the acquiring company and the acquired company operate. Accordingly,
auditors should use their knowledge of those environments and their professional
judgment in applying the guidance of this Practice Aid to each acquisition.
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6.2

RESPONSIBILITY FOR ACQUIRED IPR&D ESTIMATES

6.2.01

Overview

6.2.02
Accounting estimates are pervasive throughout financial statements.
Generally accepted auditing standards (GAAS) in the United States define an
accounting estimate as an approximation of a financial statement element, item, or
account. Some accounting estimates, such as allowances for uncollectible accounts,
pension accruals, or provisions for warranty claims, may be considered “routine” in the
sense that those estimates are often derived from analysis of historical experience with
past events and transactions over an extended period of time. The measurement of
other accounting estimates may be subject to significantly more uncertainty because the
estimates derive from expectations of future events that may or may not correspond to
past experience with similar events and transactions. An estimate of the fair value of
IPR&D acquired in a business combination is an example of an accounting estimate
that is highly dependent on expectations of future events and transactions for which
information based on historical experience may not be relevant to the evaluation of the
assumptions underlying the estimated fair value of acquired IPR&D.
6.2.03
Statement on Auditing Standards (SAS) No. 57, Auditing Accounting Estimates
(AICPA, Professional Standards, vol. 1, AU sec. 342), defines the respective
responsibilities of management and the auditor with respect to accounting estimates and
provides guidance to auditors in obtaining and evaluating sufficient competent evidential
matter to support significant accounting estimates in an audit of financial statements.
6.2.04

Management’s Responsibility for Accounting Estimates

6.2.05
Management’s responsibility for accounting estimates included in the financial
statements is described in SAS No. 57 (AU sec. 342.03) as follows:
Management is responsible for making the accounting estimates included in
the financial statements. Estimates are based on subjective as well as objective
factors and, as a result, judgment is required to estimate an amount . . . .
Management’s judgment is normally based on its knowledge and experience
about past and current events and its assumptions about conditions it expects
to exist and courses of action it expects to take.
6.2.06
Management also is responsible for establishing processes for developing
accounting estimates. Those processes, which may or may not be documented or formally
applied, normally include the following steps noted in SAS No. 57 (AU sec. 342.05):

•
•
•
•
•

Identifying the relevant factors that may affect the accounting estimate.
Accumulating relevant, sufficient, and reliable data on which to base the estimate.
Developing assumptions that represent management’s judgment of the most likely
circumstances and events with respect to the relevant factors.
Determining the amount of the estimate based on the assumptions and other
relevant factors.
Determining that the accounting estimate is presented in conformity with applicable
accounting principles and that disclosure is adequate.
136

6.2.07
The risk of material misstatement of accounting estimates normally varies
with the complexity and subjectivity associated with the process, the availability and
reliability of relevant data, the number and significance of assumptions that are made,
the degree of uncertainty associated with the assumptions, and the qualifications and
expertise of the personnel developing the accounting estimate.
6.2.08
Developing an estimate of the fair value of acquired IPR&D in a business
combination is a subjective and complex process. R&D projects in process should be
identified and evaluated for their potential to result in marketable products. The stage of
completion of each project should be estimated and expectations of costs to complete
should be developed. Estimated future revenues and related costs associated with each
project that is expected to result in a marketable product should be forecasted, and the
assumptions and bases for them should be documented. Chapter 5 discusses the
development of forecasts of cash flows.
6.2.09
Auditor’s Responsibility in Evaluating the Reasonableness
of Accounting Estimates
6.2.10
SAS No. 57 (AU sec. 342.04) states that “the auditor is responsible for
evaluating the reasonableness of accounting estimates made by management in the
context of the financial statements taken as a whole.” The auditor’s objectives when
evaluating accounting estimates, including the fair value of acquired IPR&D, are to
obtain sufficient competent evidential matter to provide reasonable assurance that—

•
•
•

All accounting estimates that could be material to the financial statements have been
developed.
Those accounting estimates are reasonable in the circumstances.
The accounting estimates are presented in conformity with applicable accounting
principles and are properly disclosed.

6.2.11
To accomplish those objectives with respect to the estimated fair value of
acquired IPR&D, best practices indicate that the auditor should design and perform
substantive auditing procedures to evaluate whether all of the following are true:

•
•
•

All tangible and intangible assets acquired and all liabilities assumed have been
identified and allocated an appropriate portion of the purchase price.
The valuation methodology used to the estimate fair value of the acquired IPR&D is
appropriate.
The assumptions underlying the income approach used to develop the fair value of
acquired IPR&D are not unreasonable in the circumstances.

6.2.12
An acquiring company may engage the services of a valuation specialist to
estimate the fair value of certain assets acquired, including IPR&D, and the auditor may
choose to use that specialist’s work as evidential matter in performing substantive tests
of management’s estimate of the fair value of the acquired IPR&D. Alternatively, the
auditor may engage a valuation specialist and consider the specialist’s work as an
integral part of the auditor’s substantive testing. SAS No. 73, Using the Work of a
Specialist (AICPA, Professional Standards, vol. 1, AU sec. 336), provides guidance to
the auditor in both of those situations. Subsequent sections of this Practice Aid titled
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“Engagement Planning Considerations” and “Performing Substantive Procedures”
provide guidance concerning the auditor’s use of a valuation specialist in planning and
performing the audit.

6.3
6.3.01

ENGAGEMENT PLANNING CONSIDERATIONS
Audit Risk Model

6.3.02
SAS No. 47, Audit Risk and Materiality in Conducting an Audit (AICPA,
Professional Standards, vol. 1, AU sec. 312.12), states that “the auditor should consider
audit risk and materiality both in (a) planning the audit and designing auditing
procedures, and (b) evaluating whether the financial statements taken as a whole are
presented fairly, in all material respects, in conformity with generally accepted
accounting principles.” Audit risk is the risk that the auditor may unknowingly fail to
modify appropriately his or her opinion on financial statements that are materially
misstated. The auditor’s consideration of materiality is a matter of professional judgment
and is influenced by his or her perception of the needs of a reasonable person who may
rely on the financial statements in making an investment or credit decision.1
6.3.03
The auditor should plan the audit so that audit risk will be reduced to a low
level, that is, in his or her professional judgment, appropriate for expressing an opinion
on the financial statements. The nature, timing, and extent of the procedures to be
applied in an audit are a matter of the auditor’s professional judgment, based on his or
her evaluation of the risk of material misstatement of the financial statements taken as a
whole and the specific facts and circumstances. However, the procedures adopted
should be adequate to achieve the auditor’s specific objectives and reduce detection
risk to a level acceptable to the auditor. The evidential matter obtained should be
sufficient for the auditor to form conclusions concerning the validity of the individual
assertions embodied in the components of financial statements, and should provide a
reasonable basis for the expression of an opinion.
6.3.04
An audit of financial statements is a cumulative process. The auditor may
become aware of an acquisition involving acquired IPR&D while performing procedures
relating to acceptance or continuance of a client or an engagement, during engagement
planning, while obtaining an understanding of an entity’s internal controls, while
performing reviews of interim financial statements, or while conducting fieldwork.
Knowledge of such an acquisition may alter the auditor’s judgment about the levels of
inherent and control risks and his or her preliminary judgment about materiality. In that
situation, the auditor may wish to reevaluate the nature, timing, and extent of auditing
procedures he or she plans to apply.
6.3.05

Knowledge of the Business

6.3.06
SAS No. 22, Planning and Supervision (AICPA, Professional Standards, vol.
1, AU 311.06), states:
1 SEC Staff Accounting Bulletin No. 99, “Materiality,” presents a discussion of materiality considerations
that are applicable to the financial statements of Securities and Exchange Commission registrants.
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The auditor should obtain a level of knowledge of the entity’s business that will
enable him [or her] to plan and perform [the] audit in accordance with
generally accepted auditing standards. That level of knowledge should enable
[the auditor] to obtain an understanding of the events, transactions, and
practices that, in [the auditor’s] judgment, may have a significant effect on the
financial statements. The level of knowledge customarily possessed by
management relating to managing the entity’s business is substantially greater
than that which is obtained by the auditor in performing the audit. Knowledge
of the entity’s business helps the auditor in:
a.
b.
c.

d.
e.

Identifying areas for special consideration.
Assessing conditions under which accounting data are produced, processed,
reviewed, and accumulated within the organization.
Evaluating the reasonableness of estimates, such as valuation of inventories,
depreciation, allowances for doubtful accounts, and percentage of completion
of long-term contracts.
Evaluating the reasonableness of management representations.
Making judgments about the appropriateness of the accounting principles
applied and the adequacy of disclosures.

6.3.07
The auditor should obtain a knowledge of the business that includes, for
example, the types of products and services sold by the business, and its production,
marketing, distribution, and compensation methods. Auditors also should consider matters
and trends affecting the industry in which the acquiring company operates, such as
economic conditions, changes in technology, government regulations, and competitive
conditions, to the extent they may have an effect on the financial statements being audited.
6.3.08
Knowledge of the acquiring company’s business is ordinarily obtained through
experience with the company or its industry, and inquiry of company personnel. Working
papers from prior years may contain useful information about the nature of the
business, organizational structure, operating characteristics, and transactions that may
require special consideration. Other sources include industry publications and
periodicals, research reports or offering memoranda of other entities in the industry,
participation in industry conferences, trade associations, and other persons in the
auditor’s firm who may be knowledgeable about the industry.
6.3.09
In planning the audit, auditors may find procedures such as those described in
paragraphs 6.3.10 through 6.3.34 of this Practice Aid useful in obtaining knowledge about
an acquisition, including the acquiring company’s procedures for allocating the purchase
price among the tangible and intangible assets acquired and liabilities assumed.
6.3.10

Obtaining an Understanding of the Acquisition

6.3.11
Inquiry of management is an effective procedure for obtaining knowledge of
events and transactions that require consideration in planning the audit. If a business
combination has occurred or is contemplated before period end, the auditor should
consider making inquiries of the chief executive officer, the chief financial officer,
representatives of the client’s marketing, business development, R&D or technology
departments, and of other client personnel familiar with the acquisition. Such inquiries
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should enable the auditor to gain an understanding of the nature of the acquisition and
any special terms that may be associated therewith. Information obtained from
discussions with management and acquiring company personnel may help the auditor
identify matters that need to be corroborated with evidence obtained from other
procedures, including confirmation from independent sources outside the company.
6.3.12
Reading and understanding the terms of acquisition agreements, due diligence
reports, acquired company prospectuses or offering memoranda, analysts’ reports,
appraisals, board minutes and other related board materials, and preacquisition
disclosures made by the acquired company will help the auditor obtain an understanding
of the nature of the assets acquired (including IPR&D) and liabilities assumed, and the
relative importance of the various components acquired.
6.3.13

Timing Considerations

6.3.14
If the acquisition has not been consummated at the commencement of audit
planning and the auditor plans to use the work of a valuation specialist as evidential
matter in performing substantive tests, the auditor should consider completing many of
the procedures to be performed in connection with the use of the work of a valuation
specialist during the audit planning process. For example, the auditor should consider
performing the following procedures before the valuation study is completed to identify
any issues or concerns the auditor may have with the competence or objectivity of the
valuation specialist or with the valuation methodology or assumptions:

•
•
•

Evaluate the qualifications of the valuation specialist.
Evaluate any relationships that may exist between the valuation specialist and the client.
Obtain an understanding of—
 The types and sources of information to be provided by the company to the

valuation specialist.
 The methods and significant assumptions to be used by the valuation specialist.
 The scope and nature of the conclusions expected to be included in the valuation

specialist’s report.
 Whether the valuation specialist intends to follow the best practices discussed in

the Practice Aid, and, if not, where the valuation specialist plans to deviate from
the best practices.
6.3.15
If the transaction was consummated before audit planning, the auditor should
consider performing the audit procedures related to the allocation of the purchase price,
including the evaluation of the valuation specialists’ work, early in the audit so that
issues that arise may be resolved in a timely manner.
6.3.16

Personnel Considerations

6.3.17 Complex acquisitions, including those involving IPR&D, may require the
assignment of more experienced auditors and more extensive supervision. GAAS
requires that audit team members be assigned to tasks and supervised commensurate
with their level of knowledge, skill, and ability so that they can evaluate the audit
evidence they are examining. Also, the auditor responsible for the overall performance
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of the audit should possess a level of knowledge of the acquiring company’s business
and its operating characteristics sufficient to understand the events, transactions, and
practices that may have a significant effect on the financial statements being audited.
However, management will possess a level of knowledge about the acquiring company’s
business substantially greater than that obtained by the auditor in performing an audit.
6.3.18
Best practices suggest that senior engagement team personnel should direct
the planning of the substantive procedures applied in evaluating the reasonableness of
the significant valuation assumptions. The extent of involvement by the engagement
partner and manager generally depends on—

•
•
•
•

The experience of the personnel who will be performing the substantive procedures.
The complexity of the acquired and acquiring companies businesses.
The significance of the acquisition and the amount of the IPR&D charge in relation to
the financial statements taken as a whole.
The auditor’s assessment of the risk factors that relate to potential misstatements
arising from fraudulent financial reporting (see paragraph 6.3.35).

6.3.19
The auditor should consider whether expertise is available within his or her
firm to evaluate the valuation methodology. If the auditor concludes the requisite
expertise is not available within his or her firm, best practices suggest that the auditor
should engage the services of a valuation specialist to assist in that evaluation process.
6.3.20

Use of a Valuation Specialist

6.3.21
The sophistication of the acquiring company’s management and the skills of
its personnel have a direct bearing on the substantive procedures to be performed by
the auditor and the amount of reliance the auditor may place on client-performed
procedures. In the unusual situation in which the acquiring company is experienced in
accounting for acquisitions and competent in applying valuation techniques (including
those appropriate to acquired IPR&D) and has developed its own valuation
methodology, the auditor may conclude that the acquiring company need not engage an
independent valuation specialist. Companies that do not have in-house IPR&D valuation
expertise often engage an independent valuation specialist.
6.3.22

•
•

Specialists typically are engaged in the following ways:

Management engages or employs a valuation specialist and the auditor uses that
specialist’s work as evidential matter in performing substantive tests to evaluate the
allocation of purchase price.
The auditor engages a valuation specialist to assist the auditor in evaluating the valuation
procedures and findings performed by, or at the request of, the acquiring company.

6.3.23
Regardless of the manner in which the valuation specialist is engaged, the
auditor should follow the guidance provided in SAS No. 73 (AU secs. 336.08-.09) to—

•
•

Evaluate the professional qualifications of the valuation specialist.
Obtain an understanding of the work performed or to be performed, including the
methods and assumptions to be used, the scope of the conclusions to be reached,
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•

and the report to be issued; and the appropriateness of the valuation specialist’s
work for the auditor’s purposes.
Evaluate the relationship of the valuation specialist to the acquiring company.

6.3.24

Qualifications of the Specialist

6.3.25
SAS No. 73 (AU sec. 336.08) states that the auditor should consider the
following when evaluating the professional qualifications of the specialist in determining
that the valuation specialist possesses the necessary skill or knowledge:

•
•
•

The professional certification, license, or other recognition of the competence of the
specialist in his or her field.
The reputation and standing of the specialist in the views of peers and others
familiar with the specialist’s capability or performance.
The specialist’s experience in the type of work under consideration.

6.3.26
Following are factors the auditor should consider in assessing the
qualifications of the valuation specialist:

•
•
•
•

Whether the specialist possesses an accreditation in valuation issued by a
recognized body, such as the American Society of Appraisers, the Institute of
Business Appraisers, or the AICPA.
Whether the specialist is experienced in the valuation of tangible and intangible
assets (including IPR&D) acquired in a business combination.
Whether the specialist has valuation experience in the acquired company’s industry
or is otherwise knowledgeable of that industry.
Whether the specialist is familiar with the best practices discussed in this Practice Aid.

6.3.27
If the auditor is uncertain whether the valuation specialist has the requisite
qualifications, the auditor should consult with the appropriate acquiring company
management to determine whether another specialist should be engaged who does
possess the requisite skills and experience to perform the valuation. The auditor also
may engage a qualified valuation specialist to review the work of the acquiring
company’s valuation specialist or otherwise assist the auditor in evaluating the
qualifications of the acquiring company’s valuation specialist.
6.3.28

Relationship of the Specialist to the Acquiring Company

6.3.29
The auditor should evaluate the relationship of the valuation specialist to the
acquiring company and acquired company, paying particular attention to any situations
in which the companies have the ability—through employment, ownership contractual
rights, family relationships, or otherwise—to directly or indirectly control or significantly
influence the valuation specialist’s work.
6.3.30
There is no single, uniform set of conflict of interest standards applicable to
valuation specialists; each credentialing body establishes the ethical standards
applicable to its own members. For example, Uniform Standards of Professional
Appraisal Practice (USPAP) requires that the valuation specialist disclose, in the

142

valuation report, the existence of any circumstances that might be deemed to
present a conflict of interest. Nondisclosure of any such matter is a breach of USPAP
standards. If the valuation specialist’s report does not disclose any relationships with
the acquiring company, the auditor ordinarily would not question such matters. If the
auditor is uncertain about the possibility of a relationship between the acquiring
company and the valuation specialist, the auditor should consider contacting the
specialist and inquiring about any relationship between the acquiring company and
the valuation specialist.
6.3.31
If a relationship between the acquiring company and the valuation specialist is
disclosed or otherwise identified, the auditor should contact the valuation specialist and
obtain a full understanding of the nature of the matter in order to assess its potential
impact, if any, on the valuation study. For example, the valuation specialist may disclose
that the valuation firm receives a $5,000 per month retainer from the acquiring company
to ensure the valuation firm’s availability to provide services on short notice. If the
valuation firm is a large, well-known firm, it is unlikely that such a retainer would unduly
influence the work of the valuation firm. Such a retainer, if paid to a small or single
member valuation firm, could lead to the auditor’s further consideration of the
relationship. If the auditor is uncertain about whether the existence of a relationship is
significant, the auditor may wish to consult with another valuation specialist to evaluate
the possible impact of the matter on the valuation study. Alternatively, the auditor could
apply the guidance in paragraph 6.3.32.
6.3.32
If the auditor is unable to conclude that the relationship would not unduly
influence the valuation study, the auditor should—

•
•

Perform the substantive procedures described in paragraph 6.4 with a heightened
degree of professional skepticism.
Pay special attention to those elements of the valuation (for example, the
assumptions) that are highly dependent on the valuation specialist’s judgment. The
evidence considered in support of the assumptions should be scrutinized for
completeness and lack of bias.

If the auditor is unable to conclude that the valuation specialist’s assumptions, methods
or findings are not unreasonable, the auditor should engage another valuation specialist
for that purpose.
6.3.33

Understanding the Work of the Specialist

6.3.34
The auditor should obtain an understanding of the nature of the work to be
performed by the valuation specialist, including—

•
•
•
•
•

The objective and scope of the specialist’s work.
The specialist’s relationship to the acquiring company.
The methods or assumptions used or to be used.
The methods and significant assumptions as compared with those used in any
previous valuations that included acquired IPR&D.
The extent to which the best practices discussed in this Practice Aid are not followed.
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•
•

The valuation specialist’s understanding that the valuation findings will be used by
the auditor to evaluate the reasonableness of the related assertions in the financial
statements.
The valuation specialist’s agreement that the valuation report will include sufficient
detail to enable the auditor to perform that evaluation.

6.3.35

OVERALL RISK ASSESSMENT

6.3.36

SAS No. 47 (AU sec. 312.26) states:

The auditor needs to consider audit risk at the individual account-balance or
class-of-transactions level because such consideration directly assists in
determining the scope of the auditing procedures for the balance or class and
related assertions.
Elements of audit risk assessment include inherent, control, and detection risk.
6.3.37
Inherent risk is the susceptibility of an assertion to a material
misstatement, assuming that there are no related controls. The risk of such
misstatement is greater for some assertions and related balances or classes than for
others. For example, complex calculations are more likely to be misstated than
simple calculations. Accounts consisting of amounts derived from accounting
estimates pose greater risks than do accounts consisting of relatively routine, factual
data. External factors also influence inherent risk. For example, technological
developments might make a particular product obsolete, thereby causing amounts to
be more susceptible to overstatement. The amount of acquired IPR&D included in
the financial statements is based on accounting estimates involving complex
calculations and depends on future developments.
6.3.38
The auditor also should consider the inherent risks typically associated with
the acquired IPR&D estimate. Overstating acquired IPR&D understates goodwill, other
intangible assets, and current period earnings. Understating acquired IPR&D overstates
goodwill and earnings in the period of acquisition. Misstatements of the acquired IPR&D
estimate of fair value may be intentional or unintentional. Intent is often difficult to
determine, particularly in matters involving extremely subjective accounting estimates,
such as the fair value of acquired IPR&D. Unreasonable accounting estimates may be
unintentional or the result of an intentional attempt to misstate the financial statements.
Although the auditor has no responsibility to determine intent, the auditor does have a
responsibility to plan and perform the audit to obtain reasonable assurance about
whether the financial statements are free of material misstatement, whether caused by
error or fraud.
6.3.39 SAS No. 55, Consideration of Internal Control in a Financial Statement Audit
(AICPA, Professional Standards, vol. 1, AU sec. 319), as amended by SAS Nos. 78 and
94, requires that the auditor obtain a sufficient understanding of internal control to plan
the audit. The auditor then should assess control risk, which is the process of evaluating
the extent to which internal control may be relied upon in designing substantive tests to
be performed. Some entities make many acquisitions during the course of a year and
have developed substantial internal controls over accounting for the acquisitions and
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the related purchase price allocations. These internal controls may ensure that
management’s objectives, including compliance with GAAP, are achieved in
determining purchase price allocations. The auditor could evaluate those controls and
assess control risk at less than maximum. However, in most situations, the auditor will
not place significant reliance on controls and will perform substantive audit procedures
to determine whether the acquired IPR&D estimate is reasonable.
6.3.40
The auditor should understand the environment in which the acquiring
company operates to be able to assess the risk of a material misstatement. For
example, pressure to meet future earnings expectations of analysts or other external
parties may provide incentives for management to intentionally misstate the acquired
IPR&D estimate. To address such risks, the auditor may want to be aware of analysts’
earnings expectations and how they might influence the acquired IPR&D estimate. An
understanding of the factors that could affect this estimate will benefit the auditor as he
or she designs appropriate substantive audit procedures.
6.3.41
SAS No. 82, Consideration of Fraud in a Financial Statement Audit (AICPA,
Professional Standards, vol. 1, AU 316.16) groups risk factors that relate to
misstatements arising from fraudulent financial reporting into the following three
categories:

•
•
•

Management’s characteristics and influence over the control environment
Industry conditions
Operating characteristics and financial stability

SAS No. 82 (AU sec. 316.17) also provides examples under each category that might
be applicable to the acquired IPR&D estimate. The individual risk factors that should be
considered may vary from entity to entity. However, the auditor should evaluate the
examples and consider their effect on the nature and extent of the substantive
procedures to be applied in the audit.
6.3.42
Risk factors relating to management’s characteristics and influence over the
control environment may include—

•

A motivation for management to engage in fraudulent financial reporting. Specific
indicators might include—
 A significant portion of management’s compensation represented by bonuses,

stock options, or other incentives.
 An excessive interest by management in maintaining or increasing the entity’s

stock price or earnings trend.
 Pressures to achieve what may be aggressive or unrealistic forecasts.

•

A failure by management to display and communicate an appropriate attitude
regarding internal control and the financial reporting process. Specific indicators
might include—
 Domination of management by a single person or small group without effective

oversight by the board of directors or audit committee.
 Management setting unduly aggressive financial targets and expectations for

operating personnel.
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 Management displaying a significant disregard for regulatory authorities.
 Management continuing to employ an ineffective accounting, information

technology, or internal auditing staff.

•
•

Nonfinancial management’s excessive participation in, or preoccupation with, the
selection of accounting principles or the determination of the acquired IPR&D
estimate.
Strained relationship between management and the current or predecessor auditor.
Specific indicators might include—
 Frequent disputes with the current or predecessor auditor on accounting,

auditing, or reporting matters.
 Unreasonable demands on the auditor including unreasonable time constraints
regarding the completion of the audit or the issuance of the auditor’s reports.
 Formal or informal restrictions on the auditor that inappropriately limit his or her access
to people or information relevant to the evaluation of the acquired IPR&D estimate.
 Domineering management behavior in dealing with the auditor, especially
involving attempts to influence the scope of the auditor’s work concerning the
determination of the acquired IPR&D estimate.
6.3.43

•
•
•

A high degree of competition (for example, the effect of not being “first to market”
with the product).
The presence of rapidly changing technology.
High vulnerability to rapid product obsolescence (for example, the effect of next
generation products on the estimated economic life of the products under
development).

6.3.44

•
•
•
•

Risk factors relating to industry conditions may include—

Risk factors relating to operating characteristics and financial stability may include—

Inability to generate cash flows from operations while reporting earnings and
earnings growth.
Financial statement elements, such as acquired IPR&D charges, based on
significant estimates that involve subjective judgments or uncertainties.
Other significant, unusual, or complex transactions (especially those close to year
end) that pose difficult “substance over form” questions.
Aggressive sales or profitability incentive programs.

6.4
6.4.01

PERFORMING SUBSTANTIVE PROCEDURES
Overview

6.4.02
Acquired IPR&D may represent a significant portion of the purchase price in
an acquisition, especially in technology-based industries. Therefore, the auditor should
design substantive procedures that are appropriate in the circumstances and can be
reasonably expected to detect a material misstatement of the estimated fair value of the
acquired IPR&D in relation to the financial statements taken as a whole.
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6.4.03
The significant financial statement assertions applicable to acquired IPR&D
are valuation and allocation (acquired IPR&D is included in the financial statements at
an amount that is reasonable in the circumstances), and presentation and disclosure
(acquired IPR&D is properly classified, described, and disclosed). Accordingly, the
auditor should design substantive audit procedures to obtain and evaluate evidential
matter that will corroborate and support these assertions.
6.4.04

Preliminary Procedures

6.4.05
The auditor should obtain an understanding of the business purposes for the
acquisition sufficient to enable the auditor to evaluate whether the accounting is
consistent with the business purpose. For example, if the business purpose of the
acquisition is primarily to obtain access to the acquired company’s existing products and
intellectual property, work force, and customer lists, one would not expect that a
significant portion of the purchase price would be allocated to acquired IPR&D. The
auditor ordinarily obtains this knowledge primarily from discussions with appropriate
acquiring company personnel (including those of the acquired company) and analysis of
due diligence or other acquisition studies performed by or for the acquiring company.
Best practices indicate that in addition to discussions with the chief executive officer and
chief financial officer, the auditor should consider discussing the business purpose of
the acquisition with (a) marketing personnel familiar with the acquired company’s
products and markets, and (b) R&D, production, and business development personnel
who are familiar with the products and product development plans related to the
acquired technology.
6.4.06

•
•
•
•
•
•
•
•
•

The auditor’s inquiries of the above parties should provide information about—

Base (or core) technology.
Historical and existing product lifecycles and changes in volumes and average
selling prices over those lifecycles.
Future products and dependency of future products on base (or core) technology.
Management’s technology development plans.
Capabilities of personnel to conduct R&D.
Markets served by the company and those it would like to serve.
Competitive conditions.
Regulatory requirements.
Sensitivity to economic conditions.

6.4.07
This listing is not meant to be all-inclusive. It is designed to illustrate a
process that the auditor undergoes and the knowledge that he or she needs of the
acquired company’s business to design effective substantive auditing procedures. The
nature of the acquired IPR&D estimate is such that virtually every situation will be
unique to the particular entity and industry to which it applies.
6.4.08
Generally, independent third party verification of management’s expectations
leading to the determination of the fair value of acquired IPR&D is not practicable. Best
practices suggest that, under these conditions, auditors should exercise a heightened
degree of professional skepticism and be alert to any information that may contradict
management’s stated expectations. Also, best practices indicate that the auditor should
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obtain and review the following types of information that may either corroborate or
contradict management’s stated expectations:

•
•
•
•

Internal budgets
Technology development plans
Materials presented to the board of directors in support of the acquisition
Other corporate documents, including Web site content and press releases

Additionally, events occurring after the acquisition date may provide the auditor with
evidence corroborating management’s expectations at the time of the acquisition.
Auditors should be skeptical when management’s expectations change shortly after the
acquisition date. Changes in management’s expectations after the acquisition date should
occur only as a direct result of events occurring subsequent to the acquisition date.
6.4.09
The information developed in performing the preliminary procedures set forth
above should be used to tailor further substantive procedures and evaluate the
reasonableness of the results.
6.4.10

Valuation Report

6.4.11
The appropriateness of the methods and the reasonableness of the
assumptions used and their application are the responsibility of the valuation specialist.
The valuation specialist prepares a valuation report that documents the results of the
specialist’s work, describes the methods and assumptions used in estimating the fair
value of the items, and expresses conclusions as to the results of the work performed.
The auditor should consider arranging to receive a copy of the draft or preliminary
valuation report and study its contents to become informed of the significant
assumptions and valuation techniques applied in the valuation of acquired IPR&D.
6.4.12
The auditor should consider whether the preliminary valuation is
unreasonable considering the knowledge of the acquiring company’s business and the
business purpose of the acquisition. That consideration includes an assessment of
whether the key assumptions appear reasonable based on the auditor’s knowledge of
the business and the IPR&D projects. If the auditor has not previously discussed the
valuation methodology and assumptions with the valuation specialist, he or she should
do so to clarify any questions or concerns the auditor may have.
6.4.13
The following provide guidance to the auditor in performing procedures to
evaluate the reasonableness of the valuation results.
6.4.14

The Valuation Methodology

6.4.15
The valuation specialist uses specialized skills and industry experience to
value acquired IPR&D. While the auditor cannot be expected to possess these skills,
the auditor should perform procedures to determine that the methodology used by the
specialist reconciles to the best practices discussed in this Practice Aid and includes
consideration of the following matters.
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6.4.16

Identification of All Intangibles

6.4.17 An appropriate valuation should identify all intangible assets acquired, including
IPR&D (see paragraph 5.3.26). However, care should be taken to exclude from the
IPR&D valuation amounts attributable to IPR&D projects that—

•
•
•
•
•
•
•
•

Are not the results of R&D costs incurred by the acquired company (see paragraph 3.1.03).
Do not have a fair value that is supported by the report (satisfactory to the auditor) of
the valuation specialist (see paragraph 3.2.02).
Are not controlled by the acquiring company or used for its economic benefits (see
paragraph 3.2.03).
Have yet to exhibit substance (see paragraph 3.2.04).
Are complete (see paragraph 3.2.04).
Have an alternative future use (see paragraph 3.2.06).
Represent base (or core) technology or other contributory assets (see paragraph 5.3.54).
Represent entity-specific synergies (see paragraph 5.3.17).

The auditor should consider, based on his or her knowledge of the acquiring company,
the industry and the particular acquisition, whether other intangibles may exist that are
not included in the valuation. Paragraph 5.3.60 references other types of intangible
assets that may be present in a business combination.
6.4.18
The auditor can accomplish this objective by reviewing the allocation of the
purchase price to the individual assets acquired. As discussed previously, generally the
auditor does not have the skills to value the assets acquired, but the auditor can
evaluate the completeness of the allocation based on his or her understanding of the
business. If this knowledge indicates intangibles or other assets that may exist for which
no allocation of fair value has been made, the auditor should discuss those matters with
appropriate acquiring company personnel, including the valuation specialist, to ascertain
that proper consideration of those other assets was made in the allocation of purchase
price for the acquisition.
6.4.19

Projects in Progress

6.4.20
The valuation specialist generally will determine the value of developed
product and base (or core) technology as well as technology under development. The
auditor should consider whether only projects in process meeting the characteristics
and attributes discussed in chapter III are included in the acquired IPR&D valuation.
While this is an area of considerable judgment, the following will assist the auditor when
evaluating in-process projects:

•
•
•
•
•
•
•

Detailed description of each project
Consideration of technological feasibility of the project
Detailed project development chart (concept to completion)
Overview of the status of the project as of the acquisition date
Detailed project cost chart (concept to completion)
The nature and complexity of the remaining development effort and schedule of the
amount and timing of expenditures required to complete the project (that is, productspecific characteristics)
Expected completion date/time to market
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•
•
•
•

Consideration of alternative uses of the project or any components thereof
Economic justification for the project, including anticipated market, market share,
and cash flow assumptions
Competitors’ activities/efforts
Industry data.

6.4.21
This listing is not intended to be all-inclusive. Rather, it is intended to provide
the auditor with guidance of matters to consider in evaluating whether all projects in
process included in the valuation have continuing viability. This information should be
obtained from appropriate acquiring company personnel and evaluated for
reasonableness based on the auditor’s knowledge of the business.
6.4.22

Significant Assumptions

6.4.23

SAS 73 (AU sec. 336.12) states:

The appropriateness and reasonableness of methods and assumptions used
and their application are the responsibility of the specialist. The auditor should
(a) obtain an understanding of the methods and assumptions used by the
specialist, (b) make appropriate tests of data provided to the specialist, taking
into account the auditor’s assessment of control risk, and (c) evaluate whether
the specialist’s findings support the related assertions in the financial
statements. Ordinarily, the auditor would use the work of the specialist unless
the auditor’s procedures lead him or her to believe the findings are
unreasonable in the circumstances. …
6.4.24
The auditor should evaluate whether the significant assumptions used by the
valuation specialist are unreasonable based on the knowledge of the business and
other information available.
6.4.25
Cash flow forecasts of IPR&D projects provided by management are among
the most subjective of all estimates. The auditor should be satisfied that the estimates
result in a valuation of acquired IPR&D that is not unreasonable. The extent of work that
an auditor performs on such estimates is a matter of professional judgment regarding—

•
•
•
•
•
•

Materiality of the acquired IPR&D.
Complexity of the transaction.
Conclusions about the thoroughness of the valuation and the qualifications of the
valuation specialist.
The asserted stage of completion of the project.
The asserted state of the technology.
The asserted assumptions used to arrive at an estimate of fair value (for example,
discount rates and forecasted revenues and expenses).

6.4.26
The cash flow forecasts provided to or prepared by the valuation specialist
should present (under the commonly used traditional approach) the best estimate of the
future cash flows expected to be derived from each IPR&D project that is expected to
be completed, using market participant assumptions (see paragraph 5.3.17) rather than
entity-specific assumptions. The auditor should perform procedures to evaluate whether
the significant assumptions are unreasonable. The auditor should determine the extent
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of the procedures he or she will perform after evaluating the extent of the valuation
specialist’s work concerning the data supporting the significant assumptions. The
auditor should consider the sources of information (both internal and external to the
company) used by the valuation specialist in developing (or evaluating) the significant
cash flow assumptions, such as expected costs to complete each IPR&D project in
process, expected product sales volumes, prices and production costs, and expected
product life cycles.
6.4.27
Matters to be considered when evaluating whether the significant cash flow
assumptions are unreasonable include the following:

•
•
•
•
•
•
•

Can information be obtained and informed judgments made about past and future
events or circumstances in support of the underlying assumptions?
Are any of the significant assumptions so subjective that no reasonable basis could
exist to prepare a forecast of cash flows that results in a reasonably reliable
measurement of fair value?
Which entities comprise market participants?
Would other persons knowledgeable in the acquiring company’s business and
industry select materially similar assumptions?
Is the length of the forecast period appropriate given the historical product life
cycles, potential for technological obsolescence, and expected market responses of
customers and competitors?
Is the market for the products expected to be produced from the technology mature
or growing? Is it volatile or stable?
Is the acquiring company well established in the market for the expected products or
a newcomer?

6.4.28
Moreover, the auditor specifically should consider the significant cash flow
assumptions that are particularly sensitive to risk of misstatement. Among the more
significant assumptions are the following:

•
•
•
•
•
•
•
•
•

Potential for introduction of new technologies that may lead to reduced selling prices
or obsolete the acquired technology
Likelihood of completion of product
Estimates of stage of completion and time to completion
Cost to complete
Product life cycle and technology development strategies
Expected sales volumes, product pricing, and expected revenues, and charges for
base (or core) technology and other contributory assets
Production and other costs, exclusive of the effects of buyer synergies
Discount rates used to present value estimated cash flows
Competitors’ expected market responses

6.4.29
While the appropriateness and reasonableness of the assumptions used and
their application are the responsibility of management and the valuation specialist, best
practices suggest that the auditor perform procedures to determine whether the
assumptions used and factors considered in developing the acquired IPR&D valuation are
unreasonable. The nature and extent of the specific procedures to be performed by the
auditor will be influenced by the extent of the procedures undertaken, and the conclusions
reached, by the valuation specialist. The following procedures should be considered:
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•

Evaluate the support for the assumptions and conclusions of the valuation specialist,
giving special attention to specific assumptions that are—





•

For significant assumptions, if practicable, obtain the internal and external sources of
information that were used in formulating the assumptions. The assumptions used
should be market participant assumptions rather than those that are entity-specific
(see paragraph 5.3.17). The following information may be useful to the auditor in
evaluating the assumptions:











•
•
•
•
•

Material to the valuation
Especially sensitive to variations
Deviations from historical patterns
Especially uncertain

Knowledge of the business
Due diligence studies
Research reports of analysts
Product plans and budgets developed by the acquiring company
Market research studies
Historical experience with new product development activities of the acquiring
company
Offering memoranda
Board of director materials prepared in support of the acquisition
Development progress subsequent to the acquisition
Forecasts provided to lenders

On a test basis, consider whether that information supports the significant assumptions.
If the information is taken from internal analyses, consider the need for testing the
supporting information.
Review the acquiring company’s business plan (including product development
plans, marketing plans and programs), budgets, and objectives, and consider their
relationship to the significant assumptions.
Consider the existence of external sources of information about the acquiring
company and its product development activities, the industry and competitors’
activities, analysts reports, and trade publications. If appropriate, consider confirming
information supporting significant assumptions with the external sources.
Inquire about and analyze any historical data used in developing the significant
assumption to assess:
 Whether the data are comparable and consistent for all periods, and
 Whether the data are sufficiently relevant for the purpose

•

If the support for significant assumptions comes from experts, such as lawyers,
engineers, economists, and investment bankers:
 Consider their professional standing and objectivity
 Review the data and business plans the acquiring company submitted to the

expert for consistency with the forecast assumptions and supporting data.
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6.4.30

Internal Consistency

6.4.31
Upon completion of the procedures enumerated above, the auditor should
assess the conclusions reached and the evaluation of the overall financial statement
presentation. This generally would include considering the internal consistency of the
results and assumptions with the acquiring company’s business plans, forecasts, press
releases, board presentations, and discussions with key personnel. When the results
are not consistent with other information disseminated by the acquiring company, the
auditor should request a reconciliation of such inconsistencies or appropriate revision of
the valuation assumptions. If the acquiring company is unable to reconcile any
inconsistencies or declines to modify the valuation assumptions, the auditor should
consider the effect of this situation on his or her report on the financial statements (see
paragraph 6.4.32).
6.4.32

Evaluating Results of Procedures Performed

6.4.33
In considering whether to rely on the findings of a valuation specialist about
the fair value of the acquired IPR&D, the auditor should evaluate whether the valuation
specialist’s procedures and findings support management’s assertion about the fair
value of acquired IPR&D in the financial statements. Ordinarily, the auditor would
accept the work of the valuation specialist unless other evidential matter developed in
the course of the audit leads the auditor to believe that the valuation specialist’s findings
are unreasonable. In that event, or in the event there is a material difference between
the valuation specialist’s findings and management’s assertion in the financial
statements about the fair value of the acquired IPR&D item, the auditor should apply
additional procedures designed to provide whatever additional information or
corroborating evidential matter is needed to resolve the matters in question.
6.4.34
If, after applying additional appropriate audit procedures, the auditor is unable
to resolve the matters, the auditor should obtain the opinion of another valuation
specialist, unless it appears to the auditor that the matters cannot be resolved. The
existence of a matter that cannot be resolved ordinarily will cause the auditor to
conclude that the audit report should be qualified, because the inability to obtain
sufficient competent evidential matter as to an assertion of material significance in the
financial statements constitutes a scope limitation, and the guidance in paragraph
6.5.07 should be considered.
6.4.35

Preliminary Purchase Price Allocations

6.4.36
Situations may arise wherein an acquiring company consummates a business
combination at or near the end of a reporting period, and the valuation specialist has been
unable to complete a detailed valuation of the acquired IPR&D. Paragraph 4.1.02
provides an accounting question and answer for those situations and indicates that a
tentative allocation of the purchase price should be made using the values that have been
determined and preliminary estimates of the fair values that have not yet been finalized.
The acquiring company may be able to make a good faith best estimate of the IPR&D
allocation because it performs due diligence before or immediately after agreeing to the
terms of the acquisition. Guidance also is provided when the acquiring company cannot
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determine a best estimate for a preliminary allocation to acquired IPR&D, but it has a
range of estimates, as may be the case in a hostile takeover situation.
6.4.37
In such situations, the auditor should ascertain that a valuation specialist has
been engaged and expects to complete the valuation study within a reasonable period
of time subsequent to the acquisition. The auditor also should ascertain that a
preliminary estimate of the IPR&D charge has been recorded and perform appropriate
procedures to evaluate the reasonableness of that preliminary estimate. In evaluating
the reasonableness of the preliminary estimate, the auditor should perform essentially
the same procedures as set forth in paragraphs 6.4.04 through 6.4.30. In addition, the
auditor should discuss with the valuation specialist the preliminary estimate and data
supporting the estimate to identify any concerns that the auditor or the valuation
specialist may have with regard to the reasonableness of the estimate recorded.
6.4.38
If the auditor is unable to satisfy himself or herself about the reasonableness
of the recorded allocation of the purchase price to the acquired IPR&D, the auditor (and
the valuation specialist, if necessary) should meet with management and resolve the
difference of opinion. It may be possible to accelerate the completion of the valuation
study, delay the issuance of the financial statements, or both, until a better estimate can
be developed. If the matter is not resolved to the satisfaction of the auditor, the
guidance in paragraph 6.5.13 should be considered.
6.4.39

Management Representations

6.4.40
The auditor should obtain representations from management regarding its
responsibility for the presentation of acquired IPR&D in the financial statements at the
appropriate amount when the amounts are material in relation to the financial
statements taken as a whole. An example of such representations follows:
In connection with the amounts recorded for the transaction to acquire
Company X, we agree with the findings of the valuation specialist in
calculating the fair value of acquired in-process research and development
(IPR&D) and have adequately considered the qualifications of the specialist
in determining whether to use the results of the specialist’s valuation as the
basis for the amount of the IPR&D charge. We believe the IPR&D assets
identified as those to be used in R&D activities meet the definition of such
assets (including that they have substance, are incomplete, and have no
alternative future use) and their fair value is estimable with reasonable
reliability. We expect to complete the development of all such assets, based
on information that is available to us at the date of the final purchase price
allocation. We believe the amount of the charge is appropriate and is
consistent with generally accepted accounting principles, including the
guidance in FASB Interpretation No. 4, and the related disclosures are
appropriate. The historical financial data provided to the valuation specialist
was prepared on a basis consistent with the company’s audited financial
statements. Forecasts and other estimates provided to the valuation
specialist are consistent with those developed for other parties, internal
use, or both. The forecasts of future cash flows used in the valuation
represent our best estimate of future conditions consistent with the
assumptions specified in the specialist’s valuation using market participant
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assumptions rather than those that are entity-specific. [If using the
traditional approach] The discount rate applied to estimated future net cash
flows appropriately reflects the nature and complexity of the remaining
development effort and the amount and timing of estimated expenditures
necessary to complete the development of the IPR&D projects. We did not
give or cause any instructions to be given to the valuation specialist with
respect to the values or amounts derived in an attempt to bias his or her
work, and we are not otherwise aware of any matters that have had an
adverse effect on the independence or objectivity of the specialist.
6.4.41
The auditor should consider whether other representations concerning the
accounting for the acquisition should be obtained from management.

6.5

REPORTING CONSIDERATIONS

6.5.01
The purpose of this section is to identify best practices in addressing reporting
matters relating to acquired IPR&D that could arise in the course of performing
substantive audit procedures. Issues could result from concerns over the auditor’s
ability to rely on the work of the specialist or to obtain competent evidential matter in
support of the financial statement assertion as to the IPR&D valuation, the estimation or
presentation of the acquired IPR&D amounts in conformity with GAAP, and the auditor’s
association with IPR&D disclosures outside of the financial statements, such as in
management’s discussion and analysis (MD&A).
6.5.02

Reliance on the Work of the Specialist

6.5.03
If, upon the successful completion of the substantive procedures set forth in
paragraph 6.4, the auditor determines that the specialist’s findings support
management’s assertions about the valuation of the acquired IPR&D, the auditor
usually would conclude that sufficient competent evidential matter has been obtained.
Generally, the auditor should not refer to the work or findings of the specialist in the
auditor’s report on the financial statements. Reference to the specialist might be
misunderstood to be a qualification of the auditor’s opinion or a division of responsibility,
neither of which is intended.
6.5.04
Circumstances may arise, as a result of the report or the findings of the
specialist, wherein the auditor decides to add explanatory language to the auditor’s
standard report in the form of an emphasis paragraph, or when a departure from an
unqualified opinion on the financial statements is required. Reference to and
identification of the specialist may be made in the auditor’s report if in the auditor’s
judgment the reference will facilitate an understanding of the reason for the explanatory
paragraph or the departure from an unqualified opinion.
6.5.05
SAS No. 58, as amended, provides guidance with respect to the addition of
an explanatory paragraph in the auditor’s report to emphasize a matter regarding the
financial statements. For example, an acquiring company may incur a significant IPR&D
charge that could affect the comparability of the current period results of operations with
those of the preceding period. In that situation, the auditor may wish to direct attention
to the disclosures of the business combination and the IPR&D charge by means of an
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emphasis paragraph in the auditor’s report. Emphasis paragraphs are never required;
they may be added solely at the auditor’s discretion. A cursory review of current practice
indicates that emphasis paragraphs are rarely, if ever, used in connection with a
business combination.
6.5.06
If, as a result of performing audit procedures on the acquired IPR&D, the
auditor concludes that a departure from an unqualified opinion is required, the form of
the auditor’s report will be governed by the nature of the circumstances giving rise to the
need for the report modification. The requirements of the Securities and Exchange
Commission (SEC) staff concerning qualified opinions on financial statements filed with
the SEC are set forth in Staff Accounting Bulletin 13 (Topic 1E) and would be applicable
to financial statements filed with the SEC.
6.5.07

Scope Limitations

6.5.08
The auditor is able to express an unqualified opinion on the financial
statements only if the audit has been performed in accordance with GAAS, and if the
auditor has been able to apply all the audit procedures considered necessary in the
circumstances. Restrictions on the scope of the audit, whether imposed by the acquiring
company or by circumstances, such as the timing of the audit work, the inability to
obtain competent evidential matter, or an inadequacy of the accounting records, may
require the auditor to modify the report on the financial statements.
6.5.09
The auditor’s decision to express a qualified opinion or to disclaim an opinion
because of a scope limitation depends on the auditor’s assessment of the importance of
the omitted audit procedures in relation to the auditor’s ability to form an opinion on the
financial statements taken as a whole. That assessment will be affected by the nature
and magnitude of the potential effect of a misstatement of acquired IPR&D and its
significance to the financial statements being audited.
6.5.10
When the auditor is unable to resolve disagreements regarding the
reasonableness of the work of the valuation specialist (see paragraph 6.4.32), the
auditor ordinarily will conclude that the audit report should be qualified because the
inability to obtain sufficient competent evidential matter as to an assertion of material
significance in the financial statements constitutes a scope limitation. SAS No. 58 (AU
sec. 508.22–.32) provide additional guidance to the auditor with respect to scope
limitations (as distinguished from uncertainties) and their effect on the auditor’s report.
6.5.11
The procedures described above should be applied in situations in which the
limitation on the scope of the audit is imposed by circumstances beyond the control of
the acquiring company or the auditor, such as a lack of historical or other information to
enable the auditor to evaluate the reasonableness of the significant assumptions used
by the valuation specialist to estimate the fair value of the acquired IPR&D. In the rare
situation in which a restriction that significantly limits the scope of the audit is imposed
by the acquiring company, the auditor ordinarily should disclaim an opinion on the
financial statements.
6.5.12
Situations may arise where an acquiring company that lacks the sophistication
to perform its own valuation (see paragraph 6.3.21), refuses to engage a valuation
specialist and makes their own estimate of the fair value of the acquired IPR&D. In those
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circumstances, the auditor should consider insisting that the acquiring company engage
a qualified independent valuation specialist. The acquiring company may suggest that
the auditor perform the valuation and propose adjustments to the recorded estimate.
For public registrants, the SEC staff believes that an auditor’s independence would be
impaired by performing such services for an audit client since he or she would be in the
position of auditing their own work. The client’s refusal to engage a qualified
independent valuation specialist may result in a lack of competent evidential matter in
support of the amount assigned to acquired IPR&D. In that situation, the lack of such
evidential matter would constitute a scope limitation, as discussed in paragraph 6.5.11.
6.5.13

GAAP Departures

6.5.14
After performing the requisite audit procedures, including evaluating the
findings of the valuation specialist, the auditor may conclude that management’s
assertions in the financial statements about the identification of or estimate of the fair
value of the acquired IPR&D are not presented or measured in conformity with GAAP.
This situation could arise from unresolved differences of opinion over whether all
intangibles (for example, base [or core] technology) have been properly identified and
valued, the appropriateness of the valuation methodology, or the reasonableness of the
significant valuation assumptions (for example, the discount rate applied to compute the
present value of estimated future net cash flows). When financial statements are
materially affected by a departure from GAAP and the auditor has performed an audit in
accordance with GAAS, the auditor should issue a qualified or adverse opinion on the
financial statements. In deciding whether the effects of a GAAP departure are
sufficiently material to require either a qualified or adverse opinion, the auditor should
consider not only the dollar magnitude of the departure but should also consider the
qualitative implications of the matter.2
6.5.15
Auditor’s Responsibility for Information in Documents Containing
Audited Financial Statements
6.5.16
The auditor’s responsibility for information published in certain documents
containing audited financial statements is described in SAS No. 8, Other Information in
Documents Containing Audited Financial Statements (AICPA, Professional Standards,
vol. 1, AU sec. 550.04) as follows:
Other information in a document may be relevant to an audit performed by an
independent auditor or to the continuing propriety of his report. The auditor’s
responsibility with respect to information in a document does not extend
beyond the financial information identified in his report, and the auditor has no
obligation to perform any procedures to corroborate other information
contained in a document. However, he should read the other information and
consider whether such information, or the manner of its presentation, is
materially inconsistent with information, or the manner of its presentation,
appearing in the financial statements. [Footnote omitted.]

2

SEC Staff Accounting Bulletin No. 99, “Materiality,” presents a discussion of materiality considerations
that are applicable to the financial statements of Securities and Exchange Commission registrants.
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6.5.17
Accordingly, the auditor should read the acquired IPR&D disclosures in the
MD&A presented in annual reports to shareholders and other documents to consider
whether the disclosures are consistent with the auditor’s knowledge of the client and the
audited financial statements.
6.5.18
While the auditor does not have an obligation to corroborate acquired IPR&D
information presented outside the financial statements, if such information is materially
inconsistent with the audited financial statements, the auditor should discuss these
matters with appropriate acquiring company personnel. If the inconsistencies are not
corrected to the auditor’s satisfaction, the auditor should follow the guidance set forth in
SAS No. 8 (AU secs. 550.05-.06).

6.6

OTHER CONSIDERATIONS—INTERIM PERIOD REPORTING

6.6.01
An auditor may become aware of an acquisition involving IPR&D while
performing a review of interim period financial information in accordance with SAS No.
71, Interim Financial Information (AICPA, Professional Standards, vol. 1, AU sec. 722)
as amended by SAS No. 90. That guidance notes that the objective of a review of
interim financial information is to provide a basis for reporting whether the auditor is
aware of any material modifications that should be made for the information to conform
with GAAP. Procedures applied in performing a review of interim financial information
generally are limited to inquiries and analytical procedures concerning significant
accounting matters relating to the interim financial information. Those procedures do not
contemplate (a) tests of accounting records through inspection, observation, or
confirmation; (b) obtaining corroborating evidential matter in response to inquiries; or (c)
the application of certain other procedures ordinarily performed during an audit.
6.6.02
When a business combination has been reported in interim period financial
statements that are the subject of a SAS No. 71 review, the auditor ordinarily would
make inquiries of management and perform analytical procedures designed to ascertain
whether the business combination as a whole appears to have been accounted for in
conformity with GAAP. When making inquiries and performing analytical procedures
with respect to a material IPR&D charge, the auditor should consider performing the
following procedures:

•
•
•

Inquire of the CEO and CFO about the business purpose for the acquisition, the principal
products, processes, and types of assets acquired, and whether a valuation specialist
was engaged to value the acquired IPR&D and has rendered a valuation report.
Determine whether the amount allocated to acquired IPR&D is preliminary and
subject to completion of a valuation study. If so, ascertain that its preliminary nature
is properly disclosed in the financial statements.
If a valuation report has been rendered, the report should be read and the assumptions
and findings considered for consistency with the amounts reported in the financial
statements and for reasonableness, based on the auditor’s knowledge of the acquiring
company’s business and the industry, and for conformity with the best practices set forth
in this Practice Aid. The auditor also should consider whether a discussion of the
valuation assumptions and methodology with the valuation specialist would be helpful in
enhancing the auditor’s understanding of the estimation of the IPR&D charge.
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6.6.03
The auditor should consider obtaining, in the representation letter, a specific
representation concerning the valuation of and accounting for the acquired IPR&D similar to
that presented in paragraph 6.4.32, tailored as appropriate for the specific circumstances.
6.6.04
If, based on performing the procedures set forth above, the auditor has
reason to believe the acquiring company’s estimation or presentation of the acquired
IPR&D may not be in conformity with GAAP, the auditor should discuss his or her
concerns with the acquiring company’s senior management and perform additional
procedures, such as those noted in paragraph 6.4, as may be necessary to determine
whether a material misapplication of GAAP or appropriate valuation practices may have
occurred. If the additional procedures confirms a material error in the determination or
recording of the IPR&D charge, and the interim period financial information has not
been issued or filed with the SEC on Form 10-Q in the case of a public company, the
interim period financial information should be corrected before issuance or filing of Form
10-Q. If Form 10-Q already has been filed, management should be advised to discuss
with its legal counsel the need to disclose publicly, such as in a Form 8-K Current
Report, that the previously issued interim period financial information requires
restatement and to prepare appropriate public filings to correct that interim information.
6.6.05
If, in the auditor’s judgment, management does not respond appropriately to
the auditor’s concerns within a reasonable period of time, the auditor should inform the
audit committee (or board of directors in the absence of an audit committee) of the
matter as soon as practicable. If, in the auditor’s judgment, the audit committee (or
board of directors) does not respond appropriately to that communication, the auditor
should evaluate whether (a) to resign the review engagement, (b) to resign or decline
to stand for reelection as the acquiring company’s auditors, and (c) the actions of the
acquiring company and its audit committee trigger the auditor’s reporting obligations
(with respect to public entities) under Section 10A of the Securities Exchange Act of
1934. The auditor may wish to consult with his or her legal counsel when making
these evaluations.
6.6.06
If a business combination has not been consummated at the date of the
review of the interim financial information, the auditor should obtain from the acquiring
company’s senior management an understanding of the nature and purpose of the
transaction and review the acquiring company’s plan for completing the acquisition. The
auditor may wish to consider the matters discussed in paragraph 6.3, including the need
to engage the services of a competent independent valuation specialist. The auditor
also should consider discussing with management the extent of the disclosures that
should be made concerning the acquisition, such as disclosure in the MD&A by a
company subject to the reporting requirements of the SEC.
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EXHIBIT 6-1
Sample Audit Program — In-Process Research and Development

GENERAL

A portion of the purchase price in a business combination may be allocated to inprocess research and development (IPR&D), but IPR&D is particularly common in
acquisitions of software, electronic devices, and pharmaceutical companies. This
sample audit program outlines audit procedures that should be considered when an
acquiring company has consummated a business combination that may involve IPR&D.
This sample audit program is best read and used in conjunction with best practices
identified in chapter 6.
The procedures focus on the software, electronic devices, and pharmaceutical
industries; however, further tailoring of the recommended procedures may be necessary
in response to the specific circumstances of each acquisition. The nature and extent of
the needed tailoring may be influenced by the business, legal, and regulatory
environments in which both the acquiring company and the acquired company operate.
Accordingly, auditors should use their knowledge of those environments and their
professional judgment in tailoring the recommended procedures to each acquisition.
The services of a valuation specialist usually are required in estimating the amount of
the purchase price allocated to IPR&D. Some entities employ valuation specialists in
their organizations; others will find it necessary to engage the services of an external
valuation specialist. Regardless of who performs the valuation, the auditor should
determine that the specialist has the requisite skills and expertise to develop a valuation
of the acquired IPR&D in conformity with generally accepted accounting principles
(GAAP). In gathering audit evidence about the appropriateness of the IPR&D valuation,
the auditor also may require the assistance of a valuation specialist. That specialist may
be an employee of the auditor’s firm or may be an external valuation specialist engaged
by the auditor to assist in evaluating the reasonableness of the IPR&D valuation.
PROCEDURES

1.

Obtain an understanding of the acquisition.
a. Inquire of appropriate acquiring company personnel about the nature and business

purpose of the acquisition and whether special terms or conditions may exist.
[Persons of whom inquiry might be made include the chief executive officer, the
chief financial officer, and appropriate personnel from marketing, business
development, research and development, and technology departments. The
auditor should become familiar with the types of products and services sold by
the acquired company, and its production, marketing, distribution, and
compensation methods. The auditor also should become aware of significant
matters and trends affecting the industry, including economic conditions,
changes in technology, government regulations, and competition.]
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b. Obtain and read the acquisition agreements, due diligence reports prepared by

acquiring company personnel or other parties engaged by the acquiring
company, analyst’s reports, acquired company prospectuses or offering
memoranda, and other industry analyses pertinent to the acquisition.
c. Obtain and read presentations to the board of directors and any press releases
concerning the acquisition.
2.

3.

Ascertain the identity and affiliation of the valuation specialist. Arrange to meet with the
valuation specialist and discuss the following:
a. The objectives and scope of the valuation study.
b. Whether the valuation specialist has any relationships with the acquiring
company that might impair the valuation specialist’s objectivity.
c. The valuation specialist’s understanding of the requirements of GAAP as they
relate to the valuation, including the definition of fair value.
d. The types and sources of information to be provided by the acquiring company to
the valuation specialist.
e. The methods and significant assumptions used in the valuation, including the
selection of discount rates.
f. The consistency of methods and assumptions with previous valuations.
g. The scope and nature of the conclusions included in the valuation report.
Ascertain the following:
a. The professional competence of the valuation specialist as evidenced by

accreditation or certification, licensure or recognition by a recognized
professional organization.
b. The professional reputation of the valuation specialist as viewed by his or her
peers and others familiar with his or her capabilities or performance.
c. The experience of the valuation specialist in the industry or in the valuation of
tangible and intangible assets, including acquired IPR&D.
4.

Inquire of acquiring company personnel regarding any relationship between the
valuation specialist and the acquiring company.
[The auditor should evaluate any relationship between the valuation specialist and the
client to ascertain whether the client has the ability—through employment, ownership,
contractual rights, family relationship or otherwise—to directly or indirectly control or
significantly influence the valuation specialist’s work The valuation report should
identify such relationships.]

5.

With respect to the valuation report—
a. Determine whether the valuation methodology used reconciles to the AICPA

Practice Aid, Assets Acquired in a Business Combination to be Used in Research
and Development Activities.
b. Review the reconciliation of the valuation to the purchase price paid.
[This information is normally found in the “Valuation Analysis” section of the
valuation report.]
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c. Consider whether other intangibles exist to which a portion of the purchase has

not been allocated.
[The report should identify and value all intangibles acquired (when several
specialists are used to value intangibles, there may be more than one report, but
the intangibles should be valued).]
6.

If the income approach to valuation is used, review the cash flow forecasts and consider
whether the significant assumptions applied to the projects in process are
unreasonable.
[Among the more significant assumptions are the following:
• Potential for introduction of new technologies that may obsolete the acquired
technology
• Likelihood of project completion
• Estimates of stage of completion and time to completion
• Cost to complete
• Product life cycle and technology development strategies
• Expected sales volumes, product pricing, and expected revenues (exclusive of
amounts attributable to contributory assets and core technology)
• Production and other costs (exclusive of the effects of buyer synergies)
• Discount rates
• Competitors’ expected prices]

7.

Test the data furnished to the valuation specialist as follows:
Assess the relative importance of IPR&D to the acquisition by considering the
materials reviewed during the planning procedures as well as other materials, such
as presentations to the board, white papers, and due diligence working papers.
b. Test the mathematical accuracy of the forecasts furnished to the specialist.
c. Determine whether cash flow estimates were developed using “market
participant” assumptions. With respect to “market participant” assumptions,
paragraph 1.1.16 of the AICPA Practice Aid states:
a.

For purposes of assigning cost to the assets acquired in
accordance with FASB Statement No. 141, the amount of the
purchase price allocated to an acquired intangible asset would not
include any entity-specific synergistic value. Fair value does not
include strategic or synergistic value resulting from expectations
about future events that are specific to a particular buyer because
the value associated with those components are unique to the
buyer and seller and would not constitute market-based
assumptions. As such, entity-specific value associated with
strategic or synergistic components would be included in goodwill.
Fair value would incorporate expectations about future events that
affect market participants. If the acquiring company concludes that
the discounted cash flow method best approximates the fair value
of an acquired intangible asset, the discounted cash flows would
incorporate assumptions that market participants would use in their
estimates of future revenues and future expenses.
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[A footnote to paragraph 1.1.16 refers readers to current developments in
accounting related to market participant assumptions.]
d.
e.
f.
g.

8.

9.

Consider the amounts of R&D costs expended to date and estimated remaining
completion costs for reasonableness.
Review descriptions of the milestones achieved and compare the status with the
actual costs incurred and projected remaining costs.
Consider whether IPR&D is related to products that will be marketed externally.
Inquire of appropriate acquiring company personnel whether IPR&D has
achieved technological feasibility (or the equivalent) and has no alternative
future use.

Evaluate the overall results of the valuation. Consider—
a. Whether the size of the IPR&D charge is consistent with the overall nature of the
business and management’s purchase rationale.
b. The size of the existing base (or core) technology value relative to the IPR&D
value is reasonable.
c. The reasonableness of the IPR&D value with respect to the extent of completion
efforts remaining.
d. Whether the IPR&D value will be realizable and whether both the buyer and
seller are compensated considering the risks.
e. Major milestones achieved in the IPR&D project as of the purchase date and
their consistency with the valuation.
f. The entire purchase price allocation reflects the acquiring company’s
technology, industry position, age, reputation, and strategic plan.
Obtain a representation letter from the acquiring company that includes the following:
Management agrees with the findings of the valuation specialist.
The IPR&D assets have substance, are incomplete, and have no alternative
future use.
c. The historical financial data provided to the valuation specialist was prepared on
a basis consistent with the audited financial statements.
d. Forecasts and other estimates provided to the valuation specialist are consistent
with those developed for other parties or for internal use. The forecasts of future
cash flows used in the valuation represent management’s best estimate of
future conditions consistent with the assumptions specified in the specialist’s
valuation using market participant assumptions rather than those that are entity
specific (see the footnote to paragraph 1.1.16 of the AICPA Practice Aid).
e. Under the traditional approach, the discount rate applied to estimated future net
cash flows appropriately reflects the nature and complexity of the remaining
development effort and the amount and timing of estimated expenditures
necessary to complete the development of the IPR&D projects.
a.
b.

10.

Determine that information requiring separate disclosure in the financial statements is
properly identified in the working papers and presented in the financial statements,
including the disclosures identified in paragraph 4.2 of the AICPA Practice Aid.
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CONCLUSION
Based on the procedures performed, we are satisfied that our working papers
appropriately document that acquired IPR&D does not contain any material
misstatements, in relation to the financial statements taken as a whole. Exceptions are
attached or stated below.
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APPENDIX A
GLOSSARY OF TERMS
Base technology. (Also referred to in practice as core technology.) Those technical
processes, intellectual property, and the institutional understanding that exist within an
organization with respect to products or processes that have been completed and that
will aid in the development of future products, services, or processes that will be
designed in a manner to incorporate similar technologies.
Developed product technology. Technology as it exists in a current product(s)
offering. Today’s developed product technology may be tomorrow’s base (or core)
technology. In a valuation model that “splits” revenues or profits, developed product
technology and base (or core) technology may be combined into one category. From a
generally accepted accounting principles perspective, base (or core) and developed
technology should be separately identified if they have different amortizable useful lives.
Expected cash flow approach. When determining present value, the sum of
probability-weighted cash flows in a range of possible estimated amounts; the estimated
mean or average.
In-process research and development (IPR&D). Research and development project
that has not yet been completed. Acquired IPR&D is a subset of an intangible asset to
be used in R&D activities.
Multi-period excess earnings method. A specific application of the discounted cash
flow method, which is more broadly a form of the income approach. The most common
method used to estimate the fair value of an intangible asset.
Synergies. In the context of developing prospective financial information, the difference
between the assumptions used to estimate cash flows that are unique to an entity and
the assumptions that would be used by market participants.
Traditional approach. When determining present value, the use of a single set of
estimated cash flows.
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APPENDIX B
GLOSSARY OF ABBREVIATIONS
AICPA. American Institute of Certified Public Accountants
FASB. Financial Accounting Standards Board
FDA. Food and Drug Administration
GAAP. Generally accepted accounting principles
GAAS. Generally accepted auditing standards
IPR&D. In-process research and development
MD&A. Management discussion and analysis
PFI. Prospective financial information
R&D. Research and development
SAS. Statement on Auditing Standards
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APPENDIX C
REFERENCES
Following are titles of authoritative financial reporting literature referenced in this
Practice Aid.

STATEMENTS OF FINANCIAL ACCOUNTING STANDARDS

•
•
•
•
•
•
•
•
•
•
•
•

FASB Statement No. 2, Accounting for Research and Development Costs
FASB Statement No. 7, Accounting and Reporting by Development Stage Enterprises
FASB Statement No. 38, Accounting for Preacquisition Contingencies of Purchased
Enterprises
FASB Statement No. 68, Research and Development Arrangements
FASB Statement No. 86, Accounting for the Costs of Computer Software to Be Sold,
Leased, or Otherwise Marketed
FASB Statement No. 96, Accounting for Income Taxes, which was superseded by
FASB Statement No. 109.
FASB Statement No. 109, Accounting for Income Taxes
FASB Statement No. 121, Accounting for the Impairment of Long-Lived Assets and
for Long-Lived Assets to Be Disposed Of
FASB Statement No. 131, Disclosures about Segments of an Enterprise and
Related Information
FASB Statement No. 133, Accounting for Derivative Instruments and Hedging Activities
FASB Statement No. 141, Business Combinations
FASB Statement No. 142, Goodwill and Other Intangible Assets

ACCOUNTING PRINCIPLES BOARD OPINIONS

•
•
•

APB Opinion 16, Business Combinations
APB Opinion 17, Intangible Assets
APB Opinion 18, The Equity Method of Accounting for Investments in Common Stock

FASB STATEMENTS OF CONCEPTS

•
•
•
•

FASB Concepts Statement No. 2, Qualitative Characteristics of Accounting Information
FASB Concepts Statement No. 5, Recognition and Measurement in Financial
Statements of Business Enterprises
FASB Concepts Statement No. 6, Elements of Financial Statements
FASB Concepts Statement No. 7, Using Cash Flow Information and Present Value
in Accounting Measurements

FASB INTERPRETATIONS

•

FASB Interpretation No. 4, Applicability of FASB Statement No. 2 to Business
Combinations Accounted for by the Purchase Method
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•
•

FASB Interpretation No. 6, Applicability of FASB Statement No. 2 to Computer Software
FASB Interpretation No. 35, Criteria for Applying the Equity Method of Accounting for
Investments in Common Stock

AICPA STATEMENT OF POSITIONS

•
•
•

SOP 81-1, Accounting for Performance of Construction-Type and Certain
Production-Type Contracts
SOP 94-6, Disclosure of Certain Significant Risks and Uncertainties
SOP 98-1, Accounting for the Costs of Computer Software Developed or Obtained
for Internal Use

EMERGING ISSUES TASK FORCE ISSUES

•
•
•
•

EITF Issue No. 87-11, Allocation of Purchase Price to Assets to Be Sold
EITF Issue No. 95-21, Accounting for Assets to Be Disposed Of Acquired in a
Purchase Business Combination
EITF Issue No. 98-3, Determining Whether a Nonmonetary Transaction Involves
Receipt of Productive Assets or of a Business
EITF Issue No. 00-5, Determining Whether a Nonmonetary Transaction Is an
Exchange of Similar Productive Assets

AICPA STATEMENTS ON AUDITING STANDARDS

•
•
•
•
•
•
•
•
•
•
•
•

SAS No. 1, Codification of Auditing Standards and Procedures (AICPA, Professional
Standards, vol. 1, AU sec. 560), “Subsequent Events”
SAS No. 8, Other Information in Documents Containing Audited Financial
Statements (AICPA, Professional Standards, vol. 1, AU sec. 550)
SAS No. 22, Planning and Supervision (AICPA, Professional Standards, vol. 1, AU sec. 311)
SAS No. 47, Audit Risk and Materiality in Conducting an Audit (AICPA, Professional
Standards, vol. 1, AU sec. 312)
SAS No. 55, Consideration of Internal Control in a Financial Statement Audit
(AICPA, Professional Standards, vol. 1, AU sec. 319), as amended by SAS No. 78
SAS No. 57, Auditing Accounting Estimates (AICPA, Professional Standards, vol.1,
AU sec. 342)
SAS No. 58, Reports on Audited Financial Statements (AICPA, Professional
Standards, vol. 1, AU sec. 508), as amended by SAS No. 79
SAS No. 71, Interim Financial Information (AICPA, Professional Standards, vol. 1,
AU sec. 722)
SAS No. 73, Using the Work of a Specialist (AICPA, Professional Standards, vol. 1,
AU sec. 336)
SAS No. 82, Consideration of Fraud in a Financial Statement Audit (AICPA,
Professional Standards, vol. 1, AU secs. 110, 230, 312, and 316)
SAS No. 90, Communication With Audit Committees (AICPA, Professional
Standards, vol. 1, AU secs. 380 and 722)
SAS No. 94, The Effect of Information Technology on the Auditor’s Consideration of
Internal Control in a Financial Statement Audit (AICPA, Professional Standards, vol.
1, AU sec. 319)
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Accounting estimates
defined, 6.2.02
evaluation of, 6.2.10–6.2.12
introduction to, 6.1.01–6.1.04
management's responsibility for, 6.2.05–6.2.08
Accounting of acquired assets, 4.1.01–4.1.23
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accounting estimates issues of, 6.2.02–6.2.12
engagement planning considerations for, 6.3.02–6.3.44
reporting considerations for, 6.5.01–6.5.06
substantive procedures for, 6.4.02–6.4.41
Administrative expenses, verification of, 5.3.14
Allocation costs
to acquired assets, 3.2.05
disclosure of, 4.2.05
timing for recording of, 4.1.02–4.1.03
Alternative future use
of acquired assets, 3.2.06–3.2.11, 3.3.70–3.3.73, 3.3.75–3.3.76, 3.3.79–3.3.80, 3.3.89–3.3.90
determining, 5.3.33
Amortization, tax, 5.3.98, 5.3.102, 5.3.105–5.3.108
Asset(s). See also Intangible assets
fixed, 5.3.60–5.3.61, 5.3.64
long-lived, 5.3.71
management's role in identifying, 5.3.27–5.3.31
sale, 5.3.99
tangible, 5.3.14
treatment of, 12.1.04–12.1.05
Assets, acquired. See also Alternative future use; Valuation methods/issues
accounting of, 4.1.01–4.1.23
amortization of, 5.3.98, 5.3.102, 5.3.105–5.3.108
in business combinations, 1.1.01–1.1.05, 3.1.01–3.1.04
capitalization of costs of, 3.3.70–3.3.73
characteristics and attributes of, 3.2.02–3.2.12, 3.3.13–3.3.16
confirming existence of, 5.3.33–5.3.34
disclosure of, 4.2.01–4.2.08
economic benefits of, 3.3.17–3.3.21
fair value concept of, 1.1.07–1.1.12
identification of, 5.3.27–5.3.31
measurement criteria for, 3.3.22–3.3.26
net-of-tax approach and, 5.3.100
PFI attributable to, 5.3.39–5.3.40
on single asset basis, 1.1.14
synergistic value excluded from, 1.1.15–1.1.19
tax benefits and, 5.3.98–5.3.108
Assumptions
fair value concept and, 1.1.04
significant, 6.4.23–6.4.29
used in PFI preparation, 5.3.18
Audit(ing)
of financial statements, 6.3.04, 6.5.08–6.5.09
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risk assessment, 6.3.37–6.3.44
Auditor
accounting estimates evaluation by, 6.2.10–6.2.12
allocations issues for, 6.4.37–6.4.38
auditing procedures planning by, 6.3.02–6.3.04
audit risk assessment by, 6.3.39–6.3.40
entity's business knowledge as requirement for, 6.3.06–6.3.09
in-process projects evaluation by, 6.4.20–6.4.21
interim period reporting by, 6.6.01–6.6.06
personnel considerations issues for, 6.3.17–6.3.19
responsibility for financial statements' contents, 6.5.16–6.5.18
significant assumptions evaluation by, 6.4.23–6.4.29
understanding of acquisition by, 6.3.10–6.3.12, 6.4.05
valuation report evaluation by, 6.4.14–6.4.21
valuation specialist and, 6.3.21–6.3.27, 6.3.29–6.3.34, 6.5.03–6.5.06, 6.5.10–6.5.11

B
Base technology
basis of charge for, 5.3.64
contributory asset charge related to, 5.3.43
defined, 5.3.47
revenue split model and, 5.3.49–5.3.50
Bridge/IPO investments, 5.3.91
Business combination. See also Acquisition(s); Valuation methods/issues
acquiring assets in, 1.1.01–1.1.05, 3.1.01–3.1.04
assets' allocation issues of, 4.1.17–4.1.23
assets' disclosure in, 4.2.01, 4.2.03
future use of assets in, 3.3.75–3.3.90
PFI alternatives preparation for, 5.3.07–5.3.08
R&D projects with incompleteness in, 3.3.61–3.3.68
software development costs and, 3.3.06–3.3.07

C
Capital asset charge, 5.3.59, 5.3.64
Capital charges
allocation of, 5.3.61
defined, 5.3.56
Capitalization of costs of acquired assets, 3.3.70–3.3.73
Cash flows
after-tax, 5.3.05, 5.3.36–5.3.38, 5.3.103–5.3.104
allocation of, 5.3.41
calculating present value of, 5.3.69–5.3.96
contributory asset charge and, 5.3.55–5.3.57
discount rate and, 5.3.77
estimation of, 5.3.72
expected, 5.3.75, 5.3.78, 5.3.80
forecast, 6.4.25–6.4.26
future, 5.3.83
incremental, 5.3.102
indications of, 2.1.10–2.1.14
probability-adjusted, 5.3.79
reporting of, 4.1.14–4.1.16
risk premiums and, 5.3.85
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Combined enterprise
assets' allocation issues of, 4.1.17–4.1.23
control characteristic issues of, 3.3.15–3.3.16
PFI preparation issues of, 5.3.19
R&D sub-projects and, 3.3.58
Common stocks, accounting for investments in, 4.1.09–4.1.13
Contributory asset charge
cash flows issues and, 5.3.37, 5.3.55–5.3.57
determining, 5.3.62
principle of, 5.3.65
related to base technology, 5.3.43
vs. revenue-splitting method, 5.3.44
Contributory assets
charging returns for, 5.3.61
fair value of, 5.3.63
types of, 5.3.59–5.3.60
Control environment, risk factors related to, 6.3.42–6.3.44
Core technology. See Base technology
Cost approach, 2.1.04–2.1.05

D
Development stage enterprise, 3.3.27–3.3.29
Disclosure
of assets, 4.2.01, 4.2.03
of expenses, 4.2.05
of R&D projects, 4.2.04
of valuation methods, 4.2.02
Discounted cash flow method
after-tax cash flows and, 5.3.103–5.3.104
for R&D projects, 1.1.18
Discount rate
calculating present value of cash flows using, 5.3.69
selection of, 5.3.77, 5.3.81–5.3.96

E
Early development stage investments, 5.3.89
Economic benefits
of acquired assets, 3.3.17–3.3.21, 5.3.33
combined enterprise and, 3.3.16
Engagement
letters, 5.2.05
valuation, 5.2.03
Engagement planning considerations
audit risk model, 6.3.01–6.3.04
knowledge of business, 6.3.06–6.3.09
overall risk assessment, 6.3.36–6.3.44
personnel considerations, 6.3.17–6.3.19
timing considerations, 6.3.14–6.3.15
understanding of acquisitions, 6.3.10–6.3.12
use of valuation specialist, 6.3.21–6.3.34
Equity method, 4.1.09–4.1.13
Expected cash flow approach, 5.3.72, 5.3.74
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Expenses
attributable to IPR&D subcomponent, 5.3.53
marketing, 5.3.14

F
Fair market value (FMV), 1.1.07
Fair value estimation. See also Accounting estimates; Valuation methods/issues
of acquired assets, 1.1.08–1.1.14
assumptions and, 1.1.04
cost approach for, 2.1.04–2.1.05
defined, 1.1.03
for financial reporting, 1.1.03–1.1.07
market approach for, 2.1.07
measurement criteria for assets and, 3.3.24–3.3.29
multi-period excess earnings method for, 5.3.01–5.3.05
net-of-tax approach and, 5.3.100
summary, 1.1.21
synergistic value and, 1.1.16
traditional approach for, 5.3.71
Financial statements
assets' allocation issues and, 4.1.01–4.1.08
audit of, 6.3.04
auditor's responsibility for contents of, 6.5.16–6.5.18
disclosure of assets and expenses in, 4.2.05–4.2.06
GAAP departures in, 6.5.14
interim period reviewing of, 6.6.01–6.6.06
risk factors for frauds in, 6.3.41
Fixed assets, 5.3.60–5.3.61, 5.3.64

H
I
Income approach, fair value estimation with, 2.1.09–2.1.20, 5.3.73
Income tax benefits
with amortization, 5.3.98, 5.3.102, 5.3.105–5.3.108
computing, 5.3.98
fair value of assets and, 5.3.102
Income tax synergies, elimination of, 5.3.23
Incompleteness issues
handling, 5.3.33
related to R&D projects, 3.3.55–3.3.68
Incremental revenue, 2.1.10
In-exchange value, 1.1.07
Inherent risk
defined, 6.3.37
related to acquired IPR&D estimates, 6.3.38
In-process projects, evaluation of, 6.4.20–6.4.21
Intangible assets
basis of charge for, 5.3.64
capitalization of costs of, 3.3.70–3.3.73
examples of, 5.3.60
identification of, 6.4.17–6.4.18
measurement criteria for, 3.3.24
required levels of, 5.3.14
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synergistic value and, 1.1.17–1.1.19
tax benefits and, 5.3.98
valuation of, 2.1.07, 2.1.09–2.1.20, 5.3.01–5.3.05, 5.3.107–5.3.108
value on single asset basis, 1.1.09–1.1.14
Intellectual property, 3.3.14
Interim period reporting, 6.6.01–6.6.06
Internal-use software, 3.3.04–3.3.07
In-use value, 1.1.07
Investment value, 1.1.07
IPR&D projects. See Research and development projects

L
Liquidation value, 1.1.07

M
Management
accounting estimates responsibility for, 6.2.05–6.2.08
PFI preparation responsibility for, 5.3.10–5.3.12
representations from, 6.4.40–6.4.41
role in acquisition's control environment, 6.3.42–6.3.44
role in identifying assets, 5.3.27–5.3.31
Management's discussion and analysis (MD&A)
IPR&D charges and, 4.2.08
purpose of, 4.2.07
Manufacturing cost savings, 2.1.10
Market approach, fair value estimation with, 2.1.07
Marketing expenses, 5.3.14
Market value, fair value concept and, 1.1.07
Measurability issues
fair value estimation issues and, 3.3.31–3.3.38
related to acquired assets, 3.3.22–3.3.26, 5.3.33
Multi-period discounted cash flow method, 2.1.11
Multi-period excess earnings method
cash flow indications with, 2.1.10
fair value concept and, 1.1.21
overview of, 5.3.01–5.3.03
steps to application of, 5.3.04

N
Net working capital, verification of, 5.3.14

P
Patents, basis of charge for, 5.3.64
Present value measurements
elements of, 5.3.76
fair value as objective in using, 5.3.74
Private Securities Litigation Reform Act of 1995, 4.2.04
Process changes costs as R&D activity, 3.3.08–3.3.09
Proprietary intellectual property. See Intellectual property
Prospective financial information (PFI)
allocation of, 5.3.39–5.3.40
eliminating synergies from, 5.3.18–5.3.25
non-IPR&D activities and, 5.3.36–5.3.53
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purchase price and, 5.3.07–5.3.12
revenues' forecast in, 5.3.41–5.3.43
valuation report contents and, 5.2.07
verifying elements of, 5.3.14–5.3.16

R
R&D expenses
attributable to IPR&D subcomponent, 5.3.53
verification of, 5.3.14
Real option method, 2.1.17–2.1.20
Relief-from-royalty method, 2.1.12–2.1.15
Reporting considerations
auditor's responsibility for financial statements, 6.5.16–6.5.18
GAAP departures, 6.5.14
interim period reporting, 6.6.01–6.6.06
introduction to, 6.5.01
reliance on specialist's work, 6.5.03–6.5.06
scope limitations, 6.5.08–6.5.12
Research and development projects. See also Acquisition(s); Allocation costs; Valuation methods/issues
after-tax cash flows related to, 5.3.36–5.3.38
assets' attributes for, 3.2.03–3.2.12
assets' characteristics for, 3.2.02, 3.3.13–3.3.16
assets' economic benefits in, 3.3.17–3.3.21
confirming assets' existence in, 5.3.33–5.3.34
considerations for disclosure about, 4.2.04
fair value estimation issues and, 1.1.07–1.1.13, 3.3.27–3.3.29, 3.3.31–3.3.38
identifying assets in, 5.3.27–5.3.31
incompleteness attributes related to, 3.3.55–3.3.68
management's discussion and analysis and, 4.2.08
measurement issues related to, 3.3.22–3.3.26
phases of, 3.3.40–3.3.43
process changes as, 3.3.08–3.3.09
risk premiums for, 5.3.84
scope of, 3.3.02
software development costs and, 3.3.06–3.3.07
with substance, 3.3.45–3.3.53, 5.3.33
synergistic value issues and, 1.1.15–1.1.19
valuation of, 2.1.04–2.1.05, 2.1.07, 2.1.09–2.1.20, 5.3.93–5.3.96
venture capital for, 5.3.87
Revenue
ancillary, 5.3.36
attributable to IPR&D subcomponent, 5.3.52
forecast, 5.3.41–5.3.42
incremental, 2.1.10
related to technology migration, 5.3.45–5.3.46
synergies, 5.3.23
verifying, 5.3.14
Risk-free rate of return, 5.3.75, 5.3.77, 5.3.82
Risk premiums, 5.3.84

S
Sales costs and expenses, verification of, 5.3.14
Securities and Exchange Act of 1933, 5.2.03
Securities and Exchange Act of 1934, 6.6.05
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Securities and Exchange Commission (SEC), 4.1.08, 6.5.06
Single-period-capitalization method, 2.1.11
Start-up investments, 5.3.89–5.3.90
Stock sale, tax benefits and, 5.3.99
Substance, R&D projects with, 3.3.45–3.3.53, 5.3.33
Substantive procedures
evaluating results of procedures performed, 6.4.33–6.4.34
internal consistency, 6.4.31
management representations, 6.4.40–6.4.41
overview of, 6.4.01–6.4.03
preliminary procedures, 6.4.05–6.4.09
purchase price allocations, 6.4.36–6.4.38
significant assumptions, 6.4.23–6.4.29
valuation report, 6.4.11–6.4.21
Synergistic value/revenues
acquired assets and, 1.1.15–1.1.19
elimination of, 5.3.18, 5.3.22

T
Tangible assets, 5.3.14
Tax benefits. See Income tax benefits
Tax expenses
attributable to IPR&D subcomponent, 5.3.53
verification of, 5.3.14
Technical support expenses
attributable to IPR&D subcomponent, 5.3.53
verification of, 5.3.14
Technology migration
concept of, 5.3.48
forecasted revenues issues and, 5.3.45–5.3.46
Technology subcomponents
evaluating contribution of, 5.3.41
role in forecasting future revenues, 5.3.42
Traditional approach, fair value estimation with, 5.3.71, 5.3.73

U
Uniform Standards of Professional Appraisal Practice (USPAP), 5.2.10, 6.3.30

V
Valuation methods/issues
cost approach, 2.1.04–2.1.05
disclosure of, 4.2.02
evaluation of, 6.4.15
fair value concept and, 1.1.03–1.1.07
income approach, 2.1.09–2.1.20
introduction to, 2.1.01–2.1.02, 5.1.01–5.1.02
market approach, 2.1.07
measurability issues and, 3.3.31–3.3.38
objective of, 5.1.03
Valuation procedures
engagement acceptance, 5.2.03
engagement letters, 5.2.05
introduction to, 5.2.01
valuation report contents, 5.2.07–5.2.19
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Valuation report
evaluation of, 6.4.13–6.4.21
financial statements and, 6.6.02
preparation of, 6.4.11–6.4.12
Valuation specialist
assets' existence confirmation by, 5.3.33–5.3.34
assets' identification by, 5.3.27–5.3.31
assets' valuation by, 6.1.01–6.1.04, 6.2.12
findings, evaluation of, 6.5.03–6.5.06, 6.5.10–6.5.11
PFI preparation and verification by, 5.3.08–5.3.12, 5.3.14–5.3.16
purchase price allocations issues for, 6.4.36–6.4.38
qualifications of, 6.3.25–6.3.26
relationship to acquiring company, 6.3.29–6.3.32
significant assumptions and, 6.4.24–6.4.26
synergies elimination by, 5.3.18–5.3.25
understanding work of, 6.3.34
use of, 6.3.21–6.3.23
valuation report preparation by, 6.4.11
Venture capital
publications, 5.3.88
for R&D projects, 5.3.87
weighted average cost of capital and, 5.3.91

W
Weighted average cost of capital (WACC)
estimating discount rates and, 5.3.90
for single product companies, 5.3.91
Workforce-based assets, 5.3.60, 5.3.64
Working capital
basis of charge for, 5.3.61, 5.3.64
purpose of, 5.3.60
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